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Natural products research remains a fertile source for drug discovery due to the 
complexity, chemical diversity and biological activity of compounds discovered from 
nature. Verticillins are members of the epipolythiodioxopiperazine (ETP) alkaloid class 
of fungal metabolites and are known as potent cytotoxic agents, some with IC50 values of 
less than 10 nM. Studies showed that verticillin A has activity as a selective histone 
methyl transferases inhibitor with important anticancer properties. However, several 
challenges slowed the further development of this class of compounds. The goals of this 
project strived to address such challenges in the development of the ETP alkaloids in 
three ways: (1) enhancing the production of verticillins, (2) identifying and isolating new 
analogues of the verticillins, and (3) developing a targeted delivery approach for the 
verticillins. 
Aim 1 was achieved by analyzing different fungal strains under a suite of 
fermentation conditions. These studies were facilitated by the use of the droplet-liquid 
microjunction-surface sampling probe (droplet probe) coupled with UHPLC–PDA–
HRMS/MS, which enables chemical analysis in situ directly from the surface of the 
cultures. These experiments showed that the production of verticillins was greatly 
affected by growth conditions. Using these technologies to select the best among the 
tested growth conditions, the production of the verticillin analogues was increased in 
laboratory scale fermentation. 
Aim 2 was achieved via using a precursor-directed biosynthesis approach that was 
monitored in situ via droplet probe. To characterize the generated series of “non-natural 
natural products”, a suite of NMR and mass spectrometry data were collected. This 
approach yielded novel compounds that would be difficult to generate via synthesis. 
Furthermore, and in a collaborative manner, the generation of new analogues was also 
achieved via semisynthetic approaches that generated ester, carbonate, sulfonate and 
carbamate derivatives of the verticillins. This synthetic process was characterized by the 
use of 1H NMR to monitor the various reactions. 
Aim 3 was achieved by encapsulating verticillin A into an expansile nanoparticles 
(verticillin A-eNP). This delivery system was used to circumvent two imperative issues 
of the drug administration of verticillins. First, the verticillin A-eNP was used to shield 
healthy cells, by targeting cancerous cells, as it permits the retention of the eNPs inside 
the cancer cells and the continuous release of the drug in their acidic environment 
Secondly, the verticillin A-eNP enhanced the solubility of the poorly soluble verticillins, 
facilitating a more straight forward approach to their delivery and testing in vivo. 
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VERTICILLINS: EPIPOLYTHIODIOXOPIPERAZINE ALKALOIDS  
WITH CHEMOTHERAPEUTIC POTENTIAL 
This chapter is intended for submission to The Journal of Antibiotics and is 
presented in that style. Coauthors will include Doyle, M. G., Raja, H. A. and 




 Despite considerable advances for early detection, diagnoses, and treatment, 
cancer remains a major public health issue,1 resulting in over 1600 deaths in the United 
States daily.2 As cancer progresses, or escapes elimination by current chemotherapeutic 
strategies, tumor cells often accrue mediated drug resistance.3 This resistance can be 
caused by different mechanisms, such as the creation of a tumor microenvironment4 
(surrounding blood vessels, immune cells, fibroblasts, signaling molecules); the altered 
expression of efflux channels in the cell membrane, thereby lowering the dose of the drug 
reaching the target; and the alteration of the cellular drug target, rendering the drug 
ineffective.5 With many cancer types, these resistance mechanisms result in an almost 
impossible escape from cancer, especially when metastasis develops, often after 
chemotherapy.6-7 For these reasons, there is still a need to develop new chemical entities 
and approaches to fight against cancer. 
 Natural products have proven to be a diverse and reliable source for new scaffolds 
in the treatment of various diseases.8-9 Of the 136 anticancer small molecule drugs on the 
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market from 1940 to 2014, a total of 113 (83%) came from, or were inspired by, natural 
products.8, 10 This includes some of the front line drugs for the treatment of cancer, such 
as vincristine/vinblastine (bisindole alkaloids), taxol (paclitaxel), and 
irinotecan/topotecan (camptothecin derivatives).11   The structural diversity of fungal 
metabolites makes them a significant source for drug discovery.12-14 While much of that 
research has been in the anti-infective research space, due to the antibiotics revolution 
spawned by penicillin,15-16 researchers have shown growing interest in investigating 
fungal metabolites for anticancer purposes.17 Fungal species are hyper diverse, and 
various sources estimate 1.5 to 5.1 million species18 or 2.2 to 3.8 million species.19 The 
exact number may never been known, and regardless, only about 120,00019 to 135,00020 
are taxonomically described in the literature. Of these, it is likely that even fewer have 
been studied for bioactive secondary metabolites,21 making fungi an under investigated 
reservoir of pharmaceutical leads.17, 22-23  
 With over a decade of research on cytotoxic fungal metabolites, representing over 
500 compounds, verticillins represent an area of emphasis for our research team, 
including scaled up production, new analogue development, drug delivery, and in vitro 
and in vivo evaluation against a range of cancer models. Even though three review 
papers24-26 were published previously discussing particular aspects of the 
epipolythiodioxopiperazine (ETP) alkaloids, as a class, about ten years ago, none of these 
focused on the verticillins. Given that research on these compounds spans 50 years in 
2020, we felt that a comprehensive summary was timely, particularly with the growing 
number of publications on them over the last 8 years.27-37  
 
3 
Structure, Biosynthesis and Fungal Origin of Verticillins 
 Epipolythiodioxopiperazines alkaloids (ETPs) are a class of fungal secondary 
metabolites24, 30, 38 characterized by the presence of a polysulfur bridge on the 
dioxopiperazine moiety, and these can be subdivided into 14 groups according to distinct 
structural characteristics.26 Of those 14 groups, only three of them are dimeric, 
specifically verticillins, chaetocins and leptosins (Figure 1). The main difference between 
these is that chaetocins have methyl alcohol groups on R1 and R2, while leptosins contain 
at least one isopropyl side chain. For verticillins, R1 and R2 can be CH3, CH3CHOH, 
CH3CH2, CH2OH or acetyl. Both five membered rings in one verticillin monomer are cis-
fused, and the hydroxys at the 11 and 11ʹ positions add stability to the molecule by 
forming a hydrogen-bonding network. Indeed, Liu et al.39 reported the crystal structure of 
verticillin A (1), demonstrating that the O-H---O interactions between molecules 
facilitated the packing of crystals. All verticillins are ether and methanol insoluble, and 










Figure 1. The Basic Structure of Dimeric Epipolythiodioxopiperizine (ETP) 
Alkaloids, Showing Their Biosynthetic Origins. The color coding is used to illustrate 
the building blocks of these molecules. In red is tryptophan (Trp), common to all three 
dimeric structural classes. For verticillins, the “blue” substituent dictates the appendage at 
C-3 and C-3ʹ. For example, a methyl unit derives from alanine (Ala) or CH2OH from 
serine (Ser; purple). Alternatively, a C2H4OH derives from threonine (Thr), which can be 
oxidized to the acetyl or reduced to the ethyl. The N-methylation, common to all three 
classes, likely derives from S-adenosyl methionine. For chaetocins and leptosins, 
biosynthesis often uses Ser (purple) and/or Val (pink). Moreover, in these two classes, the 
sulfur bridge is often greater than two atoms, whereas in the verticillins, it is almost 
always two sulfur atoms.  
 
 
The structural diversity observed with the dimeric ETP alkaloids is due to 
differences in the gene clusters involved in the biosynthesis of these groups. While 
tryptophan (Trp) is used as a key unit in all of them, alanine (Ala), threonine (Thr) or 
serine (Ser) are believed to be the other building blocks used in the NRPS biosynthesis of 
these fungal metabolites.24, 42  
As an additional way to classify the dimeric ETP alkaloids, the fungi producing 
these three classes are distinct, making their classification dependent on their fungal 
origin. For example, with the verticillins, their production is often noted by Verticillium 
sp., Penicillium sp., and Gliocladium sp. Alternatively, chaetocins and leptosins are 

























































































































































































































































































































































































































































































Figure 2. Structures of the 27 Verticillins in the Literature. These are ordered 




The first verticillin was discovered in 1970 by Katagiri and colleagues at Shionogi 
research laboratory from the fungus Verticillium sp.,40 which was isolated from the 
basidiocarp of a mushroom termed “Coltricia cinnamomea;” this implies that the fungus 
was mycoparasitic. A pale yellow, ether-insoluble substance was obtained after a series 
of extractions followed by purification via crystallization in pyridine/acetone. This 
compound was analyzed using IR, MS and 1H-NMR, but its structure could not be 
elucidated completely. During this initial report, the compound was confirmed to contain 
both disulfide bridged diketopiperazine and di-indolyl moieties. The name verticillin A 

























































































































year later, the full structure and the absolute configuration of verticillin A (1) was 
determined using chemical and physico-chemical experiments, along with the 
comparisons with the close-related chaetocin (Figure 1), which was characterized 
previously by chemical and X-ray methods.43 The same research team continued working 
on this fungus, reporting both verticillin B (2) and verticillin C (3) in 1973.44 
No other analogues were reported for over twenty years until Sch 52900 (4) and 
Sch52901 (5) were disclosed by Schering-Plough, who named their new analogues with 
the first three letters of the institute name and a sequential serial number. Compounds (4) 
and (5) were isolated from the fungus Gliocladium sp, and their structures were 
characterized by spectral methods, including UV, IR, MS, and 1H- and 13C-NMR data.45 
In a separate study about sclerotium survival in soil, reported in 1999, another species of 
Gliocladium was investigated after noticing that damage was caused by this mycoparasite 
on its host. G. catenulatum was isolated from Aspergillus flavus sclerotia buried by the 
research group for two years in a Georgia cornfield.41 This fungus was cultured and 
extracted to yield three new verticillins [verticillin D (6), E (7) and F (8)], with structures 
elucidated via IR, UV, HRESIMS, and 1D and 2D NMR data. In the same year, a project 
focused on exploring marine fungal metabolites with cytotoxic activity isolated a 
Penicillium sp. from Caribbean green algae, “Avrainvillea longicaulis.” The cytotoxic 
extract was purified to yield 11ʹ-deoxyverticillin A (9) and 11,11ʹ-dideoxyverticillin A 
(10), which were both characterized by spectral methods. It could be argued that 11,11ʹ-
dideoxyverticillin A (10) is an outlier in the verticillin group, since its structure is neatly 
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identical to verticillin A (1) with the only difference being the absence of the hydroxy 
groups, classifying it to both verticillin and chaetocin groups.46  
Gliocladin A (11), gliocladin B (12) and gliocladin C (13) were isolated in 2004 
from Gliocladium sp. living in a marine environment. These metabolites lack the sulfur 
bridge, and gliocladin C (13) is considered  the only trioxopiperazine isolated from the 
fungus.47 One year later, five new compounds were discovered and included in the 
verticillin group. These latter entities were isolated from G. roseum 1A after a research 
screening freshwater fungi. Gliocladine A (14), B (15), C (16), D (17) and E (18) were 
isolated and characterized after the bioactivity directed fractionation of the a fungal 
culture on wheat medium.48 Bionectin A (19), Bionectin B (20) and Bionectin C (21) 
were isolated from Bionectria byssicola in the same year by another research group in 
Korea in the course of a project screening microbial sources for antibacterial leads.49 
Glioclatine (22) was isolated from the fermentation of Gliocladium roseum grown on a 
wheat medium.50 The new verticillin G (23) was discovered one year later by the same 
group in a further investigation of the same fungus.51 Bionectin A (19) and B (20) are 
structurally related to gliocladine C (16), D (17) and E (18), as all of these have one 
indole ring absent in their structures, making them monomeric ETPs, which are rare 
compared to the usual dimer of verticillins. These monomers still belong to the verticillin 
group because they are produced by the same fungi that produce verticillins, and it is 
believed that they are produced by the same pathway, since other dimeric verticillins 
were isolated from the same extract as the monomers. 
 
10 
In a study that aims to find novel anti-tumor entities, Chen et al. published a paper 
in 2009 where they isolated and characterized the structure of two new dimeric ETPs 
isolated from Gliocladium sp., the same fungus from which most of the verticillins were 
previously isolated. Gliocladicillin A (24) and B (25) were elucidated using HRESI-MS, 
and 1D and 2D NMR.52 Gliocladicillin C (26) was isolated by the same research group 
but was published in a Chinese patent.53 Figueroa et al.34 isolated verticillin H (27) along 
with six other verticillins after a bioactivity directed fractionation of the fermented 
















Table 1. Chronological Data, including Year Discovered, Molecular Formula, and 
the Fungal Source, for the Twenty-Seven Verticillin Analogues. (*misidentified or 
confused with Gliocladium sp.) 
 





1 Verticillin A 40, 43 1970 C30H28O6N6S4 696.83 Verticillium sp.* 
2 Verticillin B 44 1973 C30H28N6O7S4 712.83 Verticillium sp.* 
3 Verticillin C 44 1973 C30H28N6O7S5 680.77 Verticillium sp.* 
4 Sch 52900 45 1995 C31H30N6O7S4 726.86 Gliocladium sp. 
5 Sch 52901 45 1995 C31H30N6O6S4 710.86 Gliocladium sp. 
6 Verticillin D 41 1999 C32H32N6O8S4 756.88 Gliocladium catenulatum 
7 Verticillin E 41 1999 C32H28N6O8S4 752.85 Gliocladium catenulatum 
8 Verticillin F 41 1999 C32H30N6O8S4 754.87 Gliocladium catenulatum 
9 11ʹ Deoxyverticillin A 46 1999 C30H29N6O5S4 680.83 Penicillium sp. 
10 11,11ʹ Dideoxyverticillin A 46 1999 C30H29N6O4S4 664.83 Penicillium sp. 
11 Gliocladin A 47 2004 C24H24N4O3S2 480.60 Gliocladium sp. 
12 Gliocladin B 47 2004 C24H24N4O2S2 464.60 Gliocladium sp. 
13 Gliocladin C 47 2004 C22H16N4O3 384.40 Gliocladium sp. 
14 Gliocladine A 48 2005 C30H29N6O6S5 664.77 Gliocladium roseum 
15 Gliocladine B 48 2005 C30H29N6O6S6 664.77 Gliocladium roseum 
16 Gliocladine C 48 2005 C23H21N4O3S2 464.56 Gliocladium roseum 
17 Gliocladine D 48 2005 C23H21N4O3S3 432.50 Gliocladium roseum 
18 Gliocladine E 48 2005 C23H21N4O3S4 432.50 Gliocladium roseum 
19 Bionectin A 49 2006 C22H18N4O3S2 450.53 Bionectria byssicola 
20 Bionectin B 49 2006 C24H22N4O4S2 494.58 Bionectria byssicola 
21 Bionectin C 49 2006 C24H24N4O4S3 480.60 Bionectria byssicola 
22 Glioclatine 50 2006 C23H20N4O2S2 448.56 Gliocladium roseum 
23 Verticillin G 51 2007 C30H28N6O7S4 714.85 Bionectria byssicola 
24 Gliocladicillin A 52 2009 C31H30N6O5S4 694.86 Gliocladium sp. 
25 Gliocladicillin B 52 2009 C31H30N6O4S4 678.86 Gliocladium sp. 
26 Gliocladicillin C 53 2009 C32H33N6O7S4 740.88 Gliocladium sp. 




 As summarized in Table 1, it is apparent that the first verticillin, verticillin A (1) 
as well as verticillins B and C were the only verticillin isolated from Verticillium sp.40 A 
2011 study by Schenke et al.54 investigated the genes that were known to be responsible 
of the ETP verticillin like compounds. This study was performed on Verticillium dahliae 
but the authors were unable to detect any genes responsible for verticillins expression; 
even the extraction of a fermented culture of this fungus did not detect any verticillin, 
which led to uncertainties about the true ability of the fungus to be a verticillin producer. 
The group hypothesized the possibility that the isolated verticillin A (1) was from a 
different genus than Verticillium that was known to be heterogeneous. The ability of 
Clonostachys sp, the fungus from where most of the verticillins were produced, to be a 
mycoparasite of Verticillium made it possible that the original fungi was confused or 
contaminated with other fungi. In our research lab, we have identified the verticillin 
producing strains as Clonostachys sp. (Hypocreales, Ascomycota) that is 
phylogenetically similar to C. rogersoniana. 
Biosynthesis  
The investigation of the ETP class by using labeling experiments demonstrated 
that they were built up from amino acids.55-56 Studies suggest that formation of the 
diketopiperazine ring happens during the early stages of the biosynthesis process, as 
feeding experiments of sulfur atoms showed incorporation from different sources 
(methionine, cysteine or sodium sulfate).57 Verticillins, as the other groups of ETPs, are 
synthesized via a non-ribosomal peptide synthases (NRPS).42, 58 The biosynthesis 
pathway of the monomeric ETP gliotoxin was thoroughly investigated for years, making 
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it the prototype for this class of fungal metabolites. The gene cluster, and consequently, 
many enzymes playing a role in its biosynthesis were determined.59-61 
Little was known about verticillins’ biosynthetic pathway until very recently 
when Wang et al.32 identified the gene cluster (ver) from the fungus Clonostachys 
rogersoniana contributing to a better understanding of an ETP dimer’s biosynthetic 
process. Various genes located in the ver cluster proved necessary to the biosynthesis, 
since their disruption halted the production of the verticillins. The gene verP is 
considered to be responsible for amino acid condensation to form the skeleton of the 
molecule. The verA gene is believed to serve in the transportation of verticillins, its 
disruption resulted in excretion of fewer secondary metabolites. The verT gene is 
believed to be accountable for the dithiol oxidation.32  
Synthesis 
Verticillins have drawn a lot of interest by synthetic chemists because of their 
dimeric structure, which contain sulfur bridges with eight stereocenters.62 The high 
amount of stereocenters make this class very challenging for synthesis especially in the 
presence of basic, acidic and redox substructures.63 The first initiative to develop a total 
synthesis of verticillins was in 2007, where (+)-Gliocladin C (13) was achieved via an 
enantioselective approach.64 Movassaghi group relied on a hypothesis of the retro-
biosynthesis to synthesize (+)-11,11ʹ-dideoxyverticillin A (10) via 14 enantioselective 
steps. (+)-11,11ʹ-Dideoxyverticillin A (10) was the first dimeric ETP synthesized via 
reductive radical dimerization, and the establishment of the disulfide bridge was elegantly 
added after the completion of the total carbon frame via a regioselective α hydroxylation 
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of the diketopiperazine rings.62-63 The success of this synthesis strategy not only gave an 
insight about the probable biosynthesis but also opened the door for synthesis of other 
ETPs. However the yield of such synthesis was low, 0.2 g of (+)-11,11ʹ-
dideoxyverticillin A (10) was prepared from more than 10 g scale of commercially 
available amino acids derivatives.62 
Other verticillin analogues along with closely related ETP secondary metabolites 
were synthesized by the same group and during the biosynthesis, they addressed some 
challenges like the formation of C-11/C-11ʹ vicinal quaternary centers, the oxidation of 
diketopiperazine, and the stereoselective thiolation. The study resulted in a structure-
activity relationship (SAR) study and served to build a better understanding of the ETP 
class. Modifications were targeted on N-6, C-10b, C-3 and C-3/C-11a and results showed 
an increased potency when the variations were applied to C-10b and C-3/C-11a positions 
(Figure 3). A minimal changes in activity was observed when modification were applied 
on substituents on positions N-6 and C-3 make them favorable for optimizing the efficacy 
of the molecule.65-66 A high potency is related to the presence of a disulfur at C-3/C-11a, 
while the removal of the sulfur atoms or the reduction of the sulfur bridge 





Figure 3. Structure-Activity Relationship Study. Modified from Boyer et al.65 
 
 
Mechanism of Action 
Mechanism of action studies have shown that verticillin A (1) is a histone methyl 
transferases (HMTase) inhibitor with a selective activity towards G9a, GLP, SUV39H1, 
SUV39H2, MLL1 and NSD2 methyltransferases. The most selectivity of verticillin A (1) 
was observed against G9a, SUV39H1 and SUV39H2 with IC50 values of 0.54, 0.57 and 
0.48 µM, respectively.28 Paschall et al.35 discerned the selective role of verticillin A (1) in 
inhibiting the histone H3 lysine9 (H3K9) methylation, by reversing enzyme function 
displaying a decrease of H3K9me2 and H3K9me3 levels. H3K9me3 was shown to be 
responsible for Fas transcription silencing, which results in its loss of expression in 
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human colon carcinoma cells. Treatment with verticillin A (1) showed a decrease in 
H3K9me3 levels in the FAS promoter region with an increase of histone H3 lysine9 
acetylation (H3K9ac), which indicates active transcriptional chromatin and is known to 
mediate FAS expression.35 FAS-L ligand present on the surface of cytotoxic T 
lymphocyte (CTL) binding to FAS initiates an immunological reaction leading to FAS 
mediated apoptosis.68-69  
H3K4me3 levels were found to be significantly high in vitro and in vivo in 
PANC02-H7 and UN-KC-6141 pancreatic cancer cell lines and the orthotropic tumor. 
MLL1 was found to be the HMTase responsible for the methylation of the H3K4. 
Silencing the MLL1 gene in both human and mouse pancreatic cancer cells resulted in a 
decrease of H3K4me3 with a decrease of PD-L1 ligand expressed by the tumor cell. 
Being an HMTase inhibitor, verticillin A (1) inhibits MLL1 with an IC50 of 0.8 µM. 
Subsequently, a decrease of H3K4me3 levels consistent with a decrease of expression in 
a dose dependent manner was observed in both in vitro and in vivo orthotropic tumors. 
The decrease of PD-L1 resulting in its reduced binding to PD-1 present in the CTL that 
activates the immune response against the tumor cells. The same pancreatic cancer cells 
that showed a potent anti-MLL1 activity, also showed that FAS-L mechanism is 
important in tumor growth suppression in wild mice models transplanted with pancreatic 
tumor.70 
Verticillin A (1) was found to inhibit pancreatic ductal adenocarcinoma (PDAC) 
growth in a dose dependent manner and sensitized PDAC cells to gemcitabine. 
Mechanistically, verticillin A (1) caused epigenetic modification in apoptosis regulating 
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genes by altering H3K9me3 and H3K4me3 levels. Chromatin immunoprecipitation 
(ChIP) revealed that verticillin A (1) caused dysregulation of apoptotic genes by 
decreasing H3K9me3 levels at Bak , Bax and Bim promoter region and H3K4me3 level 
at Bcl-x, Mcl-1 and FLIP promoter region in PDAC cells.37 
Pharmacology 
Anticancer activity 
Most of the isolated verticillins were discovered within projects investigating 
cytotoxic secondary metabolites.40, 46 Using a fos/lac Z reporter gene assay, Chu et al. 
showed that Sch 52900 (4), Sch 52901 (5) and verticillin A (1) inhibited serum-
stimulated transcription of human c-fos promoter.45 Certain cancer cells were detected to 
produce a high level of c-fos, which is a proto-oncogene and plays a role in transition of  
cells from a quiescent to a growing state.71 These verticillin analogues exerted potent 
activity in the fos/lac Z reporter gene assay with in vitro IC50 values of 1.5, 1.8 and 0.5 
µM, respectively. Thus, verticillin A (1) exerted antitumor activity by inhibiting the 
activation of at least two signaling pathways involved in c-fos induction.45 
Leukemia is characterized by an uncontrolled propagation of white blood cells 
(WBCs) and evasion from the terminal differentiation step leading to under-developed 
WBCs. One strategy of treatment in leukemia is to induce differentiation of WBCs 
followed by apoptosis.72 Sch 52900 (4) demonstrates the ability to induce differentiation 
of 50-69% of HL-60 cells (human promyelocytic cells) at low concentrations (6.8-13.6 
nM). Mechanistically, Sch 52900 (4) caused induction of the cell cycle inhibitor p21WAF 
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and inhibition of the extracellular signal regulated kinase (ERK) that led to cellular 
apoptosis and subsequent growth arrest.73 
11,11ʹ-Dideoxyverticillin A (10) has a potent anti-tyrosine kinase activity and 
inhibitory activity towards epidermal growth factor receptor (EGFR), vascular 
endothelial growth factor receptor-1/fms-like tyrosine kinase-1 (VEGFR-1/FLT-1) and 
human epidermal growth factor receptor-2 (HER2/ErbB-2), being selectively more potent 
against EGFR and VEGFR-1 with IC50 values of 0.136 and 1.645 nM, respectively.74 
Verticillins have also been shown to cause cell cycle G2/M phase arrest in HCT-116 
colon cancer cells using in vitro and in vivo experiments.75 Similarly, Gliocladicillins A 
and B are strong anti-proliferative and pro-apoptotic agents and are demonstrated to 
inhibit proliferation of cancer cell lines HeLa, HepG2 and MCF-7 by cell cycle blockage 
in the G2/M phase.52 Moreover, 11,11ʹ-dideoxyverticillin A (10) has an anti-angiogenic 
effect and inhibits proliferation of HUVECs (human umbilical vein endothelial cells) 
with IC50 values of 0.17 and 0.39 µM for VEGF (vascular endothelial growth factor) 
stimulated  cells and serum-stimulated cells respectively.74-76 
An important study done by Liu et al.27 revealed that verticillin A (1) inhibited 
HepG2 (human liver carcinoma) tumor cell growth by inducing apoptosis in vitro and 
inhibited in vivo tumor growth at a dose of 2 mg/kg body weight. Verticillin A (1) 
showed its high potency against multiple types of cancer cells with concentrations in the 
nanomolar ranges. It has also been demonstrated that verticillin A (1) is an apoptosis 
sensitizer for different types of tumors resistant to TRAIL, a potent anticancer agent in 
vitro and in vivo. This study emphasized the importance of verticillin A (1) as a highly 
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potent, low toxicity anti-cancer agent and a strong adjuvant to overcome drug resistance 
in cancer treatment.27 11ʹ Deoxyverticillin A (9) is shown to induce autophagy in 
HCT116 human colon carcinoma cells leading to cell death.29 In another study of human 
colorectal carcinoma (CRC) xenograft model, verticillin A (1) showed its efficacy in 
overcoming metastatic human CRC resistance to 5-fluorouracil (5-FU), which is the 
standard treatment for this type of cancer. The tumor size and weight were decreased 
significantly when the mice were treated with a combination of verticillin A (1) and 5-FU 
compared to groups that received individual treatments. The investigation of the role of 
verticillin A (1) in sensitizing the cancer cells to 5-FU revealed that the mechanism of 
apoptosis induction was independent of the FAS expression. Other analysis on the mice 
liver enzymes indicated that verticillin A (1) has minimal liver toxicity at a dose of 1 
mg/kg body weight injected every other day during 10 days.35 
In a study on soft tissue sarcoma (STS), that is known to be therapeutically 
challenging due to the genetic and histological heterogeneity, verticillin A (1) showed its 
potency in inhibiting malignant peripheral nerve sheath tumor (MPNST) and 
leiomyosarcoma (LMS) growth by inducing apoptosis. In vitro experiments demonstrated 
that verticillin A (1) inhibited colony formation in STS cells, in addition to inducing 
apoptosis.  Mice xenografted with MPNST724 revealed tumor growth inhibition and 
significant reduction of tumor volumes and weights when treated with verticillin A (1) at 
a dose of 0.25 or 0.5 mg/kg of body weight.30  
In pancreatic cancer cells, upregulation of the PD-L1 ligand increased the tumor 
cells viability by evading immune response.70, 77 CTL express PD-1 receptor that binds to 
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PD-L1 overexpressed in cancer cells and this binding inhibits the CTL activity permitting 
immune checkpoint evasion. In both PANC02-H7 and UN-KC-6141 pancreatic tumors, 
PD-L1 was found to be expressed in significant higher levels in vivo, likewise, over 50% 
of tumor-infiltrating CD8+ CTLs were PD-1+. Four mice group with pancreatic tumor 
transplants received 0.5 mg/kg body weight of verticillin A (1) and 200 µg of anti-PD-L1 
either alone or in combination along with a control group. Pancreatic cancer has a poor 
response to anti-PD-L1/PD-L1 immunotherapy78 and the results from this study 
decreased tumor growth in the treated groups compared to the control. The group with 
combined treatment of verticillin A (1) and anti-PD-L1 exhibited the most significant 
growth suppression close to tumor eradication. Verticillin A (1) repressed PD-L1 
expression by inhibiting MLL1 on the tumor cells and the additive effect of combining 
the two drugs indicates the important role of verticillin A (1) in increasing the efficacy of 
the anti-PD-L1 therapy.70 
Verticillin A (1) suppressed tumor growth by inhibiting H3K9me3, resulting in a 
FAS-L mediated apoptosis or by inhibiting H3K4me3 leading to PD-L1 
immunosuppression. A similar in vivo experiment was conducted with the same 
therapeutic strategies mentioned above where the FAS-L mechanism was excluded. The 
tumor growth suppression rose to be dependent on the FAS-L and CTLs,suggesting new 
approaches of combining epigenetic and immune checkpoint blockade 
immunotherapies.36, 70  
The first pharmacokinetic and bioavailability studies were conducted on 
verticillin A (1) by Wang and colleagues who administrated the drug orally (PO), 
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intraperitoneally (IP) at a dose of 3 mg/kg and intravenously (IV) at a dose of 1 mg/Kg 
Blood plasma concentrations of verticillin A (1) were then calculated using liquid 
chromatography-tandem mass spectroscopy (LC-MS). The within and between days 
precision was <9% and the accuracy was between 90 to 105%. IP dosing results showed 
the highest systemic exposure with a maximal concentration (Cmax) of 110 nM and 
sustained plasma concentrations above 10 nM for 24 hours duration. IV and PO doses 
achieved 73 nM and 9 nM of Cmax values respectively. The high levels of active verticillin 
A (1) after IP and IV administration warrant further investigation of these routes for 
future in vivo studies.31  
Nematidical activity 
Verticillin analogues such as gliocladine A (14), B (15), C (16), D (17) & E (18), 
verticillin A (1), 11ʹ deoxyverticillin A (9), Sch 52900 (4) and Sch52901 (5) were tested 
for their anti-nematicidal effects against Caenorhabditis elegans and Panagrellus 
redivivus. The dimeric verticillins were the most effective in comparison to the 
monomeric forms containing the indole moiety. The number of sulfur atoms in the bridge 
did not influence the potency of the molecules.48  
Antimicrobial activity 
Bionectin A (19) and B (20) were tested for their antibacterial activity against 
Staphylococcus aureus, methicillin-resistant S. aureus (MRSA) and quinolone-resistant 
S. aureus (QRSA) and resulted in MIC values of 10-30 µg/mL whereas, Verticillin D (6) 




Summary and Conclusion 
To date, 27 verticillin analogues have been reported in the literature. This review 
describes this interesting group of ETP alkaloids. What differentiates verticillins from 
other ETP groups appears to be primarily based on the fungal strain producer of these 
different entities. Verticillins are biosynthesized via NPRS, and the amino acids building 
blocks used for biosynthesis are specific for this group. Recently, a study of the genome 
of C. rogersoniana identified the gene cluster (ver) contributing to a better understanding 
of the biosynthetic pathway of these molecules. Verticillin A (1) was discovered in 1970 
from the filamentous fungi Verticillium sp. that turned out to be a misidentification of the 
genus. Gliocladium sp., Penicillium sp., and Bionectria sp. are reported to be the main 
producers of verticillins. The verticillin group is characterized by its sulfur bridge, 
essential for the potency of the molecule. Verticillins are known to be antifungal and 
antibacterial and recently their anticancer activity has generated interest in the field of 
cancer drug discovery. Verticillin A (1) is shown to be a potential anti-tumor drug due to 
its specificity and toxicity towards cancer cells by modifying the epigenome and 
sensitizing cancer cells to apoptosis. This interest in the anti-cancer activity lead to a 
couple of in vitro and in vivo studies described in this review. The demand for new 
anticancer drugs and the potential shown by the verticillin group of compounds make 




MEDIA STUDIES TO ENHANCE THE PRODUCTION OF VERTICILLINS 
FACILITATED BY IN SITU CHEMICAL ANALYSIS 
This chapter has been published in The Journal of Industrial Microbiology & 
Biotechnology and is presented in that style. Amrine, C. S. M., Raja, H. A., 
Darveaux, B. A., Cedric J. Pearce, C. J., Oberlies, N. H. J Ind Microbiol 




Fungi are a rich resource for biologically active and structurally diverse secondary 
metabolites.12-14 As such, a number of authors have noted the value of investing in fungi 
as a source of new drug leads, especially to treat cancer and overcome its resistance.11, 21 
Cancer is a worldwide problem, and in the USA alone, over one million new cases were 
estimated for 2016, resulting in more than half a million cancer-related deaths.79 
As part of ongoing studies to discover new anticancer leads from filamentous 
fungi,11, 34, 80 our team has isolated hundreds of fungal metabolites over the last decade.14 
Of these, verticillins are one of the most interesting for a variety of reasons.27, 30, 34-35, 70 
This class of bioactive fungal secondary metabolites (as exemplified by compounds 1-7) 
is characterized by a dimeric structure26 and is a key member of the 
epipolythiodioxopiperazine (ETP) alkaloids. Biologically, these compounds display 
potent antitumor activity,38, 46, 52, 74, 76 along with antibacterial,41, 43, 49, 51 nematicidal 48 and 
immune induction properties.73 
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The lead compound of this class, verticillin A (1), was first discovered in 1970,40 
and since then, 27 verticillin analogues have been characterized,34 even 30 years ago, 
their cytotoxic potential was noted.38 At the time of discovery, verticillin A (1) showed an 
ED50 of 0.2 µg/mL (0.27 µM) against HeLa cells.40 In another study, verticillin A (1), 
along with the closely related analogues, Sch 52900 (5) and Sch 52901 (2), showed 
potential in preventing the transcription of c-fos promoter gene, which is a proto-
oncogene found overexpressed in a variety of cancers.45 Two analogues, 11,11ʹ-
dideoxyverticillin A (6) and 11ʹ-deoxyverticillin A (7), demonstrated in vitro cytotoxicity 
against HCT-116 (human colon carcinoma) cells in the nanomolar range.46 These later 
compounds also demonstrated an inhibitory effect of tyrosine kinase on the growth factor 
receptor, thereby leading to anti-tumor activity.74 Verticillin A showed potent activity in 
sensitizing human colorectal cancer cells to apoptosis both in vitro and in vivo, as well as, 
the ability to induce cell-cycle arrest at the G2 phase.27  
Biologically, interest has been growing in the verticillins, particularly after 
verticillin A (1) was shown to be a selective histone methyl transferases (HMT) 
inhibitor.35 The HMT inhibitory activity resulted in the demethylation of H3K9me3 of 
the silenced FAS gene, 35 thereby allowing its transcription, such that FAS was re-
expressed, triggering apoptosis mediated cell death.81 Moreover, verticillin A (1) induced 
apoptosis selectively against malignant tumor cells, while minimal effect was exhibited 
against healthy cells.30 Verticillin A (1) showed potential to overcome metastatic colon 
carcinoma resistance to 5-fluorouracil. Mice transplanted with SW620-5FU-R cells were 
treated with a combination of verticillin A (1) and 5-fluorouracil and displayed 
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significantly smaller tumors compared to the groups receiving only one of these two 
treatments.35 In a recent study conducted on pancreatic cancer by Lu et al.,70 verticillin A 
was given to two groups of mice transplanted with either PANC02-H7 or UN-KC-6141 
cells. Verticillin A was administrated alone or in combination with anti PD-L1 
(programmed death ligand) treatment to provide immunotherapy. The results 
demonstrated that verticillin A (1), in conjugation with anti PD-L1 ligand, markedly 
reduced tumor size and viability. In summary, a suite of pharmacological studies over the 
last five years has increased the interest surrounding this class of compounds. 
Despite the promising activities that verticillins have shown in vitro and in vivo, 
research has been hindered by the lack of material. In previous work, 0.66 to 1.72 mg of 
verticillin analogues (1-3) per g of extract could be isolated from large scale 
fermentations of fungal cultures containing 150 g of rice (with a total isolated of 1.6 to 
5.5 mg).34 Similarly, 0.37 to 0.85 mg of verticillin analogues were isolated per g of 
extract (with a total isolated of 3.5 to 8.0 mg).41 Based on the literature, the yields of 
these compounds were not improved greatly when grown in liquid cultures. For example, 
from a 73 L fermentation, the yield of verticillin G was 0.58 mg per g of extract (with a 
total isolated of 2.9 mg).51 In another study that used 20 L fermentations, compounds 1, 6 
and 7 were isolated with a yield of 0.25 mg, 0.61 mg and 1.14 mg per g of extract, 
respectively (with a total yield of 3.5 mg, 8.5 mg and 16 mg, respectively).46 
Furthermore, although elegant synthetic approaches have been reported for the 
preparation of various epipolythiodioxopiperazine alkaloids,62, 65-66 these processes 
require numerous reactions steps, making the large-scale production of these compounds 
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challenging. About 0.2 g of (+)-11,11ʹ-dideoxyverticillin A was prepared in 14 steps 
from ˃10 g scale of commercially available amino acids derivatives.62 In summary, the 
production of the verticillins in the literature, whether using liquid-based or solid-based 
fermentations, has been largely on the scale of only a couple mg, and most of the 
verticillins have never been synthesized. For these reasons, the adequate supply of key 
analogues must be addressed before the full pharmacological potential of these 
compounds can be realized. 
Many studies have shown the influence of media and environmental factors on 
fungal biosynthesis,82-83 where optimal nutrition is required for ideal fungal growth.84-85 
The OSMAC approach is a prominent strategy to probe the importance of fungal 
fermentation conditions, potentially generating broader chemical diversity 86-87 and/or 
targeting the enhanced production of a distinct a class of secondary metabolites. In this 
study, several fungal strains were selected from the Mycosynthetix library. These cultures 
were grown on a suite of different solid media, and productivity was assessed by taking 
advantage of new instrumentation that facilitates the screening of the chemistry of the 
cultures. The droplet-liquid microjunction-surface sampling probe (droplet probe) 
permits the in situ analysis of targeted secondary metabolites directly from the surface of 
cultures.88-89 Our goal was to enhance the biosynthesis of verticillins by identifying a 
strain that produces the highest quantity of the analogues under appropriate fermentation 





Materials and Methods 
Mycology 
Fungal cultures were provided by Mycosynthetix, Inc., via an ongoing project to 
identify diverse natural product study material as a source of anticancer drug leads.11 
Over the last decade, we have analyzed the chemistry and biological activity of thousands 
of cultures from the Mycosynthetix library, and among these, ten cultures were identified 
as being able to biosynthesize verticillin A and its analogues (compounds 1-5) based on 
published dereplication protocols.90-91 Accordingly, the following strains were chosen for 
this study: MSX74391, MSX71844, MSX58124, MSX75296, MSX75281, MSX45374, 
MSX70777, MSX59553 and MSX79542 (Table 2S). In a previous study, fungal strains 
MSX59553 and MSX79542 were both identified as Clonostachys rogersoniana.90  
Identification of fungal strains 
The different MSX strains utilized in the present study were identified to the 
genus and/or species level using the fungal ITS region (ITS1-5.8S-ITS2) of the nuclear 
ribosomal operon, which was amplified with primer combination ITS5 and ITS4 with 
primers ITS5/ITS1F and ITS4.92-93 Methods for BLAST search in NCBI GenBank and 
Maximum Likelihood phylogenetic analysis, as utilized to identify fungal strains, have 
been detailed recently.94 The BLAST search and phylogenetic analysis using taxon 
sampling.95 revealed that MSX59553, MSX79542, MSX74391, MSX58124, MSX75296, 
MSX75281, MSX45374, and MSX70777 belong to the genus Clonostachys 
(Ascomycota, Hypocreales, Bionectriaceae), while MSX71844 was identified as 
Purpureocillium lavendulum (Ascomycota, Hypocreales, Ophiocordycipitaceae) (Figure 
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1S). Phylogenetic analysis using the ITS region also showed that strains MSX59553, 
MSX45374, MSX74391, MSX79542, MSX7077, and MSX 58124 had phylogenetic 
affinities with C. rogersoniana.96 Our results were in agreement with a recent genomic 
study identifying the biosynthetic gene clusters for verticillins in C. rogersoniana.32 As 
the ITS region alone is not informative to identify species in certain orders of the 
Ascomycota, including Hypocreales,97 future taxonomic and molecular phylogenetic 
studies will incorporate sequence data from protein-coding regions to more precisely 
identify species names for verticillin-producing strains.98 The sequence data were 
deposited in GenBank (accession numbers: KX845687, KX845688, MH421853, 
MH421854, MH421855, MH421856, MH421857, MH421858, MH421859, and 
MH421860).  
For verticillin producing strains, there has been some confusion on the fungal 
taxonomy.54 Earlier studies on the chemistry of verticillin analogues have identified the 
verticillin-producing fungi as belonging to the genera Gliocladium, Penicillium, and 
Verticillium.40-41, 46 The morphology of the flask shaped phailide in all three genera can 
be a cause of confusion for non-mycologists. Moreover, fungal taxonomic names have 
been rapidly changing due to the use of molecular sequence data in the past 20 years.94 In 
addition, the name Bionectria (sexual state) has been used previously in the literature for 
a fungal strain producing verticillin G;51 which was accurate, but the use of name 
Bionectria is now phased out due to the adoption of One Fungus = One Name,99-100 in 
accordance with the recent changes concerning pleomorphic fungi in the International 
Code of Nomenclature for algae, fungi, and plants. For pleomorphic names (sexual and 
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asexual) in the family Bionectriaceae, Rossman et al.101 have proposed the use and 
protection of the asexual morph (Clonostachys) rather than the sexual morph 
(Bionectria). Despite the adoption of the name Clonostachys, the subgenus Bionectria is 
still being used in the literature. Based on our recent identification of fungal strains that 
make verticillin and its analogues, we have identified two fungal genera, Clonostachys 
spp. and Purpureocillium lavendulum,102 that biosynthesize the 
epipolythiodioxopiperazine-type alkaloids.  
Media and fermentations 
For the analysis of fungal cultures in Petri dishes, seven types of agar media were 
used, and ingredients to make these were purchased from Difco, ACROS, and Research 
Products International (RPI): malt extract agar, potato dextrose agar, yeast extract soy 
peptone dextrose agar, Spezieller Nährstoffarmer agar, Sabouraud dextrose agar, potato 
dextrose mushroom and oatmeal agar (See Table 1S for compositions). A small piece 
(~0.5 cm2) of fresh culture grown on potato dextrose agar was cut from the leading edge 
of 2-week old colony from strains MSX59553 and MSX79542 and was used to inoculate 
various types of agar media in duplicate, respectively. The plates were then incubated at 
room temperature until the cultures showed good growth as noted by the expansion of the 
colony over the surface of the medium (~3 to 4 weeks).  
Rice fermentations [(1:1 commercial white rice (variety: Carose Botan; 5 g) and 
(variety: Sona Masoori; 5 g)] were prepared by adding 10 g of rice to a Petri dish or a 250 
mL flask with 25 mL of DI-H2O, followed by autoclaving at 221 °C for 30 min. Oatmeal 
media (Old fashioned Quaker oats) was prepared using 10 g of rolled oats and ~17 mL of 
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DI-H2O, followed by autoclaving at 221 °C for 30 min. The flasks containing the rice or 
oatmeal media were inoculated with a seed culture grown in 10 mL of YESD broth media 
(2% soy peptone, 2% dextrose and 1% yeast extract) for about 5 days with agitation (100 
rpm) at room temperature. The inoculated cultures were grown at room temperature for 
~4 to 5 weeks, except for the time progression studies, where each duplicate of the 
oatmeal culture was extracted every few days, from days 2 to 35. Strains were scaled-up 
in a similar way, using 2.8 L Fernbach flasks (Corning, Inc., Corning, NY, USA). The 
medium was prepared using 150 g of either rice or oatmeal, with 300 mL or 250 mL of 
DI-H2O added for rice medium and oatmeal medium, respectively, and both sterilized at 
221 °C for 30 min. In addition, and as noted in more detail in the supplement (Figure S7), 
augmenting the oatmeal media with amino acids was also examined. However, this did 
not result in significant differences in the biosynthesis of verticillins, and thus, this line of 
inquiry was not pursued further. 
Extraction of fungal cultures 
Each culture was chopped with a spatula to ensure thorough extraction. For the 
cultures grown on Petri dishes, the chopped pieces were transferred into 150 mL flasks. 
Solutions of 60 mL of 1:1 chloroform:methanol (CHCl3:MeOH) were poured in each 
flask, followed by overnight shaking (100 rpm) at room temperature. The cultures were 
filtered by vacuum, and then the filtrates were mixed with 90 mL of CHCl3 and 150 mL 
of H2O and stirred for 30 min. The mixtures were transferred into a separatory funnel, 
where the bottom organic layer was evaporated in vacuo and reconstituted with 100 mL 
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of 1:1 acetonitrile:methanol (CH3CN:MeOH) and 100 mL hexanes. Again, the defatted 
organic layers were collected and evaporated in vacuo. 
In situ analysis of fungal metabolite profiles via the droplet probe coupled with 
UPLC-PDA-HRMSMS/MS 
The use of the droplet probe with fungal cultures has been detailed previously 89 
and several examples have been published.103-107 A CTC/LEAP HTC Pal auto-sampler 
was converted to a droplet probe with assistance from colleagues at Oak Ridge National 
Laboratories.108-109 Microextractions (3-5 µL) were performed on precise spots directly 
on fungal cultures using a 1:1 solution of MeOH:H2O. The extractions were injected onto 
a UPLC, and the chromatographic method followed previous protocols 91 used in the 
dereplication of fungal extracts. A Waters Acquity UPLC system was used with a BEH 
C18 column (Waters; 50 mm x 2.1 mm x 1.8 µm) heated to 40 °C and a mobile phase 
using a gradient from 15% to 100% CH3CN; the other solvent was 0.1% formic acid-
H2O. The run utilized a flow rate of 0.3 mL/min for 10 min. UV data were collected from 
190 to 500 nm and the eluent was split into a Thermo Fisher Scientific Q Exactive Plus 
mass spectrometer via electrospray ionization (ESI). MS data were collected from 150-
2000 m/z at a resolution of 70,000 while alternating between positive and negative 
modes. MS/MS was performed with an HCD value of 35, and Xcalibur software was 
used for the primary analysis.  
Analysis of fungal metabolite profiles via UPLC-PDA-HRMSMS/MS 
Extracts of the plates and flasks were dissolved separately in 1:1 MeOH:dioxane 
to elaborate concentrations of 2.5x10-2, 0.5 or 2.0 mg/mL; 3 μL were injected directly 
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onto the UPLC-PDA-HRMSMS/MS system. In addition to HRMS and MSMS data, 
retention times and UV data were used as mutually supportive data.  The relative peak 








































































































































































Figure 4. Structures of Verticillin A and Related Analogues. Compounds 1-5 were the 





Results and Discussion 
Different fungal strains biosynthesize distinct patterns of verticillin analogues  
The dereplication protocol was used to identify fungal strains that produced 
verticillins 91 (Table 2S). Extracts of suspected verticillin producing strains from our 
library were screened using UPLC-HRMS, revealing a higher production of verticillin 
analogues within the organic extracts of both strains MSX59553 and MSX79542 (Figure 
5). The graph shows the relative percentage of the targeted verticillin analogues as 
measured in triplicate. In order to more accurately compare the total production of the 
secondary metabolites, the calculations were normalized to the largest value and 
multiplied by the total mass of the defatted organic extract of each strain. Interestingly, 
some strains produced higher amounts of verticillin D (8) but only low levels of 
verticillin A (1) and related analogues (and vice versa), suggesting that the biosynthetic 
pathway for these analogues were somewhat different, even though the fungi were 





Figure 5. Relative Production of Various Verticillin Analogues grown on rice for four 
weeks across ten different fungal strains as measured by LC-HRMS in three replicates. 
Strains MSX59553 and MSX79542 demonstrated the highest relative biosynthesis of the 
targeted verticillin analogues (compounds 1-5). Interestingly, specific strains (such as 
MSX75296 and MSX75281) showed the biosynthesis of higher amounts of verticillin D 
(8), corresponding to low to minimal production of the other analogues. 
 
 
Use of the droplet probe for in situ chemical analysis to optimize the production of 
verticillins 
Optimization of fermentation parameters is a well-established approach to 
enhance the yield of compounds biosynthesized by microorganisms.110-111 The alteration 
of media parameters had an important role in varying the biosynthesis of secondary 
metabolites in numerous fungal strains.112-115 In most cases investigations of optimal 
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fermentation conditions are targeted for specific active compounds, such as 
antibiotics.116-118 
Toward this end, the variation of culture media showed the most immediate 
results. A visual difference in the growth of the two fungal strains (MSX59553 and 
MSX79542) was noted (Figure 6). Guttates, which we and others hypothesize 
concentrate secondary metabolites,103, 119-121 were noted when these were grown on Oat-
A, YESDA, and PD-mushroom agar (Figure S6), but not found on the fungi grown on the 
other nutrient media.   
During this study solid media were chosen over submerged liquid media, despite 
the advantages of the latter in offering control over the fermentation parameters and the 
simplification of scale up for industrial purposes.122 Pragmatically, we do not have the 
facilities for large-scale liquid fermentation, and moreover, liquid media for the 
production of verticillins did not show promise in the literature.45-46, 51 Furthermore, the 
chemistry of the cultures grown on solid media could be studied readily in situ via the 
droplet probe. In addition, solid fermentation is closer to the natural habitat of fungi, 
offering the mycelium a support for growth 123 and permitting better oxygen circulation 
than can be achieved by the high viscosity of liquid fermentation.124 Previous 
comparative studies showed a notably higher productivity of pure compounds when 
microorganisms were grown on solid media, in comparison to liquid cultures.116, 125-129 









     























Figure 6. Top: Photos of Strains MSX59553 (top) and MSX79542 (bottom). These fungal cultures were grown on 
SDA, PD-mushroom, Oat-A, SNA and PDA(A)/ MEA(B)/ YESDA (C) (from left to right respectively) for four weeks. 
Fungal growths were morphologically distinct based on media, and guttates were observed only on cultures grown on 
PD-mushroom and Oat-A. Bottom: Relative Biosynthesis of Verticillin Analogues via Droplet Probe Directly from 
the Surface of the Strains MSX59553 (bottom left) and MSX79542 (bottom right).
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The in situ microextractions by droplet probe were analyzed by UPLC-HRMS to 
identify the targeted verticillin analogues in each culture. Previously, a dereplication 
strategy 89 demonstrated the effectiveness of direct identification of secondary 
metabolites from cultures grown in Petri dishes. The peak areas of targeted compounds 
were averaged to build graphs (Figure 6). For each culture condition, three sampling 
points were acquired on duplicate plates (n=6). However, error bars were not calculated 
for two reasons. First, the three different spots represent different fungal growth stages, 
essentially oldest to youngest when sampling radially from the center. Also, the fungal 
growth morphology on each media had different traits, such as guttates (liquid droplets) 
or mycelium (filamentous hyphal growth). Due to this inherent biological variability, the 
recovery of the 5 µL droplet during microextraction was not always precisely the same 
(Figure 2S). 
The targeted secondary metabolites (Figure 4) were eluted within a retention time 
windows of 5.30-6.30 min on the 10 min gradient method. Parameters such as retention 
time, UV profile, mass range within 5 ppm, and fragmentation patterns were used to 
identify the structurally related analogues.90 The production of these compounds was 
compared by measuring the percentage of the relative production of each compound 
normalized to the largest value. The biosynthetic profile varied according to the 
respective growth media. Both strains showed essentially zero to slight production of 
verticillin analogues in SDA, SNA, MEA and PDA media. Interestingly, a recent study 
on the gene clusters of verticillin biosynthesis noted PDA as a condition where the genes 
for biosynthesis were not expressed,32 our phenotypic data (i.e. secondary metabolites) 
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were supportive of their genotypic data. Of all the conditions examined, Oat-A was the 
most productive for verticillin biosynthesis in MSX79542 (Figure 6). Similar results were 
observed with Oat-A in strain MSX59553, although two other media also showed 
promise (YESD and PD-mushroom). 
Production of the targeted secondary metabolites verified by quantification via 
UPLC-HRMS  
We next evaluated the production of verticillins on Oat-A vs. readily available 
substrates, such as breakfast oatmeal and rice (Figure 3S). The UPLC-HRMS analysis of 
the in situ microextraction on the surface of the three media via the droplet probe were 
plotted as the relative percentages of the peak normalized according to the compound 
with highest production (Figure 7 A & B). These results revealed a higher production of 
the targeted secondary metabolites on oatmeal and Oat-A media compared to the rice. For 
strain MSX79542, cultures grown on Oat-A showed the highest production, as the fungus 
expressed guttates (Figure 6S), which have been shown to be concentrated in secondary 
metabolites.119-120  
The cultures on Oat-A did not grow as three-dimensional as those grown on rice 
or breakfast oatmeal. We hypothesized that the three-dimensional character may be 
beneficial for total verticillin production and thus, the same in situ microextracted Petri 
dishes were extracted in their entirety, and oatmeal and rice had the highest extract 
amounts (Figure 4S). The peak areas of the compounds of interest were calculated in 
their respective total defatted mass of the extract. Then, those numbers were normalized 
according to the compound of highest production to give a more accurate comparison of 
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the different profiles of verticillin biosynthesis. Regular oatmeal demonstrated the highest 
amounts of the targeted secondary metabolites (Figure 7 C & D). 
 
 
Figure 7. Relative Production of Verticillin Analogues via Droplet Probe Directly 
from the Surface of Strains MSX59553 (A) and MSX79542 (B) Grown for Four 
Weeks. Oatmeal agar showed a higher amount of analogues, likely due to the formation 
of guttates on the surface of the culture. The same cultures grown on the Petri dishes, and 
used previously for the droplet probe analysis, were fully extracted and then analyzed via 
UPLC-HRMS to generate graphs (C) and (D), which represent the relative total 
production of verticillin analogues by strains MSX59553 and MSX79542, respectively. 
The relative percentages were normalized by multiplying the peak areas by the weight of 
their corresponding organic extracts (Fig 2S supplementary information). The results 
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In order to make a more accurate comparison and quantify the amounts of 
verticillins from the organic extracts of the two strains MSX59553 and MSX79542, 
cultures were fermented in three biological replicates using rice and oatmeal for 
comparative purposes. Oat-A was excluded from this comparison because the agar media 
forces the fungus to grow mainly on the surface of the culture, and that contributed to a 
low extract weight compared to the other cultures grown for the same amount of time 
(Figure 4S). 
Verticillin amounts were calculated via UPLC-HRMS calibration curves prepared 
using purified analogues. To determine the amounts of verticillin analogues produced in 
mg per flask of growth, the previous numbers were multiplied by the defatted extract 
mass of each flask. The defatted weights of organic extracts were higher in the strain 
grown on oatmeal than when it was grown on rice (Figure 5S). Both fungal strains 
demonstrated the ability to produce higher amounts of verticillin analogues when grown 
on oatmeal compared to the rice media. Also, using one way ANOVA, strain MSX59553 
expressed significantly higher amounts of secondary metabolites when grown on oatmeal 
than the same strain grown on rice or strain MSX79542 grown on either rice or oatmeal 
(P < 0.005) (Figure 8 B & C). 
 
42 
Figure 8. The Amounts of the Secondary Metabolites of Interest in mg Present in 
Each Culture of Strains MSX59553 and MSX79542. These cultures were grown on 
rice or oatmeal media for four weeks in three biological replicates (A). The quantity of 
Sch52901 (2), the verticillin analogue produced in the highest amount by the fungal 
strains was calculated per flask. The data plotted are means + SD of three biological 
replicates per medium and per strain. The quantity of 2 produced by strain MSX59553 
grown on oatmeal showed a significant difference relative to the same strain grown on 
rice and also compared to strain MSX79542 grown on oatmeal and rice respectively (** 
P < 0.004, *** P < 0.0003) (B). Similarly the sum of all verticillin analogues showed a 
significant difference between the oatmeal culture of strain MSX59553 and the other 
growth conditions (** P < 0.005, *** P < 0.0003) (C). 
 
MSX59553                                      MSX79542 
 





The extraction and isolation of verticillin analogues from strain MSX59553 
grown on a large scale on rice versus that on oatmeal for the same amount of time (5 
weeks) was compared. When fermenting on oatmeal, there was a yield of 67.3 mg of 
verticillins 1-5 per g of extract (with a total weight of pure verticillin analogues isolated 
being 174.8 mg). Alternatively, when rice was used as a medium, there was 63.3 mg of 1-
5 per g of extract (with a total weight of 107.6 mg of purified verticillins). Growth of this 
fungal culture on oatmeal or rice showed enhanced production of the verticillins, 
substantially exceeding what had been reported in the literature to date.  
Profile of secondary metabolites based on different growth times  
Duplicate cultures of MSX59553 grown on oatmeal were sampled over 5 weeks 
to investigate the effect of incubation time on production of secondary metabolites. The 
amount of verticillin A was calculated from a calibration curve after injecting 0.025 
mg/mL of the extract of each flask. This preliminary amount was multiplied by the total 
mass of the defatted organic extract to normalize the results (Figure 9). The production of 
verticillins increased up to day seven, after which the production of verticillins plateaued 
by day 22. Interestingly, a decrease of verticillin A was noticed after day 22 until day 35, 
which was notable since fungal cultures are routinely grown for approximately 4 weeks 
in laboratory settings. Thus, our study showed that an average of 11 days was enough 
time for the biosynthesis, which shortened turnaround time for the scaled-up production 




Figure 9. Amounts of Verticillin A (mg) Produced by MSX59553 per Flask Growth During 
a Period of 35 Days. The cultures were extracted then analyzed using UPLC-HRMS. The 
compound accumulated up to 22 days and then was apparently destroyed after longer incubation 
times (presumably, as the stationary growth phase ended). These data are means ± SD of two 




The verticillins are a class of fungal metabolites whose biological activity against 
a suite of anticancer assays has stimulated recent interest. However, our challenge was to 
supply them on a large enough scale, so as to facilitate further preclinical studies. This 
study showed that fermentation on Quaker oatmeal significantly enhanced the 
biosynthesis of verticillin analogues in strain MSX59553; whereas we once could isolate 
about 10 mg after about 5 weeks of growth on rice medium, we can now produce about 
20 mg in 11 days on oatmeal medium. To examine a suite of fermentation conditions 
efficiently, we demonstrated the use of the droplet probe to measure the chemistry of 
fungal cultures in grown in Petri dishes in situ. Parallel studies of extracts from those 
Petri dishes using a more traditional natural products extraction approach followed by 




























reliability of chemical results from droplet probe analyses. For laboratory-scale 
production, we are confident that a version of the described procedures could be used to 
supply verticillins on the single to multi-gram scale. However, further research, 
potentially exploring a suite of options, ranging from liquid fermentations to semi- and/or 
total synthesis, may be required should the need for kg quantities arise.  
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ENGINEERING FLUORINE INTO EPIPOLYTHIODIOXOPIPERAZINE 
ALKALOIDS (VERTICILLINS) VIA PRECURSOR DIRECTED BIOSYNTHESIS 
This chapter is intended for submission to Organic Letters and is presented in that 
style. Coauthors will include Long, J. L., Raja, H. A., Kurina, S., Burdette, J. E., 
Pearce, C. J., and Oberlies, N. H. 
 
 
 Fluorine and nitrogen have similar natural abundances, yet only 12 secondary 
metabolites (five compound classes) have been discovered that include a fluorine, and 
none were fungal derived.131-132 Interest in the fluorination of drug leads started in the 
1950’s after the success of 9-α-fluorohydrocortisone,133 and this was followed by 5-
fluorouracil, which is still used in chemotherapy.134-135 The introduction of even a single 
fluorine often enhances pharmacological properties,131, 136 such as potency, pKa, 
membrane permeability, metabolism, and pharmacokinetics.137-139 Fluorinated 
compounds increased from 2% of marketed drugs in the 1970’s to approximately 20-30% 
today.138, 140 Notably, more than 30% of the most prescribed drugs contain fluorine,140 
including fluoxitine141 (Prozac), ciprofloxacin142-143 (Ciprobay), sitagliptin144 (Januvia), 
and rosuvastatin (Crestor), which was the 13th most prescribed drug in 2013, surpassing 
its fluorinated predecessor, atorvastatin (Lipitor).145 
Despite the advantages of fluorination, its incorporation in natural product derived 
drug leads is challenging.146 Several strategies have been developed toward synthetic and 
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semisynthetic methods for selective fluorination.147-148 However, this remains difficult in 
structurally complex natural products, which can be sensitive to degradation.149 
As an alternative, precursor-directed biosynthesis harnesses the biosynthetic 
machinery of a microorganism by introducing analogous building blocks to those used 
naturally.149-151 For example, incorporating fluorinated amino acids into culture media of 
the fungus Beauveria bassiana resulted in analogues with cytotoxicity against metastatic 
prostate cancer cells.152 Another example was flurithromycin, a fluorinated analogue of 
erythromycin with improved bioavailability and longer half-life.153-154 Recently, this 
technique was used for biosynthesizing fluorinated peptaibols.155 
Given the potential benefit of fluorinating lead natural products, we applied this 
approach to the verticillins (1-3), fungal metabolites also termed 
epipolythiodioxopiperazine (ETP) alkaloids.26 Verticillin A (3)40 and its conjurers showed 
nanomolar cytotoxicity against a panel of cancer cell lines.34, 38, 45, 74 Compound 3 is a 
selective histone methyltransferases (HMTases) inhibitor.35 In pancreatic cancer, 3 
inhibited the methyltransferase enzyme MLL1 with an IC50 value of 0.8 µM resulting in 
demethylation of histone H3K4me3, consistent with a decrease of PD-L1 (programmed 
death ligand 1) expression. In vivo orthotropic tumors in mice transplanted with either 
PANC02-H7 or UN-KC-6141 cells had significantly smaller tumor size when treated 
with a combination of 3 and anti PD-L1.70 In a separate study, a combined treatment of 3 
and 5-fluorouracil in a murine model of metastatic colon carcinoma exhibited 
significantly smaller tumors compared to control.35 In total, 3 has shown promise in both 
in vitro and in vivo cancer models. 
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Several ways to fluorinate verticillins could be envisaged. The Movassaghi group 
has made impressive progress on the synthesis of ETPs. However, they reported the total 
synthesis of 11,11ʹ-dideoxyverticillin A, lacking key OH moieties.62, 66 Semisynthesis 
could suffer from disulfide bridge integrity under the fluorination conditions, resulting in 
a loss of activity.65 Taking into consideration the increasing interest in verticillin 
pharmacology, their amino acid composition and how that fits with NRPS biosynthesis,42, 
156 and the ability to scale their production via fermentation,33 we hypothesized that 
verticillins were ideal candidates for precursor-directed biosynthesis by providing 
fluorinated 5-F-DL-tryptophan (5-F-DL-Trp) to the fungus Clonostachys rogersoniana 
(strain MSX59553).  
Strain MSX59553 was grown on oatmeal agar (OMA) with a racemic mixture of 
5-F-Trp (375 ppm, Figure S9). Those cultures were analyzed in situ via a droplet probe 
coupled to a UPLC-PDA-HRESIMS-MS/MS system.33, 89, 103, 106, 109 The microextraction 
of the culture surface (control vs fluorinated medium) displayed characteristic peaks for 
verticillin H (1) [m/z 725.1345 ([M + H]+)], Sch 52901 (2) [m/z 711.1185 ([M + H]+)], 
and verticillin A (3) [m/z 697.1030 ([M + H]+)]. In addition, in the medium containing 5-
F-DL-Trp, several peaks for analogues were detected. The substitution of F into the 
verticillins increased the molecular ion by 17.99 amu for monofluorination, as noted by 
m/z 743.1249, 729.1090, and 715.0933, corresponding to the incorporation of a 
fluorinated Trp unit in the biosynthesis of 1-3, respectively.  Additionally, peaks that were 
shifted by twice 17.99 amu [i.e. m/z 761.1161, 747.0997 and 733.0856] were observed, 
indicating difluorination into the same three molecules, respectively (Figures S6-S8). 
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To isolate material for structural characterization and bioassay, the same strain 
was grown on OMA containing 5-F-DL-Trp (375 ppm). This culture was subjected to a 
couple transfers to the same fluorinated medium, allowing the microorganism to adapt. 
Then, the strain was cultured on oatmeal, since it was optimal for lab scale production of 
verticillins.33 The growth flasks were supplemented with 500 ppm 5-F-DL-Trp (Figure 
S4\9), since this concentration was optimal for introducing fluorinated amino acids into 
peptaibols.155 
After 28 days of fermentation, the HRESIMS data of the organic extract of the 
culture confirmed incorporation of 5-F-Trp in 1-3 on one or both sides of the dimeric 
verticillins. Natural product purification yielded seven fluorinated analogues: 9-F-
verticillin H (4), 9-F-Sch 52901 (5), 9ʹ-F-Sch 52901 (6), 9-F-verticillin A (7), 9,9ʹ-diF-
verticillin A (8), 9,9ʹ-diF-verticillin H (9) and 9,9ʹ-diF-Sch 52901 (10). The 
monofluorinated analogues were in a ratio of about 1:10 relative to the parents; 
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Figure 10. Structures of Verticillins (1-3) and the Fluorinated Analogues (4-10) 
Obtained via Precursor-Directed Biosynthesis. 
 
 
Compounds 1-10 were purified as light-yellow amorphous powders. The 
structures of compounds 1-3 were established by favorable comparisons of the 
HRESIMS and 1D NMR data to literature.34, 45 The protonated molecular ion [M + H]+ of 
compounds 4-7 were noted at m/z 743.1231, 729.1071, 729.1064 and 715.0908 
respectively. These data corresponded to a gain of 17.99 amu relative to the parents, 
indicating the replacement of a proton by a fluorine and representing the formulae: 
C32H31FN6O6S4 (4), C31H29FN6O6S4 (5), C31H29FN6O6S4 (6) and C30H27FN6O6S4 (7).  
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The structures of 4-8 were characterized via 1D and 2D NMR data, including 19F 
NMR spectra (Figures S12-S41). The non-fluorinated parents (i.e. 1 and 3) of 4 and 7, 
respectively, are symmetrical dimers and became asymmetric via monofluorination 
(Figure 11). This was evident in the aromatic region (δH 6.5-8.0 ppm), where H-7, H-7ʹ, 
H-8, H-8ʹ, H-10 and H-10ʹ resonated as individual peaks (Figures S13 and S33), and the 
H-9 signal was replaced by fluorine. Compound 2 is asymmetric, and thus 
monofluorination resulted in two possible analogues (5 and 6), whose aromatic protons 
exhibited distinct patterns, and as with 4 and 7, proton H-9 (in 5) or H-9ʹ (in 6) were 




Figure 11. Comparison of the 1H NMR Spectra of Verticillin H (1), 9-F-verticillin H 
(4), and 9,9ʹ-di F-verticillin H (9). All spectra were recorded in CDCl3 at 500 MHz.  
 
 
While in lower abundance, the characterization of the difluorinated analogues 
followed similar logic. For example, compounds 8-10 with m/z 733.0826, 761.1135 and 
747.0983 respectively, demonstrated a gain of 35.99 amu relative to their parents (1-3), 
corresponding to C30H26F2N6O6S4 (8), C32H30F2N6O6S4 (9) and C31H28F2N6O6S4 (10). In 
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the aromatic region of the 1H NMR spectra of 8 and 9 (Figure 11, S39 and S44) 
symmetry was evident, comparable to 3 and 1, while 10 remained asymmetric. Signals 








































Table 2. 1H NMR Data for 4-10 in CDCl3. [700 MHz for 4-8 and 500 MHz for 9-10].  
 
Position δH, mult (J in Hz) (4) (5) (6) (7) (8) (9) (10) 
1 - - - - - - - 
3 - - - - - - - 
4 - - - - - - - 
5a 5.68, s 5.67, s 5.70, s 5.67, s 5.65, s 5.66, s 5.66, s 
6a - - - - - - - 




























9 - - 6.81, td 
(7.7, 1.0) 
- - - - 














10a - - - - - - - 
10b - - - - - - - 
11 5.16, s 5.15, s 5.15, s 5.14, s 5.13, s 5.15, s 5.14c, s  
11a - - - - - - - 
12 3.02a, s 3.02, s 
3.01, s 
3.03, s 3.01a, s  3.01, s 3.04, s 3.02d, s 


















 - 1.26, t 
(7.1) 
1.26, t (7.0) 
6-NH 5.05, s 5.05, s 5.15, s 4.99, s 5.01, s 5.66, s 5.05e, s,  
11-OH 5.59, s 5.59, s 5.63, s 5.69, s 5.76, s 5.07, s 5.66f, s 
1ʹ - - - - - - - 
3ʹ - - - - - - - 
4ʹ - - - - - - - 
5aʹ 5.70, s 5.70, s 5.68, s 5.69, s 5.65, s 5.66, s 5.66, s 
6aʹ - - - - - - - 
































- 6.82, td 
(7.7, 1.0) 
- - - 














10aʹ - - - - - - - 
10bʹ - - - - - - - 
11ʹ 5.14, s 5.13, s 5.13, s 5.12, s 5.13, s 5.15, s 5.15c, s 
11aʹ - - - - - - - 
12ʹ 3.03a, s 3.01, s 2.99, s 2.99a, s  3.01, s 3.04, s 3.04d, s 
13ʹ 2.17, m, 
2.38, m 
1.90, s 1.89, s 1.88, s, 
1.90, s 
1.91, s 2.19, m, 
2.39, m 
1.91, s 
14ʹ 1.22b, t 
(7.2) 
   - 1.26, t 
(7.1) 
 
6ʹ-NH 5.15, s 5.10, s 4.99, s 5.10, s 5.01, s 5.66, s 5.07e, s 
11ʹ-OH 5.64, s 5.74, s 5.70, s 5.73, s 5.76, s 5.07, s 5.77f, s 
a-f Assignments may be interchangeable   
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19F NMR experiments are beneficial for such studies,157 and 1H-19F couplings 
were supportive of the structural assignments. The 1H NMR spectra of compounds 4-7 
(Table 2) showed resonances for seven aromatic protons in the range of 6.58-7.84 ppm, 
and three of those were coupled with the fluorine on the same ring system (Figures S17, 
S23, S30 and S37). Difluorinated 8-10 demonstrated only six signals in the aromatic 
region of the 1H NMR spectra with similar J values for 1H-19F couplings (Figures S43, 
S46 and S49).  
The characterization of 4-10 was supported by 2D NMR data (COSY, HSQC and 
HMBC, Tables S6-12). The position of fluorine was confirmed by the 2JCH and 3JCH 
HMBC correlations between the protons on the fluorinated benzene ring and C-9, which 
was a doublet due to 13C-19F coupling (δc 157.6 ppm, J=235.3-236.9 Hz). As with the 1H 
NMR data, the 13C NMR spectra displayed a loss of symmetry for 4 and 7. Six carbon 
doublets were observed in the aromatic region (111.1-157.6 ppm), confirming the 
incorporation of fluorine. Moreover, in the 19F NMR experiment, the δF values were in 
the same range -123.2 to -123.0 ppm with a similar coupling pattern (td), consistent with 
the pattern observed in the fluorinated building block (δF -124.9 ppm, Figure S51). In 
addition, 19F-HMQC data demonstrated a clear correlation of the fluorine with the 
doublet carbon at C-9 or C-9ʹ (Figures S18, S24, S31, S38 and S52). Due to the 
symmetry in 8 and 9, one peak with a td splitting pattern was observed in the 19F NMR 
spectra (Figures S43 and S46). Alternatively, 10 showed two overlapping peaks (td) at -
122.9 ppm due to asymmetry (Figure S49). Importantly, the HMBC data showed a 3JCH 
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correlation between the aromatic proton H-7 and the doublet carbon peak at δc ~158 ppm 
in 8-10.  
HRESIMS/MS experiments were used to distinguish between the incorporation of 
the fluorine into 5 vs 6, since those compounds were asymmetric. The fragmentation of 
these resulted in m/z 380.0555 and m/z 348.0452 for 5, and m/z 362.0608 and 366.0388 
for 6, as predicted (Figures S24 and S31). 
 
Table 3. 13C NMR Data for 4-8 in CDCl3. [175 MHz]. 
 
Position δC, mult (J C-F coupling in Hz)  
(4) (5) (6) (7) (8) 
1 167.1 167.1 167.1 166.1 166.0 
3 77.4a 77.5 77.4 73.0a 73.0 
4 161.4 161.4 161.4 162.2 162.3 
5a 82.0 82.0 81.9 82.0 81.9 
6a 144.9, d (1.3) 144.9, d (1.1) 148.7 144.8, d (1.2) 144.8 
7 111.1, d (8.5) 111.1, d (8.5) 110.8 111.2, d (8.6) 111.3, d (8.3) 
8 116.6, d (24.5) 116.6, d (23.6) 130.1 116.6, d (24.7) 116.7, d (23.9) 
9 157.6, d (235.6) 157.6, d (236.3) 120.5 157.6, d (236.2) 157.6, d (236.9) 
10 115.5, d (25.4) 115.5, d (25.7) 128.2 115.5, d (25.5) 115.6, d (26.6) 
10a 130.8, d (8.5) 130.8, d (8.6) 128.9 130.8, d (8.6) 130.4, d (8.7) 
10b 65.9, d (1.9) 65.9, d (1.9) 65.6 66.0, d (1.6) 65.8, d (1.6) 
11 83.8 83.7 83.0 83.6 83.4 
11a 76.6 76.6 76.7 76.4 76.2 
12 28.0 28.0 28.0 27.20 a 27.2 
13 24.6 a 24.5 24.6 17.4 17.5 
14 9.9 a 9.8 9.8 - - 
1ʹ 167.1 166.1 166.1 166.1 166.0 
3ʹ 77.5 a 72.9 73.0 72.9 a 73.0 
4ʹ 161.4 162.3 162.3 162.3 162.3 
5aʹ 81.9 81.9 82.0 81.9 81.9 
6aʹ 148.8 148.7 144.8, d (1.4) 148.6 144.8 
7ʹ 110.8 110.8 111.2, d (8.5) 110.8 111.3, d (8.3) 
8ʹ 130.1 130.2 116.6, d (23.8) 130.1 116.7, d (23.9) 
9ʹ 120.5 120.5 157.6, d (236.0) 120.5 157.6, d (236.9) 
10ʹ 128.2 128.3 115.6, d (25.5) 128.2 115.6, d (26.6) 
10aʹ 128.9 128.9 130.8, d (8.6) 128.9 130.4, d (8.7) 
10bʹ 65.5 65.6 66.0 d (1.9) 65.7 65.8, d (1.6) 
11ʹ 83.0 82.8 83.6 82.8 83.4 
11aʹ 76.7 76.4 76.3 76.3 76.2 
12ʹ 28.0 27.2 27.2 27.18 a 27.2 
13ʹ 24.5 a 17.5 17.5 17.423 17.5 
14ʹ 9.8 a - - - - 
a Assignments may be interchangeable   
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The NRPS pathway is characterized by the presence of epimerization domains to 
catalyze the conversion of L amino acids into D amino acids and vice versa,158-159 
suggesting the possible incorporation of both 5-F-Trp enantiomers. The proposed 
biosynthesis of diketopiperazine rings in gliotoxin,160 and a study of acetylaranotin,161 
shows that the configuration at the α carbon of Trp is lost via hydroxylation followed by 
dehydration . To test this, two biological replicates were analyzed using 5-F-D-Trp, 5-F-
L-Trp or 5-F-DL-Trp doped separately into OMA media, along with a control. In situ 
analysis via droplet probe demonstrated signals for 1-3 in the control, and in all three 
fluorination experiments, signals for 1-10 were observed (Figures S53-S58). Mutually 
supportive data was noted by traditional natural products extraction of the same plates via 
measuring relative peak areas of 1-10 (Figure S59). As expected based on previous 
studies,155 the highest incorporations were observed with 5-F-L-Trp. 
The cytotoxicity of 1-10 was assessed against three cell lines: melanoma (MDA-
MB-435), breast (MDA-MB-231) and ovarian (OVCAR3) cancers.34, 162-163 The 
fluorinated analogues were with similar potency to the parent compounds, with IC50 
values ranging from 30 to 900 nM (Table 4). This indicated that fluorination did not 
negatively impact cytotoxicity, at least in vitro. Studies are planned to examine these 










Table 4. Cytotoxicity of Compounds 1-10. 
 
Compound IC50(nM) MDA-MB-231 OVCAR 3 MDA-MB-435 
Verticillin H (1) 71 101 88 
Sch 52901 (2) 22 30 30 
Verticillin A (3) 43 37 37 
9-F-Verticillin H (4) 46 39 49 
9-F-Sch 52901 (5) 37 37 39 
9ʹ-F-Sch 52901 (6) 70 104 72 
9-F-Verticillin A (7) 230 181 237 
9,9ʹ-di F-Verticillin A (8) 59 75 65 
9,9ʹ-di F-Verticillin H (9) 844 919 826 
9,9ʹ-di F- Sch 52901 (10) 105 175 127 
Taxol (control) 166 5 0.4 
MDA-MB-435: Human melanoma cancer cells, OVCAR3: Human ovarian cancer cells, 
MDA-MB-231: Human breast cancer cells. 
 
 
This is the first study using a precursor-directed biosynthetic approach to generate 
analogues of verticillins and is the first report of fluorination in any manner. Importantly, 
these compounds displayed nanomolar cytotoxicity in vitro. As observed via in situ 
monitoring of the fungal cultures, the incorporation of 5-F-L-Trp was higher than 5-F-D-
Trp, but a racemic mixture was used for cost effectiveness and because the configuration 
at the α carbon was likely ablated during biosynthesis. In addition to the medicinal 
chemistry advantages that a fluorinated analogue might present, these non-natural natural 
products may be patentable, which is a current challenge in natural products research.164 
Experimental Section 
General experimental procedures 
All solvents were obtained from Fisher Scientific and used without further 
purification. The 5-F-DL-Tryptophan was purchased from Acros Organics, 5-F-D-
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Tryptophan and 5-F-L-Tryptophan were purchased from Biosynth® NMR data were 
collected in CDCl3 using either a JEOL ECA-500 NMR spectrometer (JEOL USA, Inc.) 
operating at 500 MHz for 1H, 470 MHz for 19F and 125 MHz for 13C, an Agilent 700 
MHz NMR spectrometer (Agilent technologies, Inc., Santa Clara, CA, USA) operating at 
700 MHz for 1H and 175 MHz for 13C, or a Bruker AVANCE III 600 (Bruker Corp., 
USA) operating at 600 MHz spectrometer for 1H and 150 MHz for 13C. Chemical shift 
values were referenced to the residual solvent signals for CDCl3 (δH 7.25 and δC 77.2) 
and conveyed in δ ppm; multiplicity was showed as: s = singlet, d = doublet, t = triplet 
and m = multiplet; coupling constants were reported in Hz. HRESIMS data were obtained 
using Thermo QExactive Plus mass spectrometer (Thermofisher, San Jose, CA, USA) 
with an electrospray ionization source. The higher energy dissociation (HCD) used a 
normalized energy of 30 eV for all the compounds to obtain MS/MS data. Droplet probe 
analysis for the in situ detection of the biosynthesis of secondary metabolites in fungal 
cultures was performed using a droplet-LMJ-SSP coupled with a Waters Acquity ultra 
performance liquid chromatography (UPLC) system (Waters corp.) coupled with a 
Thermo QE Plus via procedures described previously.88-89, 103-106, 109 Microextractions 
were performed using a droplet of 1:1 MeOH:H2O. Three different spots were extracted 
in triplicate by delivering 5 µL of the solvent from a syringe to the surface of the culture 
then aspiring it back after ~2 sec of interaction to be injected into the UPLC-MS system. 
The UPLC separation was performed using an Acquity BEH C18 column (50 mm x 2.1 
mm i.d., 1.7 µm) equilibrated at 40 ºC and a flow rate set at 0.3 mL/min. The mobile 
phase comprised a linear gradient CH3CN/H2O with 0.1% HCOOH starting at 15% 
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CH3CN to 100% over 8 min. The mobile phase was held for another 1.5 min at 100 % 
CH3CN before going back to the starting conditions. Flash column chromatography was 
carried out with a Teledyne ISCO combiflash Rf connected to ELSD and PDA detectors 
with UV detection set at 200-400 nm with a specific wavelength set at 300 nm. The 
HPLC separation was achieved using Varian ProStar HPLC system connected to a 
ProStar 335 photodiod array detector (PDA) with UV detection set at 240 nm and 300 
nm. Preparative normal phase HPLC purification of samples was performed on a silica (5 
µm; 250 x 21.2 mm) column using a flow rate of 21.24 mL/min of a mobile phase 
consisting of EtOAc and Hexanes. Optical rotation data were acquired on a Rudolph 
Research Autopol III polarimeter (Rudolph Research Analytical, Flanders, NJ, USA). 
The UV data were acquired using a Varian Cary 100 Bio UV-Vis spectrometer (Varian 
Inc., Walnut Creek, CA, USA).  
Fungal strain identification 
Fungal strain MSX59553 from the Mycosynthetix culture collection was utilized 
in the present study. Strain MSX59553 was isolated by Dr Barry Katz in January 1992 
from leaf litter;33-34, 90 It was identified as Clonostachys rogersoniana (Hypocreales, 
Ascomycota).33 The sequence data for this fungal strain have been deposited in GenBank 
and accession numbers are cited in recent publications.33, 90 
Fermentation, extraction, and isolation 
To prepare Petri dishes, fungal strain MSX59553 was grown on oatmeal agar 
(OMA, Difco). A small piece of agar along with mycelium from the growing edge of the 
colony was transferred onto oatmeal agar that was supplemented with either 5F-DL-Trp, 
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5F-D-Trp, or 5F-L-Trp (2 mL of filter sterilized 5F-Trp solution that was added to 150 
mL of the oatmeal agar after autoclaving). The fungal strain was cultivated on this 
fluorine supplemented medium for few weeks and transferred two times during its growth 
onto newly prepared 5F-DL-Trp supplemented oatmeal agar Petri plates, so as to 
acclimatize the fungal strain to fluorinated building blocks. The same procedure was 
followed to prepare Petri dishes that contains separately one of the two stereoisomers of 
Trp separately. 
Subsequently, flasks were prepared for the scale up of the site directed 
biosynthesis experiment, with the aim of isolating the new fluorinated analogues. A small 
piece of agar along with fungal mycelium grown on the 5F-DL-Trp fluorinated oatmeal 
agar was added to a YESD broth with 464 ppm of 5F-DL-Trp (660 µL of the 7500 ppm 
into 10 mL of YESD; 20 g soy peptone, 20 g dextrose, 5 g yeast extract, 1 L H2O). The 
fungus was grown for a period of 3 days at 23 ºC agitated at 100 rpm using an orbital 
shaker. Fungal colonies grown in YESD broth were transferred into 250 mL Erlenmeyer 
flasks containing breakfast oatmeal (Old fashion Quaker oats). The oatmeal was prepared 
by adding 10 g of breakfast oatmeal with 17 mL of DI-H2O and autoclaved at 221 ºC for 
30 min. An additional 1.2 mL of the 7500 ppm 5F-DL-Trp solution was added to the 
breakfast oatmeal (495 ppm). The flasks were incubated statically at room temperature 
for approximately 3 weeks until the cultures showed completion of initial growth phase 
corresponding to the production of secondary metabolites. 
After fermentation, 60 mL of 1:1 MeOH:CHCl3 was added to each growth flask, 
the culture was chopped using a spatula, and then shaken for 16 h at 100 rpm. The extract 
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was filtrated under vacuum, and 90 mL of CHCl3 and 150 mL of H2O were added to the 
eluent. The solvents were transferred into a separatory funnel, and the organic layer was 
drawn off and evaporated in vacuo. This material was reconstituted using 100 mL of 1:1 
MeOH:CH3CN and 100 mL of hexanes and then partitioned in a separatory funnel. The 
MeOH:CH3CN layer was drawn off and evaporated in vacuo. This defatted organic 
extract (3.9 g) was adsorbed on Celite 545 (Acros Organics) and fractionated via flash 
chromatography on a 40 g RediSep Rf Gold Si-gel column using a gradient solvent 
system of hexanes-CHCl3-MeOH at a flow rate of 40 mL/min over 53.3 column volumes 
(CV) for a duration of 63.9 min. Fractions were collected every 25.0 mL and pooled 
according to the UV and ELSD profiles, resulting in six fractions (F1-F6). Fraction F2 
(750.11 mg) was observed to contain both the targeted masses of verticillins analogues 
and the high UV signal at 301 nm, which is characteristic of the presence of verticillins. 
As such, F2 was subjected to a second flash chromatography on three stack 4 g RediSep 
Rf Gold Si-gel column using a gradient solvent system of hexanes-CHCl3-MeOH at a 
flow rate of 18 mL/min over 155.0 column volumes (CV) for a duration of 41.3 min. 
Fractions were collected every 5.0 mL and pooled according to the UV and ELSD 
profiles, resulting in twelve fractions (Fʹ1-Fʹ12). MS- directed purification showed that 
fractions Fʹ3, Fʹ5 and Fʹ7 contained both parent and fluorinated analogues of the 
verticillins. To purify these, fractions Fʹ3, Fʹ5 and Fʹ7 were subjected to preparative normal 
phase HPLC using Silica column with an isocratic method at 30%, 25%, and 30% of 
EtOAc, respectively. The separations were performed with a flow rate of 21.24 mL/min 
over 25, 52 and 54 min for Fʹ3, Fʹ5 and Fʹ7 respectively. This chromatography led to the 
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isolation of compounds 1 (19.3 mg, tR = 15.5 min), 4 (2.8 mg, tR = 16.7 min) and 9 (0.2 
mg, tR = 18.5 min) from Fʹ3 , compounds 2 (24.8 mg, tR = 33.5 min), 5 (2.7 mg, tR = 36.2 
min), 6 (1.8 mg, tR = 41.0 min) and 10 (0.2 mg, tR = 46.5 min) from Fʹ5, and compounds 
3 (9.3 mg, tR = 27.0 min), 7 (1.3 mg, tR = 30.5 min) and 8 (0.1 mg, tR = 36.5 min) from 
Fʹ7. 
9-F-Verticillin H (4). Light yellow powder, [α]D26 + 567 (c 0.3, CHCl3); UV 
(MeOH) λmax (log ε) 223 (3.22) nm, 309 (2.90) nm; 1H NMR (CDCl3, 700 MHz) δ = 
1.22 (t, J = 7.2 Hz, 3H), 1.25 (t, J = 7.2 Hz, 3H), 2.17 (m, 2H), 2.38 (m, 2H), 3.02 (s, 
3H), 3.03 (s, 3H), 5.05 (s, 1H), 5.14 (s, 1H), 5.15 (s, 1H), 5.16 (s, 1H),  5.59 (s, 1H), 5.64 
(s, 1H), 5.68 (s, 1H), 5.70 (s, 1H), 6.58 (dd, J = 8.6 Hz, 4.4 Hz, 1H), 6.65 (dd, J = 7.6 Hz, 
1.0 Hz, 1H), 6.83 (td, = 7.6 Hz, 1.0 Hz, 1H), 6.86 (td, J = 8.6 Hz, 2.7 Hz, 1H), 7.15 (td, J 
= 7.6 Hz, 1.2 Hz, 1H), 7.63 (dd, J = 9.4 Hz, 2.7 Hz, 1H), 7.83 (dd, J = 7.6 Hz, 1.2 Hz, 
1H); 13C NMR (CDCl3, 175 MHz), δ = 9.8, 9.9, 24.5, 24.6, 28.0, 65.5, 65.9 (d, J = 1.9 
Hz), 76.6, 76.7, 77.4, 77.5, 81.9, 82.0, 83.0, 83.8, 110.8, 111.1 (d, J = 8.5 Hz), 115.5 (d, J 
= 25.4 Hz), 116.6 (d, J = 24.5 Hz), 120.5, 128.2, 128.9, 130.1, 130.8 (d, J = 8.5 Hz), 
144.9 (d, J = 1.3 Hz), 148.8, 157.6 (d, J = 235.6 Hz), 161.4, 167.1 (Table S6) HRESIMS 
m/z 743.1231 [M + H]+ (calcd for C32H32F1N6O6S4, m/z 743.1245). 
9-F-Sch 52901 (5). Light yellow powder, [α]D26 + 595 (c 0.2, CHCl3); UV 
(MeOH) λmax (log ε) 242 (3.67) nm, 310 (3.56) nm; 1H NMR (CDCl3, 700 MHz) δ = 
1.22 (t, J = 7.2 Hz, 3H), 1.90 (s, 3H), 2.17 (m, 2H), 2.37 (m, 2H), 3.01 (s, 3H), 3.02 (s, 
3H), 5.05 (s, 1H), 5.10 (s, 1H), 5.13 (s, 1H), 5.15 (s, 1H),  5.59 (s, 1H), 5.67 (s, 1H), 5.70 
(s, 1H), 5.74 (s, 1H), 6.58 (dd, J = 8.6 Hz, 4.4Hz 1H), 6.66 (dd, J = 7.7 Hz, 1.0 Hz, 1H), 
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6.84 (td, J = 7.7 Hz, 1.0 Hz,  1H), 6.86 (td, J = 8.6 Hz, 2.7 Hz, 1H), 7.15 (td, J = 7.7 Hz, 
1.2 Hz, 1H), 7.61 (dd, J = 9.4 Hz, 2.7 Hz, 1H), 7.84 (dd, J = 7.7 Hz, 1.2 Hz, 1H); 13C 
NMR (CDCl3, 175 MHz), δ = 9.8, 17.5, 24.5, 27.2, 28.0, 65.6, 65.9 (d, J = 1.9 Hz), 72.9, 
76.4, 76.6, 77.5, 81.9, 82.0, 82.8, 83.7, 110.8, 111.1 (d, J = 8.5 Hz), 115.5 (d, J = 25.7 
Hz), 116.6 (d, J = 23.6 Hz), 120.5, 128.3, 128.9, 130.2, 130.8 (d, J = 8.6 Hz), 144.9 (d, J 
= 1.1 Hz), 148.7, 157.6 (d, J = 236.3 Hz), 161.4, 162.3, 166.1, 167.1 (Table S7); 
HRESIMS m/z 729.1071 [M + H]+ (calcd for C31H30F1N6O6S4, m/z 729.1088). 
9ʹ-F-Sch 52901 (6). Light yellow powder, [α]D26 + 543 (c 0.21, CHCl3); UV 
(MeOH) λmax (log ε) 236 (3.58) nm, 309 (3.41) nm; 1H NMR (CDCl3, 700 MHz) δ = 
1.25 (t, J = 7.2 Hz, 3H), 1.89 (s, 3H), 2.18 (m, 2H), 2.39 (m, 2H), 2.99 (s, 3H), 3.03 (s, 
3H), 4.99 (s, 1H), 5.13 (s, 1H), 5.15 (s, 2H),  5.63 (s, 1H), 5.68 (s, 1H), 5.70 (s, 2H), 6.58 
(dd, J = 8.6 Hz, 4.4Hz, 1H), 6.65 (dd, J = 7.7 Hz, 1.0 Hz, 1H), 6.81 (td, J = 7.7 Hz, 1.0 
Hz, 1H), 6.87 (td, J = 2.7 Hz, 8.6 Hz, 1H), 7.13 (td, J = 7.7 Hz, 1.3 Hz, 1H), 7.64 (dd, J = 
9.4 Hz, 2.7 Hz, 1H), 7.81 (dd, J = 7.7 Hz, 1.3 Hz, 1H); 13C NMR (CDCl3, 175 MHz), δ = 
9.8, 17.5, 24.6, 27.2, 28.0, 65.6, 66.0 (d, J = 1.9 Hz), 73.0, 76.3, 76.7, 77.4, 81.9, 82.0, 
83.0, 83.6, 110.8, 111.2 (d, J = 8.5 Hz), 115.6 (d, J = 25.5 Hz), 116.6 (d, J = 23.8 Hz), 
120.5, 128.2, 128.9, 130.1, 130.8 (d, J = 8.6 Hz), 144.8 (d, J = 1.4 Hz), 148.7, 157.6 (d, J 
= 236.0 Hz), 161.4, 162.3, 166.1, 167.1 (Table S8); HRESIMS m/z 729.1064 [M + H]+ 
(calcd for C31H30F1N6O6S4, m/z 729.1088). 
9-F-Verticillin A (7). Light yellow powder, [α]D26 + 700 (c 0.13, CHCl3); UV 
(MeOH) λmax (log ε) 239 (3.90) nm, 309 (3.43) nm; 1H NMR (CDCl3, 500 MHz) δ = 
1.88 (s, 3H), 1.90 (s, 3H), 2.99 (s, 3H), 3.01 (s, 3H), 4.99 (s, 1H), 5.10 (s, 1H), 5.12 (s, 
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1H), 5.14 (s, 1H),  5.67 (s, 1H), 5.69 (s, 2H), 5.73 (s, 1H), 6.58 (dd, J = 8.6 Hz, 4.4, 1H), 
6.65 (dd, J = 7.7 Hz, 1.0 Hz, 1H), 6.82 (td, J = J = 7.7 Hz, 1.0 Hz, 1H), 6.86 (td, J = 8.6 
Hz, 2.7 Hz, 1H), 7.14 (td, J = 7.7 Hz, 0.9 Hz, 1H), 7.61 (dd, J = 9.4 Hz, 2.7 Hz, 1H), 7.82 
(dd, J = 7.7 Hz, 0.9 Hz, 1H); 13C NMR (CDCl3, 175 MHz), δ = 17.4, 27.18, 27.2, 65.7, 
66.0 (d, J = 1.6 Hz), 72.9, 73.0, 76.3, 76.4, 81.9, 82.0, 82.8, 83.6, 110.8, 111.2 (d, J = 8.6 
Hz), 115.5 (d, J = 25.5 Hz), 116.6 (d, J = 24.7 Hz), 120.5, 128.2, 128.9, 130.1, 130.8 (d, J 
= 8.6 Hz), 144.8 (d, J = 1.2 Hz), 148.6, 157.6 (d, J = 236.2 Hz), 162.2, 162.3, 166.1 
(Table S9); HRESIMS m/z 715.0908 [M + H]+ (calcd for C30H28F1N6O6S4, m/z 715.0932). 
9,9ʹ-diF-Verticillin A (8). Light yellow powder, [α]D26 + 400 (c 0.14, CHCl3); UV 
(MeOH) λmax (log ε) 239 (3.66) nm, 315 (3.50) nm; 1H NMR (CDCl3, 700 MHz) δ = 
1.91 (s, 6H), 3.01 (s, 6H), 5.01 (s, 2H), 5.13 (s, 2H), 5.65 (s, 2H), 5.76 (s, 2H), 6.59 (dd, J 
= 8.6 Hz, 4.4 Hz, 2H), 6.86 (td, J = 8.6 Hz, 2.7 Hz, 2H), 7.60 (dd, J = 9.4 Hz, 2.7 Hz, 
2H); 13C NMR (CDCl3, 175 MHz), δ = 17.5, 27.2, 65.8 (d, J = 1.6 Hz), 73.0, 76.2, 81.9, 
83.4, 111.3 (d, J = 8.3 Hz), 115.6 (d, J = 26.6 Hz), 116.7 (d, J = 23.9 Hz), 130.4 (d, J = 
8.7 Hz), 144.8, 157.6 (d, J = 236.9 Hz), 162.3, 166.0 (Table S10); HRESIMS m/z 
733.0826 [M + H]+ (calcd for C30H27F2N6O6S4 , m/z 733.0837). 
9,9ʹ-diF-Verticillin H (9). Light yellow powder, [α]D26 + 1360 (c 0.1, CHCl3); UV 
(MeOH) λmax (log ε) 234 (3.21) nm, 309 (2.95) nm; 1H NMR (CDCl3, 500 MHz) δ = 
1.26 (t, J = 7.1 Hz, 6H), 2.19 (m, 1H), 2.39 (m, 1H), 3.04 (s, 6H), 5.07 (s, 2H), 5.15 (s, 
2H), 5.66 (s, 4H), 6.59 (dd, J = 8.6 Hz, 4.4 Hz, 2H), 6.88 (td, J = 8.6 Hz, 2.6 Hz, 2H), 
7.60 (dd, J = 9.4 Hz, 2.6 Hz, 2H); (Table S11); HRESIMS m/z 761.1135 [M + H]+ (calcd 
for C32H31F2N6O6S4, m/z 761.1150). 
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9,9ʹ-diF-Sch 52901 (10). Light yellow powder, [α]D26 + 1890 (c 0.1, CHCl3); UV 
(MeOH) λmax (log ε) 226 (3.23) nm, 315 (2.97) nm; 1H NMR (CDCl3, 500 MHz) δ = 
1.26 (t, J = 7.0 Hz, 3H), 1.91 (s, 3H), 2.19 (m, 1H),  2.39 (m, 1H),  3.02 (s, 3H), 3.04 (s, 
3H), 5.05 (s, 1H), 5.07 (s, 1H), 5.14 (s, 1H), 5.15 (s, 1H), 5.66 (s, 3H), 5.77 (s, 1H), 6.59 
(m, J = 8.8 Hz, 4.4 Hz, 2H), 6.86 (td, J = 8.8 Hz, 2.8 Hz, 1H), 6.88 (td, J = 8.8 Hz, 2.8 
Hz, 1H),  7.61 (m, J = 9.4 Hz, 2.8 Hz,, 1H),  7.63 (m, J = 9.4 Hz, 2.8 Hz,1H); (Table 
S12); HRESIMS m/z 747.0983 [M + H]+ (calcd for C31H29F2N6O6S4 , m/z 747.0994). 
Cytotoxicity assay 
Human melanoma cancer cells (MDA-MB-435), human breast cancer cells 
(MDA-MB-231) and human ovarian cancer cells (OVCAR3) were obtained from the 
American Type Culture Collection (Manassas, VA). The cell lines were cultured in RPMI 
1640 medium containing fetal 10% bovine serum, 100 unites/mL penicillin and 100 
µg/mL streptomycin. The cells were grown at 37 ºC under 5% CO2, and then harvested 
during the log-phase growth by trypsinization followed by two washing to remove all 
traces of enzymes. Cells were seeded in 96-well clear, flat-bottom plate (Microtest 96, 
Falcon) at a density of 5000 cells per well. Each plate was incubated overnight at 37 ºC 
under 5% CO2. Samples dissolved in DMSO were diluted and added to the appropriate 
wells to give final concentrations of 20, 4, 0.8, 0.16, and 0.032 µM for pure compounds, 
and a total volume of 100 µL and 0.5% DMSO per well. The cells with the test samples 
were then incubated for 72 h at 37 ºC. Cell viability was examined using a commercial 
absorbance assay (CellTiter 96® AQueous One Solution Cell Proliferation Assay, Promega 
Corp, Madison, WI). IC50 values were determined as the concentration required to 
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diminish cellular growth by 50% compared to the untreated controls after 72 h of 
continuous exposure. Taxol (Paclitaxel) was used as a positive control. 
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SEMI-SYNTHSIS OF EPIPOLYTHIODIOXOPIPERAZINE 
ALKALOID ANALOGUES 
This chapter is intended for submission to ACS Medicinal Chemistry Letters and 
is presented in that style. Coauthors will include Huntsman, A. C., Doyle, M. G., 




In 2019, it is estimated that there will be over 1.7 million cases of cancer 
diagnosed, with over 600 thousand deaths, just in the United States, making it the second 
leading cause of death in the country.2 Despite monumental advances in detection and 
treatment of cancer over the last four decades, some types of cancer, such as pancreatic 
and ovarian, are still extremely difficult to treat effectively.165 Many researchers in the 
natural products community are well versed in the history of medicines from nature, 
where over 60% of the current anticancer drugs originate.11, 166 However, what may not 
be apparent is the number of those that were derived, sometimes semi-synthetically, from 
a parent natural product. This later group represents 40% of the US FDA small-molecule 
approved drugs between 1981 and 2014, including 22% of new anticancer drugs.10  
Natural product leads have often been the inspiration for semi-synthetic analogues.167-168 
New compounds that retain the privilege scaffold afforded by nature169-170 are of 
importance for exploring structure-activity relationships,171-173 overcoming challenges 
such as drug resistance,174 expanding opportunities for discovery of new drug 
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candidates,175 and supplying material on larger scales.176-179 A key example of 
semisynthesis was the production of taxotere,180-181 a 10- deacetyl /erf-butyl carbamate 
derivative of taxol,182 which was designed with the goal of yielding a more water soluble 
analogue with equal antitumor activity.183 Esterification and linkage via carbamate and 
carbonate functionalities of the hydroxy at position C-7 on taxol was also proposed for 
analogous reasons.179, 184-187 For similar solubility improvements, derivatives of 
camptothecin (CPT)188 were synthesized by adding hydrophilic groups to a hydroxy on 
position C-10 via a carbamate linkage. Two prominent examples that resulted in potent 
cytotoxic analogues with enhanced aqueous solubility are irinotecan (also known as CPT-
11)189-190 and topotecan.179, 191-192 Irinotecan has a [4-(1-piperidino)-1-piperidino 
carbonyloxy] group at C-10 and an ethyl group at C-7, whereas topotecan has a hydroxy 
and a positively charged dimethyl aminomethyl group at C-10 and C-9, respectively.179, 
189, 193-195 There are many other examples of semi-synthetic analogues of natural products 
that became FDA approved drugs, with ixabepilone one of the most recent examples196-
197 198, lending validation to this approach.  
Verticillins are part of the epipolythiodioxopiperazine alkaloids (ETP) class of 
fungal secondary metabolites,24, 30, 38 produced by the filamentous fungi Verticillium sp., 
Penicillium sp., and Gliocladium sp.26 This class of compounds is characterized by a cis-
fused five membered rings and a sulfur bridge.39 Even in the earliest studies, acetylation 
of verticillins was shown to enhance the solubility of verticillins compared to parent 
fungal metabolite (verticillin A).40-41 
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Many studies have underlined the importance of verticillins as a potential anti-
cancer agent.34, 45-46 Recently verticillin A was found to be a selective inhibitor of histone 
methyl transferases (HMTases) like SUV39H1, SUV39H2, G9a, HTM, MLL1 and 
GLP.28 A study by Paschall et al.35 demonstrated that verticillin A inhibited H3K9 
methylation on the FAS promoter in colon carcinoma; this mode of action resulted in 
restoring the Fas expression, and led to cell apoptosis. Moreover, significantly smaller 
tumor sizes were revealed after treating xenograft mice with a combination of verticillin 
A and 5-fluorouracil. Metastatic colon carcinoma cells showed to be sensitized to 5-
fluorouracil.35 Similarly, verticillin A inhibited MLL1 in pancreatic cancer cells. MLL1 is 
responsible of the methylation of histones H3K4me3 resulting in higher PD-L1 
expression. Treatment with a combination of verticillin A and anti PD-L caused the 
reduction of binding to PD-1, thus activation the immune response.70  
Verticillins illustrates one of the scaffolds that enthrall synthetic chemists because 
of their dimeric structure that include ten stereocenters, and a sulfur bridges.62 Based on 
their retro-biosynthesis hypothesis, the Movassaghi group succeeded in the synthesis of 
(+)-11,11ʹ-dideoxyverticillin A. The total synthesis was accomplished via 
enantioselective steps.62-63 The success of this synthesis strategy gave an insight about 
synthesis of other ETPs.  
A SAR study from the same group demonstrated that the verticillins’ high 
potency is related to the presence of a disulfur bridge at C-3/C-11a, while the removal of 
the sulfur atoms or the reduction of the sulfur bridge diminish/abolish the activity of 
verticillins.49, 65, 67 
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Herein, we report a novel series of semisynthetic verticillin analogues by linking 
diverse groups via ester, carbamate, carbonate, and sulfonate functionalities on the 
secondary hydroxy group on position C-11. The reactions were monitored with observing 
the loss of the symmetry via 1H NMR. The structures of the new compounds were 
supported by 1H and 13C NMR and HRESIMS. Antitumor potential was evaluated in 
vitro via three types of cancer cell lines, and the IC50 values were in the order of the 
nanomolar range. 
Results and Discussion 
The verticillins class is originally isolated from the fungus Clonostachys sp. and 
demonstrated activity against cancer cell lines in vitro and in vivo.27, 34, 70 This class of 
ETPs was always an inspiration for synthetic chemists. A total synthesis of one of this 
class analogues, (+)-11,11ʹ-dideoxyverticillin A was achieved by Kim et al.62 In the 
current study, verticillins, represented by verticillin H (1), was used as an inspiration to 
generate semisynthetic analogues in an attempt to produce new metabolites with 
improved solubility. 
Starting from the isolated and purified Verticillin H (1), different groups were 
introduced to the position C-11. Several chemical reactions were performed in parallel 
starting with 1. The first series of ester derivatives were obtained by reacting 1 with 
acetic anhydride overnight at room temperature as described for the acetylation of 
verticillin D,41 afforded 3 as a major product (47% yield). In a similar way, the reaction 
of 1 with succinic anhydride overnight at room temperature, afforded 4 (53% yield). 
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The following ester analogues, 5, 6, and 7, were synthesized by reacting 1 with 
butyryl chloride, cyclopropanecarbonyl chloride, and pivaloyl chloride, respectively. The 
reaction yielding to 5 (44% yield) was realized at room temperature for 4 hours, while 6 
(82% yield) was obtained after 3 hours at room temperature. These later reactions were 
realized in an NMR tube and monitored by tracking the desymetrization of the aromatic 
region δ 6.5-8.0 ppm. The reaction yielding 7 was completed after 22 hours at room 
temperature with 86% yield, the presence of dimethylaminopyridine in this later reaction 























































































R=Me: 12, 71% yield








































R=propyl: 5, 44% yield
R=tbutyl: 7, 86% yield
R=OCH2CH3: 8, 57% yield
R=cyclopropane: 6, 82% yield
DCM or CDCl3
, Et3N
*DMAP required for full conversion 
to VertH-4 and VertH-7
 
Scheme 1. Semisynthesis of Ester Derivatives 3, 4 and 12 and the Carbonate 
Derivative 5, 6, 7, and 8. The percent yields were calculated based on isolated product. 
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Compound 1 was reacted with ethyl chloroformate in the presence of 
dimethylaminopyridine for 3 hours at room temperature to produce the carbonate 
analogue 8 (57% yield). This reaction was realized in an NMR tube in a similar way as 
the reaction yielding compound 5, 6 and 7. The sulfonate derivative 9, was obtained by 
reacting 1 with 4-fluorobenzenesulfonyl chloride with the presence of 

















































Scheme 2. Semisynthesis of Sulfonate Derivative 9. The percent yields were calculated 
based on isolated product. 
 
The carbamate derivatives of 1 were realized in a two steps reaction.199 First, 
compound 1 was reacted with carbonyldimidazole in the presence of potassium 
hydroxide for 2 hours at 50-55 °C (eventually becoming a clear solution) at which time 
transfer to an NMR tube confirmed consumption of starting material. After transferring 
back into the reaction vessel, either methylamine or dimethylamine was added 
respectively, the reaction mixture was stirred overnight at room temperature resulting in 
18% yield 10 and 43% yield 11 respectively (Scheme 3).  
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In nearly all cases, the reaction mixture was then concentrated in vacuo providing 
a residue that was purified by HPLC. For compounds 10 and 11 after in vacuo 
concentration, the reaction mixture was dissolved in ethyl acetate and washed with 
several portions of water. The combined organics were rinsed with brine, dried over 






























































R=H: 10, 18% yield
R=Me: 11, 43% yield
R
 
Scheme 3. Semisynthesis of Carbamate Derivatives 10 and 11. The percent yields 
were calculated based on isolated product. 
 
 
The succinate derivative reaction was applied on verticillin A (2) to successfully 
generate 12 with a yield of 71%. By this reproduction of the reaction result, we 
hypothesize the ability of the different verticillin analogues on ongoing effectively 
through the proposed reactions in a similar way.  
In all the previous reactions, the linkage of different groups to 1 was established 
in only one side of the symmetrical dimer. The presence of a bulky groups on position C-
11 was well tolerated on one side resulting in the loss of the symmetry of the compound. 
The 1D NMR spectra of the ester derivatives (3, 4, 5, 6, 7 and 12), carbonate (8), 
sulfonate (9), and the carbamates (10 and 11) were characterized by a notable doubling of 
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signals that illustrated the loss of symmetry of the original compound. A distinct singlet 
peak in the range between 6.73 and 7.11 ppm was observed in all 1H NMR spectra 
integrating for one proton, was found to represent H-11. The downfield shift of this peak 
compared to H-11ʹ (~ 5 ppm) of the same molecule and the parent compound H-11, 
proves the linkage of the new chain to OH-11. 
More characteristic peaks were noticed in the 1H NMR spectra of the synthesized 
compounds such as a singlet at 2.46 ppm in 3 with two extra carbons at 22.1 and 168.3 
ppm corresponding to the acetate group at OH-11. The NMR and HRESIMS data (m/z 
825.1502 [M+H]+) for compound 4 supported a molecular formula of C36H36N6O9S4. 
Two dt at 2.68 and 2.88 ppm and two ddd at 3.06 and 3.18 ppm with four extra carbon 
shifts, two around ~28 ppm and two at 170.9 and 173.9 ppm demonstrating the presence 
the succinate group. 
Comparison of the NMR data between 1 and 5 showed the appearance of seven 
new proton peaks at the following chemical shifts; 1.11 (t), 1.93 (m), 2.61 (m), and 2.74 
(m) ppm integrating for three, two, one and one proton respectively. The 1H NMR 
spectrum of derivative 6 demonstrated the presence of multiplet at 1.13, 1.25, 1.48, and 
1.96 ppm respectively and additional four carbon shifts at 9.2, 9.5, 13.6, and 172.7 ppm. 
The NMR and HRESIMS data (m/z 809.1894 [M+H]+) for compound 7 supported a 
molecular formula of C37H40N6O7S4. A singlet at 1.46 ppm integrating for nine protons 
were observed in the proton spectra corresponding to the three new methyl groups. The 
carbonate derivative 8 showed the addition of characteristic peaks at 1.49 (t) and 4.54 (q) 
ppm compared to the proton spectrum of 1, along with an addition of three shifts in the 
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13C NMR spectrum at 14.6, 66.0, and 153.7. In compound 9, two aromatic shifts at 7.22 
and 8.11 ppm integrating for two protons each were observed. These peaks correspond to 
the fluorobenzyl sulfonate group linked to C-11. Moreover, six additional carbon signal 
were detected in the aromatic region of the 13C NMR spectrum. 19F NMR offered an 
additional proof of the linkage of the latter group to 1. The J coupling values of the 19F 
peak (J = 8.0 Hz, 4.8 Hz) is shown to be shared with the aromatic peaks at 7.22 ppm (J = 
8.6 Hz, 8.0 Hz) and 8.11 ppm (J = 8.6 Hz, 4.8 Hz). In the carbamate series, 10 showed 
the appearance of a doubled at 3.06 ppm and a multiplet at 4.86 ppm in the proton NMR. 
In the 1H NMR of 11, the dimethyl carbamate derivative showed two singlet shifts were 
integrating for three protons each at 3.01 and 3.14 ppm.  
This set of compounds was evaluated for its in vitro cytotoxic properties against 
the human melanoma cancer cells (MDA-MB-435), human breast cancer cells (MDA-
MB-231), and human ovarian cancer cells (OVCAR3). Growth inhibition was measured 
after a 72h exposure to the compound as previously described34, 162. The IC50 results of 
the new derivatives demonstrated a potency of the order of nanomolar (Table 5). 
Compound 1 and 2 derivatives showed a similar potency compared in the order of 
nanomolar compared to their parent compound against the three cancer cells suggesting 













MDA-MB-231 OVCAR 3 MDA-MB-435 
Verticillin H (1) 31 229 44 
Verticillin A (2) 23 36 18 
3 21 96 41 
4 13 133 21 
5 - - - 
6 12 105 24 
7 20 72 21 
8 7 137 11 
9 49 79 31 
10 21 68 22 
11 12 19 9 
12 12 33 9 
Taxol (control) 0.1 171 1.4 
MDA-MB-435: Human melanoma cancer cells, OVCAR3: Human ovarian cancer cells, 
MDA-MB-231: Human breast cancer cells. 
 
 
In summary, a series of verticillin analogues were synthesized with ester, 
carbonate, sulfonate, and carbamate linkages. These reactions were monitored essentially 
via 1H NMR to investigate the completion of the reaction. These compounds retained 
cytotoxic potency at the nanomolar level.  
Experimental Section 
General experimental procedures 
All solvents were obtained from Fisher Scientific. NMR data were collected in 
CDCl3 using either a JEOL ECS-400 spectrometer (JEOL USA, Inc.) operating at 400 
MHz for 1H and 100 MHz for 13C, or JEOL ECA-500 NMR spectrometer (JEOL USA, 
Inc.) operating at 500 MHz for 1H, 470 MHz for 19F and 125 MHz for 13C, or an Agilent 
700 MHz NMR spectrometer (Agilent technologies, Inc., Santa Clara, CA, USA) 
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operating at 700 MHz for 1H and 175 MHz for 13C. Chemical shift values were 
referenced to the residual solvent signals for CDCl3 (δH 7.25 and δC 77.2) and reported in 
δ ppm; multiplicity was showed as: s = singlet, d = doublet, t = triplet, q = quartet and m 
= multiplet; coupling constants were conveyed in Hz. Thermo QExactive Plus mass 
spectrometer (Thermofisher, San Jose, CA, USA) with an electrospray ionization source 
was utilized to collect HRESIMS data. The UPLC separation was achieved using an 
Acquity BEH C18 column (50 mm x 2.1 mm i.d., 1.7 µm) equilibrated at 40 ºC and a flow 
rate set at 0.3 mL/min. The mobile phase comprised a linear gradient CH3CN/H2O with 
0.1% HCOOH starting at 15% CH3CN to 100% over 8.5 min. Flash column 
chromatography was carried out with a Teledyne ISCO combiflash Rf connected to 
ELSD and PDA detectors with UV detection set at 200-400 nm with a specific 
wavelength set at 300 nm. The HPLC separation was achieved using Varian ProStar 
HPLC system connected to a ProStar 335 photodiod array detector (PDA) with UV 
detection set at 240 nm and 300 nm. Semi-preparative reverse phase HPLC purification 
of samples was performed on a Luna 5 µm silica (2) (100 A°, 250 x 10.0 mm) column 
using a flow rate of 4.6 mL/min of a mobile phase consisting of H2O with 1% formic acid 
and MeOH.  
Cytotoxicity assay 
Human melanoma cancer cells (MDA-MB-435), human breast cancer cells 
(MDA-MB-231) and human ovarian cancer cells (OVCAR3) were produced from the 
American Type Culture Collection (Manassas, VA). RPMI 1640 medium (fetal 10% 
bovine serum, 100 unites/mL penicillin and 100 µg/mL streptomycin) was used to culture 
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cell lines. The cells were grown at 37 ºC under 5% CO2, then harvested during the log-
phase growth by trypsinization followed by two washing to remove all traces of enzymes. 
96-Well clear, flat-bottom plate (Microtest 96, Falcon) was used to seed the cells at a 
density of 5000 cells per well. Each plate was incubated overnight at 37 ºC under 5% 
CO2. Sample concentrations of 20, 4, 0.8, 0.16, and 0.032 µM of were prepared by 
dissolving the pure compounds in DMSO, and a total volume of 100 µL and 0.5% DMSO 
were added to the appropriate wells. The cells with the test samples were incubated for 72 
h at 37 ºC. Cell viability was examined using a commercial absorbance assay (CellTiter 
96® AQueous One Solution Cell Proliferation Assay, Promega Corp, Madison, WI). IC50 
values were designated as the concentration required to reduce cellular growth by 50% 
compared to the untreated controls after 72 h of continuous exposure. Parent’s 
compounds; verticillin H and verticillin A were tested in comparison with the synthetic 
compounds and Taxol (Paclitaxel) was used as a positive control. 
Fermentation, extraction, and isolation 
A fungal strains MSX59553 from the Mycosynthetix culture collection identified 
to be Clonostachys rogersoniana was utilized in the present study.33, 90 Erlenmeyer flasks 
containing 10 g of breakfast oatmeal were used in fermenting MSX59553 fungal strains 
over 11 days. Those solid media were extracted with 60 mL of acetone, each flask culture 
was chopped using a spatula, and then shaken for 16 h at 100 rpm. The extract was 
filtrated under vacuum then evaporated, the solid extract was reconstituted in 90 mL of 
EtOAc partitioned against 150 mL of H2O. The solvents were transferred into a 
separatory funnel, and the organic layer was drawn off and evaporated in vacuo. This 
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material was re-formed using 100 mL of 1:1 MeOH:CH3CN and 100 mL of hexanes. The 
MeOH: CH3CN layer was drawn off and evaporated in vacuo. The defatted organic 
extract was adsorbed on Celite 545 (Acros Organics) and fractionated via flash 
chromatography on a 40 g RediSep Rf Gold Si-gel column using a gradient solvent 
system of hexanes-CHCl3-MeOH at a flow rate of 40 mL/min over 53.3 column volumes 
(CV) for a duration of 63.9 min. Fractions were collected every 25.0 mL and pooled 
according to the UV and ELSD profiles, resulting in six fractions (F1-F6). Fraction F1 and 
F3was observed to contain both the targeted masses of verticillin H and verticillin A, 
respectively. F1 and F3 was subjected to further purifications via partitions of MeOH: 
CH3CN against hexanes. The semisynthetic products were purified via reverse phase 
chromatography with a flow rate of 21.24 mL/min over 20 to 55 min.  
Experimental procedures  
Compound 3: Following the procedure reported for the acetylation of Verticillin 
D,41 A solution of Verticillin H (1) (4 mg, 0.006 mmol), pyridine (0.2 mL), and acetic 
anhydride (1.5 mL) was stirred overnight at room temperature.  The reaction was 
quenched with water and extracted with ethyl acetate.  The combined organics were 
rinsed with 2M HCl, brine, and then dried over sodium sulfate, and concentrated in 
vacuo.  The remaining solid was purified by HPLC to afford 3 (2.2 mg, 0.0028 mmol, 
47% yield) as light-yellow powder. 1H NMR (CDCl3, 700 MHz) δ = 1.20 (t, J = 7.2 Hz, 
3H), 1.21 (t, J = 7.2 Hz, 3H), 2.12 (m, 1H), 2.16 (m, 1H), 2.36 (m, 2H), 2.46 (s, 3H), 2.94 
(s, 3H), 3.00 (s, 3H), 5.02 (d, J = 1.2 Hz, 1H), 5.17 (s, 1H), 5.17 (s, 1H), 5.18 (s, 1H), 
5.22 (s, 1H), 5.43 (d, J = 1.2 Hz, 1H), 6.64 (d, J = 7.6 Hz, 1H), 6.68 (d, J = 7.7 Hz, 1H), 
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6.85 (td, = 7.6 Hz, 1.1 Hz, 1H), 6.88 (td, J = 7.7 Hz, 1.0 Hz, 1H), 6.95 (s, 1H), 7.15 (td, J 
= 7.6 Hz, 1.2 Hz, 1H), 7.19 (td, J = 7.7 Hz, 1.2 Hz, 1H), 7.65 (d, J = 7.7 Hz, 1H), 7.93 (d, 
J = 7.6 Hz, 1H); 13C NMR (CDCl3, 175 MHz), δ = 9.8 (2C), 22.1, 24.5, 24.7, 28.0, 28.5, 
65.0, 65.9, 75.2, 76.7, 77.7, 78.3, 80.1, 81.9, 82.5, 83.1, 110.5, 111.1, 120.5, 120.7, 125.9, 
128.4, 128.6, 129.0, 130.3, 130.5, 148.5, 149.0, 161.2, 161.3, 164.1, 166.8, 168.3. 
HRESIMS m/z 767.1433 [M + H]+ (calcd for C34H35N6O7S4, m/z 767.1450). 
Compound 4: General Procedure for Succinates: A suspension of Verticillin H 
(1) (17 mg, 0.023 mmol), succinic anhydride (50 equiv., 38 mg), 4-
dimethylaminopyridine (0.25 equiv., 0.009 mL of a 0.2 M solution in chloroform-d), and 
pyridine (50 equiv., 0.030 mL) in dimethylformamide (1 mL) was stirred at room 
temperature overnight, during which time the mixture became a clear solution. Solvent 
was then removed by vacuum distillation and the remaining solid was purified by HPLC 
to afford 4 (10 mg, 0.012 mmol, 53 % yield) as a light-yellow powder. 1H NMR (CDCl3, 
700 MHz) δ = 1.20 (t, J = 7.4 Hz, 3H), 1.21 (t, J = 7.2 Hz, 3H), 2.14 (m, 2H), 2.36 (m, 
2H), 2.68 (dt, J = 17.5, 4.1 Hz, 1H), 2.88 (dt, J = 17.1, 4.1 Hz, 1H), 2.92 (s, 3H), 3.00 (s, 
3H), 3.06 (ddd, J = 17.1, 12.1, 4.1 Hz, 1H), 3.18 (ddd, J = 17.5, 12.1, 4.1 Hz, 1H), 5.02 
(d, J = 1.9 Hz, 1H), 5.17 (s, 1H), 5.18 (s, 1H), 5.18 (s, 1H), 5.20 (s, 1H), 5.52 (d, J = 1.9 
Hz, 1H), 6.64 (d, J = 7.7 Hz, 1H), 6.67 (d, J = 7.8 Hz, 1H), 6.84 (t, = 7.7 Hz, 1H), 6.90 (t, 
J = 7.8 Hz, 1H), 7.00 (s, 1H), 7.14 (t, J = 7.7 Hz, 1H), 7.19 (td, J = 7.8 Hz, 1.2 Hz, 1H), 
7.76 (d, J = 7.7 Hz, 1H), 7.92 (d, J = 7.8 Hz, 1H); 13C NMR (CDCl3, 175 MHz), δ = 9.7, 
9.8 , 24.5, 24.7, 28.1, 28.4, 28.5, 30.1, 65.1, 65.7, 75.0, 77.3, 77.9, 78.3, 80.4, 81.0, 82.5, 
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83.1, 110.5, 111.0, 120.6, 120.7, 126.1, 128.2, 128.9, 129.2, 130.3, 130.4, 148.4, 148.8, 
161.2, 161.2, 164.2, 166.7, 170.9, 173.9. HRESIMS m/z 825.1502 [M + H]+ (calcd for 
C36H37N6O9S4, m/z 825.1504). 
Compound 5: A solution of Verticillin H (1) (1 mg, 0.002 mmol), butyryl 
chloride (50 equiv., 0.01 mL), and triethylamine (70 equiv., 0.02 mL) in dichloromethane 
(0.25 mL) was stirred at rt for 4 hours before being quenched with water and extracted 
with ethyl acetate. The combined organic layers were dried over sodium sulfate and 
concentrated in vacuo prior to purification by HPLC to afford 5 (0.7 mg, 0.0009 mmol, 
44 % yield) as an off-white powder. 1H NMR (CDCl3, 500 MHz) δ = 1.11 (t, J = 7.4 Hz, 
3H), 1.20 (t, J = 7.2 Hz, 3H), 1.21 (t, J = 7.2 Hz, 3H), 1.93 (m, 2H), 2.13 (m, 2H), 2.37 
(m, 2H), 2.61 (m, 1H), 2.74 (m, 1H), 2.93 (s, 3H), 3.00 (s, 3H), 5.03 (d, J = 1.2 Hz, 1H), 
5.16 (s, 1H), 5.18 (s, 1H), 5.19 (s, 1H), 5.22 (s, 1H), 5.42 (d, J = 1.2 Hz, 1H), 6.64 (d, J = 
7.6 Hz, 1H), 6.68 (d, J = 7.7 Hz, 1H), 6.86 (td, J= 7.7 Hz, 1.1 Hz, 1H), 6.90 (td, J = 7.6 
Hz, 1.1 Hz, 1H), 7.00 (s, 1H), 7.16 (td, J = 7.6 Hz, 1.3Hz, 1H), 7.20 (td, J = 7.7 Hz, 1.2 
Hz, 1H), 7.70 (d, J = 7.6 Hz, 1H), 7.92 (d, J = 7.7 Hz, 1H); 13C NMR (CDCl3, 175 MHz), 
δ = 9.8, 13.9, 18.0, 24.5, 24.8, 28.0, 28.5, 29.7 (2 C), 65.1, 65.9, 75.2, 76.6, 77.7, 78.4, 
79.9, 81.7, 82.5, 83.1, 110.5, 111.1, 120.6, 120.7, 126.0, 128.3, 128.7, 129.1, 130.3, 
130.4, 148.5, 148.9, 161.2, 161.3, 164.0, 166.8, 171.1. HRESIMS m/z 795.1715 [M + 
H]+ (calcd for C36H39N6O7S4, m/z 795.1763). 
Compound 6: A solution of Verticillin H (1) (3 mg, 0.004 mmol), 
cyclopropanecarbonyl chloride (5 equiv., 0.002 mL), and triethylamine (10 equiv., 0.006 
mL) in chloroform-d (1 mL) was added to an NMR tube.  The reaction was monitored for 
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completion by looking for desymmetrization of the aromatic region in the NMR 
(completion observed as early as 30 minutes). After 3 hours at room temperature, the 
reaction mixture was then concentrated in vacuo providing a residue that was purified by 
HPLC to afford 6 (2.6 mg, 0.003 mmol, 82% yield) as an off-white powder. 1H NMR 
(CDCl3, 500 MHz) δ = 1.13 (m, 2H), 1.21 (m, 6H), 1.25 (m, 1H), 1.48 (m, 1H), 1.96 (m, 
1H), 2.13 (m, 2H), 2.36 (m, 2H), 2.95 (s, 3H), 3.00 (s, 3H), 5.13 (d, J = 1.3 Hz, 1H), 5.18 
(s, 1H), 5.20 (s, 2H), 5.22 (s, 1H), 5.36 (d, J = 1.3 Hz, 1H), 6.65 (d, J = 7.6 Hz, 1H), 6.69 
(d, J = 7.7 Hz, 1H), 6.85 (t, J= 7.6 Hz, 1H), 6.89 (t, J = 7.7 Hz, 1H), 6.94 (s, 1H), 7.15 
(td, J = 7.7 Hz, 1.2Hz, 1H), 7.20 (td, J = 7.6 Hz, 1.0 Hz, 1H), 7.84 (d, J = 7.6 Hz, 1H), 
7.90 (d, J = 7.7 Hz, 1H); 13C NMR (CDCl3, 125 MHz), δ = 9.2, 9.5, 9.8, 9.9, 13.6, 24.6, 
24.9, 28.1, 28.7, 29.8, 65.3, 66.0, 75.3, 77.9, 78.6, 80.3, 81.7, 82.6, 83.4, 110.6, 111.2, 
120.7, 120.8, 126.2, 128.4, 128.9, 129.2, 130.4, 130.6, 148.6, 149.0, 161.3, 161.4, 164.3, 
166.9, 172.7. HRESIMS m/z 793.1582 [M + H]+ (calcd for C36H37N6O7S4, m/z 
793.1606). 
Compound 7: A solution of Verticillin H (1) (5 mg, 0.007 mmol), pivaloyl 
chloride (10 equiv., 0.009 mL), triethylamine (15 equiv., 0.015 mL), and 
dimethylaminopyridine (0.25 equiv., 0.01 mL of a 0.2 M solution in chloroform-d) in 
chloroform-d (1 mL) was stirred 22 hours at room temperature, after which transfer to an 
NMR tube confirmed consumption of starting material.  The reaction mixture was then 
concentrated in vacuo providing a residue that was purified by HPLC to afford 7 (4.88 
mg, 0.006 mmol, 86 % yield) as an off-white powder. 1H NMR (CDCl3, 400 MHz) δ = 
1.21 (m, 6H), 1.46 (s, 9H), 2.14 (m, 2H), 2.36 (m, 2H), 2.92 (s, 3H), 2.98 (s, 3H), 5.13 (s, 
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1H), 5.16 (s, 1H), 5.17 (s, 2H), 5.19 (s, 1H), 5.30 (s, 1H), 6.63 (d, J = 7.6 Hz, 1H), 6.69 
(d, J = 7.7 Hz, 1H), 6.85 (t, J= 7.6 Hz, 1H), 6.91 (t, J = 7.7 Hz, 1H), 7.11 (s, 1H), 7.14 (t, 
J = 7.7 Hz, 1H), 7.20 (t, J = 7.6 Hz, 1H), 7.83 (d, J = 7.6 Hz, 1H), 7.90 (d, J = 7.7 Hz, 
1H); 13C NMR (CDCl3, 100 MHz), δ = 9.9 (2 C), 24.7, 24.9, 27.7 (3 C), 28.0, 28.6, 29.8, 
39.4, 64.8, 66.1, 75.7, 77.9, 78.7, 80.9, 81.1, 82.7, 83.4, 110.7, 111.4, 120.5, 120.8, 125.9, 
128.2, 129.1, 129.9, 130.4, 130.5, 148.3, 148.7, 161.4, 161.5, 164.0, 166.9, 176.8. 
HRESIMS m/z 809.1894 [M + H]+ (calcd for C37H41N6O7S4, m/z 809.1919). 
Compound 8: A solution of Verticillin H (1) (5 mg, 0.007 mmol), ethyl 
chloroformate (5 equiv., 0.003 mL), triethylamine (10 equiv., 0.01 mL), and 
dimethylaminopyridine (0.25 equiv., 0.009 mL of a 0.2 M solution in chloroform-d) in 
chloroform-d (1 mL) was added to an NMR tube.  After 3 hours (consumption of starting 
material observed after 90 minutes) at room temperature, the reaction mixture was 
concentrated in vacuo providing a residue that was purified by HPLC to afford 8 (2.7mg, 
0.004 mmol, 57 % yield) as an off-white powder. 1H NMR (CDCl3, 500 MHz) δ = 1.18 
(t, J= 7.2 Hz, 3H), 1.22 (t, J= 7.2 Hz, 3H), 1.49 (t, J= 7.1 Hz, 3H), 2.14 (m, 2H), 2.36 (m, 
2H), 2.95 (s, 3H), 3.01 (s, 3H), 4.54 (q, J= 7.1 Hz, 2H), 5.10 (s, 1H), 5.14 (s, 1H), 5.18 (s, 
1H), 5.19 (s, 1H), 5.22 (s, 1H), 5.52 (d, J = 1.2 Hz, 1H), 6.65 (m, 2H), 6.75 (s, 1H), 6.88 
(m, 2H), 7.16 (m, 2H), 7.79 (d, J = 7.7 Hz, 1H), 7.92 (d, J = 7.8 Hz, 1H); 13C NMR 
(CDCl3, 125 MHz), δ = 9.9 (2 C), 14.6, 24.6, 24.8, 28.1, 28.6, 29.8, 65.3, 65.6, 66.0, 
75.5, 76.7, 77.7, 78.5, 82.0, 82.5, 83.3, 84.0, 110.7, 111.0, 120.8, 121.1, 127.0, 128.4, 
128.6, 128.7, 130.5, 148.7, 148.9, 153.7, 161.2, 161.3, 164.4, 167.0. HRESIMS m/z 
809.1894 [M + H]+ (calcd for C35H37N6O8S4, m/z 809.1919). 
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Compound 9: A solution of Verticillin H (1) (6 mg, 0.008 mmol), 4-
fluorobenzenesulfonyl chloride (5 equiv., 8 mg), triethylamine (10 equiv., 0.012 mL), and 
dimethylaminopyridine (0.25 equiv., 0.01 mL of a 0.2 M solution in chloroform-d) in 
chloroform-d (1 mL) was stirred 22 hours at room temperature, after which transfer to an 
NMR tube confirmed consumption of starting material.  The reaction mixture was then 
concentrated in vacou providing a residue that was purified by HPLC to afford 9 (2.9 mg, 
0.003 mmol, 41 % yield) as an off-white powder. 1H NMR (CDCl3, 500 MHz) δ = 1.13 
(t, J= 7.0 Hz, 3H), 1.21 (t, J= 7.2 Hz, 3H), 2.05 (m, 1H), 2.17 (m, 1H), 2.30 (m, 1H), 2.37 
(m, 1H), 2.66 (s, 3H), 3.00 (s, 3H), 5.16 (s, 1H), 5.17 (s, 1H), 5.21 (s, 2H), 5.69 (s, 2H), 
6.61 (d, J= 7.8 Hz, 1H), 6.66 (d, J= 7.7 Hz, 1H), 6.73 (s, 1H), 6.85 (t, J= 7.8 Hz, 1H), 
6.94 (t, J = 7.7 Hz, 1H), 7.14 (t, J = 7.7 Hz, 1H), 7.22 (m, J = 8.6 Hz, 8.0 Hz 3H), 7.87 
(d, J= 7.8 Hz, 1H), 7.94 (d, J= 7.7 Hz, 1H), 8.11 (m, J = 8.6 Hz, 4.8 Hz, 2H); 13C NMR 
(CDCl3, 125 MHz), δ = 9.9 (2 C), 24.7 (2 C), 28.1, 28.4, 66.0, 66.8, 76.4, 77.3, 77.8, 
79.6, 80.7, 82.1, 83.6, 88.7, 110.7, 111.0, 115.9, 116.1, 120.5, 120.9, 126.7, 128.4 (2 C), 
129.1, 130.5 (2 C), 130.6, 130.7, 148.8, 149.0, 160.8, 161.4, 162.4, 164.5, 166.6 (d, J= 
194.9 Hz), 166.9. HRESIMS m/z 883.1171 [M + H]+ (calcd for C38H36FN6O8S5, m/z 
883.1182). 
Compound 10: General Procedure for Carbamates.199 A slurry of Verticillin H 
(1) (5 mg, 0.007 mmol), carbonyldiimidazole (15 equiv., 34 mg), potassium hydroxide 
(cat., 2 mg), and dimethylaminopyridine (0.25 equiv., 0.014 mL of a 0.2 M solution in 
chloroform-d) in chloroform-d (1 mL) was stirred at 50-55 °C (eventually becoming a 
clear solution) for 2 hours at which time transfer to an NMR tube confirmed consumption 
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of starting material. After transferring back into the reaction vessel, methylamine (5 
equiv., 0.008 mL) was added and the resulting reaction mixture was stirred overnight at 
room temperature.  The reaction mixture was then concentrated in vacuo providing a 
residue that was dissolved in ethyl acetate and washed with several portions of water 
(back extracted with ethyl acetate). The combined organics were rinsed with brine, dried 
over sodium sulfate, and concentrated in vacuo prior to purification by HPLC to afford 
10 (1 mg, 0.0013 mmol, 18 % yield) as an off-white powder. 1H NMR (CDCl3, 700 
MHz) δ = 1.18 (t, J= 7.2 Hz, 3H), 1.21 (t, J= 7.2 Hz, 3H), 2.12 (m, 2H), 2.36 (m, 2H), 
2.93 (s, 3H), 2.99 (s, 3H), 3.06 (d, J= 4.8 Hz, 3H), 4.86 (m, 1H), 5.12 (d, J=1.9 Hz, 1H), 
5.15 (s, 1H), 5.18 (s, 1H), 5.19 (s, 1H), 5.21 (s, 1H), 5.32 (d, J= 1.9 1H), 6.64 (d, J= 7.7 
Hz, 1H), 6.67 (d, J= 7.7 Hz, 1H), 6.85 (m, 2H), 6.88 (s, 1H), 7.14 (t, J= 7.7 Hz, 1H), 7.18 
(t, J = 7.7 Hz, 1H), 7.48 (d, J = 7.7 Hz, 1H), 7.94 (d, J= 7.7 Hz, 1H); 13C NMR (CDCl3, 
175 MHz), δ = 9.8 (2 C), 24.6, 24.7, 28.0, 28.5, 28.6, 29.7, 50.9, 65.1, 65.8, 76.1, 77.9, 
78.4, 81.4, 81.5, 82.5, 83.2, 110.6, 111.1, 120.2, 120.7, 128.6, 128.8, 129.1, 130.2, 130.4, 
148.5, 149.1, 155.2, 161.2, 161.3, 164.3, 166.5. HRESIMS m/z 782.1550 [M + H]+ (calcd 
for C34H36N7O7S4, m/z 782.1559). 
Compound 11: Utilizing dimethylamine, in the general procedure for carbamates, 
Verticillin H (1) (10 mg, 0.014 mmol) afforded 11 (4.5 mg, 0.006 mmol, 43 % yield) as 
an off-white powder. 1H NMR (CDCl3, 500 MHz) δ = 1.20 (t, J= 7.4 Hz, 6H), 2.13 (m, 
2H), 2.36 (m, 2H), 2.92 (s, 3H), 2.98 (s, 3H), 3.01 (s, 3H), 3.14 (s, 3H), 5.14 (d, J=2.9 
Hz, 1H), 5.20 (s, 2H), 5.21 (s, 1H), 5.24 (s, 1H), 5.33 (d, J= 3.0, 1H), 6.65 (d, J= 7.8 Hz, 
1H), 6.67 (d, J= 7.8 Hz, 1H), 6.84 (m, 2H), 6.96 (s, 1H), 7.15 (m, 2H), 7.50 (d, J = 7.7 
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Hz, 1H), 7.96 (d, J= 7.7 Hz, 1H); 13C NMR (CDCl3, 125 MHz), δ = 9.9 (2 C), 24.7, 24.8, 
28.1, 28.6, 65.2, 65.5, 77.0, 77.2, 77.3, 77.8, 78.2, 78.6, 81.0, 82.1, 82.7, 83.6, 110.9, 
111.4, 120.1, 120.9, 126.4, 128.9, 129.0, 129.4, 130.3, 130.5, 148.7, 149.3, 155.7, 161.4, 
161.6, 164.5, 166.3. HRESIMS m/z 796.1724 [M + H]+ (calcd for C35H38N7O7S4, m/z 
796.1715). 
Compound 12: Utilizing the general procedure for succination previously 
described, Verticllin A (1) (5 mg, 0.008 mmol) afforded 12 (4.5 mg, 0.006 mmol, 71 % 
yield) as a white powder. 1H NMR (CDCl3, 400 MHz) δ = 1.87 (s, 3H), 1.88 (s, 3H), 2.66 
(dt, J= 17.3 Hz, 3.7 Hz, 1H), 2.85 (dt, J= 17.3 Hz, 3.7 Hz, 1H), 2.90 (s, 3H), 2.97 (s, 3H), 
3.04 (dt, J= 17.3 Hz, 3.7 Hz, 1H), 3.18 (dt, J = 17.3 Hz, 3.7 Hz, 1H), 5.11 (s, 1H), 5.15 
(s, 3H), 5.52 (d, J= 1.8 Hz, 1H), 6.64 (d, J = 7.7 Hz, 1H), 6.67 (d, J = 7.7 Hz, 1H), 6.84 
(t, J = 7.7 Hz, 1H), 6.88 (t, = 7.7 Hz, 1H), 6.98 (s, 1H), 7.16 (m, 2H), 7.73 (d, J = 7.7 Hz, 
1H), 7.90 (d, J = 7.7 Hz, 1H); 13C NMR (CDCl3, 100 MHz), δ = 17.6, 17.8 , 27.4, 27.7, 
28.5, 30.2, 65.3, 66.0, 73.4, 73.8, 74.8, 77.3, 80.4, 81.1, 82.4, 83.0, 110.7, 111.2, 120.7, 
120.8, 126.2, 128.3, 129.0, 129.3, 130.4, 130.5, 148.4, 148.8, 162.2, 162.3, 163.2, 165.8, 
171.0, 174.2. HRESIMS m/z 797.11584 [M + H]+ (calcd for C34H33N6O9S4, m/z 
797.1191). 
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VERTICILLIN A-EXPANSILE NANOPARTICLES REDUCE TUMOR BURDEN IN 
HIGH GRADE SEROUS OVARIAN CANCER 
This chapter has been modified from the one accepted for publication in 
Molecular Cancer Therapeutics to focus on the expansile nanoparticles work. The 
chapter is presented in the style of that journal. Coauthors include Salvi, A., 
Austin, J. R., Kilpatrick, K., Russo, A., Lantvit, D., Calderon-Gierszal, E., Mattes, 





Ovarian cancer is the fifth leading cause of death among women and is the most 
lethal tumor type of the female reproductive tract.200 In 2019, an estimated 22,530 women 
in United States will be diagnosed with ovarian cancer and about 13,980 women will 
succumb to the disease.165 The most common and deadly histological subtype of ovarian 
cancer is high grade serous ovarian cancer (HGSOC). However, most patients develop 
chemoresistance and ultimately die from recurrent disease. Chemoresistance is 
multifaceted and likely arises both from mechanisms of resistance to the current therapy, 
or through immune cell evasion.201-204  
One avenue to identify new therapies that may avert the chemoresistance problem 
is through the investigation of natural product drug leads with both unique chemical 
structures and modes of action, such as the verticillins.11 The verticillins are 
epipolythiodioxopiperazine (ETP) alkaloids, and largely exist as dimers containing both 
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diketopiperazine moieties and disulfide bridges. This group of secondary metabolites is 
usually isolated from terrestrial and marine filamentous fungi, such as Verticillium sp., 
Penicillium sp. and Gliocladium sp. that belong to Sordariomycetes and 
Eurotiomycetes.34, 40 Verticillin A was the first discovered analogue in 1970, and to date, 
27 verticillin analogues are described in the literature.34, 40, 44  
Enabled by recent advances in fungi fermentation and isolation, the role of 
verticillin A as an anti-cancer agent is actively being investigated.33-34 Verticillin A 
selectively inhibits histone methyltransferases (HMTases) such as SUV39H1, SUV39H2, 
G9a, HTM, MLL1 and GLP.35, 70 In colon carcinoma, verticillin A inhibited H3K9 
methylation on the FAS promoter, restored Fas expression, and caused cell death by 
apoptosis.35 Furthermore, mice treated with a combination of verticillin A and 5-
fluorouracil displayed significantly smaller tumors and sensitized metastatic colon 
carcinoma cells to 5-fluorouracil.35 Additionally, verticillin A suppressed metastatic 
colon cancer cell immune evasion and chemoresistance.35 In pancreatic cancer cells, 
verticillin A inhibited MLL1, a HMTase responsible for H3K4 methylation, leading to 
decreases in H3K4me3 levels and PD-L1 expression. Lower PD-L1 expression led to 
reduced binding to PD-1 and activation of an immune response along with an enhanced 
chemotherapeutic response.70 In a recent study with pancreatic ductal adenocarcinoma 
cells, verticillin A differentially altered H3K9me3 and H3K4me3 levels leading to 
expression of pro-apoptotic genes and inhibition of anti-apoptotic genes.37 
Despite the promising results of verticillin A cytotoxic assays, however, its high 
toxicity interferes with the healthy cells. Studies performed using peripheral nerve sheath 
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tumor cells report toxicity and weight loss in mice treated with verticillin A.30 Therefore, 
the choice of a delivery system can be important for cancer treatment. Higher 
concentration of the drug can be provided via a local drug delivery system that delivers 
directly to the cancer cells.205 A study of pharmacokinetics and bioavailability of 
verticillin A in mice showed that intraperitoneal delivery was preferred compared to 
intravenous and oral administration.31 To improve the delivery of the drug to the targeted 
cells, the use of nanoparticles represents an emerging technology.206-207 Lately, many 
studies were conducted to ensure a higher dose of drug released from the nanoparticles 
during a longer period of time, resulting in nanoparticles synthesized by a “control-
released” polymer that swells in certain environmental conditions, such as the acidic pH 
that corresponds to the microenvironment of cancer cells.207 
Expansile nanoparticles (eNPs) permit the release of the drug in an acidic 
environment (i.e. pH 4-5) corresponding to the pH of the lysosomes that are formed from 
endosomes.208 The swelling of eNPs in acidic pH was assessed using different 
instrumentations and techniques. The sizes of those eNPs were more than 350 times the 
original size over a number of days.208 Another study from the same group showed that 
the accumulation of paclitaxel-loaded pH-responsive expansile nanoparticles (PTX-
eNPs) inside tumor cells permitted the delivery of more than 100 times higher dose of 
taxol. The retention of eNPs inside the cell permitted the maintenance of a high 




During this study we were able to synthesize 5% loaded Verticillin A-expansile 
nanoparticles (verticillin A-eNPs). These nanoparticles induced cell death in HGSOC 
cells. The animals treated with verticillin A-eNPs reduced tumor burden in vivo and 
showed no morphological signs of liver toxicity compared to free verticillin A. Together, 
these findings validate verticillin A as a potential anti-cancer compound and highlight 
verticillin A-eNPs as a promising drug delivery strategy.  
Materials and Methods  
Verticillin A purification and synthesis of expansile nanoparticles  
Verticillin A was isolated and characterized from Clonostachys rogersoniana 
(strain MSX59553) as detailed previously following a recently published fermentation 
optimization strategy.33-34 The purity of the isolated verticillin A was assessed via UPLC 
and 1H-NMR. The synthesis of verticillin A-eNPs and eNPs was performed using a 
miniemulsion polymerization method (Figure 12) as previously described.209-211 Scanned 
electron microscope images were taken (Figure S73), and a calibration curve of verticillin 
A was built to calculate the encapsulation efficiency, which was found to be 76.9% 
(Figure S73). These data demonstrate the presence of 0.9 mg of verticillin A/ml of the 







Figure 12. Verticillin A-eNP Synthesis. The synthesis followed a modified procedure 
developed by Colby et al.208-209 The aqueous phase contains surfactant while the organic 
phase contains the pre-polymerized eNP polymer and verticillin A. This solution was 
emulsified with a probe sonicator to create a suspension of organic phase droplets in the 
aqueous phase. The organic solvent was evaporated, leaving behind verticillin A 
encapsulated inside eNPs. Finally, a last step of dialysis was done on the solution to 




Animals and xenograft experiments  
All animals were treated in accordance with NIH Guidelines for the Care and Use 
of Laboratory Animals and the established Institutional Animal Use and Care protocol at 
the University of Illinois, Chicago. Xenograft studies utilized NCr nu/nu athymic female 
mice 6-8 weeks in age (Taconic). Mice were housed in a temperature and light-controlled 
environment (12 hours light and 12 hours dark) and provided food and water ad libitum. 
For xenograft experiments, OVCAR8-RFP cells (5 x 106) were injected intraperitoneally 
(IP) per mouse and tumor growth was monitored using Xenogen IVIS® Spectrum In Vivo 
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Imaging System (PerkinElmer) as previously described.212 Once all the mice formed 
tumors (~4 weeks), the mice were separated into 2 treatment groups and dosed once 
every two days with 0.5 mg/kg of verticillin A encapsulated nanoparticles (eNP-VA) and 
empty nanoparticles (eNP) for a total of 12 days. Mice were IVIS imaged twice weekly 
(535 nm excitation, and 620 nm emission, Exposure time: 2 seconds, F stop: 2). Living 
Image 4.0 software was used to quantify the average abdominal radiant efficiency and 
normalization was performed using Day 0 radiant efficiency. At week 7, all animals were 
sacrificed, and tumors were collected for histological analysis.  
Results  
Verticillin A induces cytotoxicity in HGSOC cell lines in vitro  
Verticillin A has been shown to inhibit the growth of colon cancer, pancreatic 
cancer, leiomyosarcoma and malignant peripheral nerve sheath tumor cells.30, 35, 37, 70 In 
order to determine if verticillin A inhibited growth of ovarian cancer cells, three validated 
models of HGSOC, OVSAHO, OVCAR4 and OVCAR8 were used. Taxol was used as 
positive control. Verticillin A was found to inhibit the growth of all three cell lines with 
IC50 values of 60 nM, 47 nM and 45 nM in OVSAHO, OVCAR4 and OVCAR8, 
respectively (Table 6).  
 
Table 6. IC50 Values of OVSAHO, OVCAR4 and OVCAR8 Cells Treated with 
Verticillin A and Chemotherapeutic Control Taxol. (vehicle: DMSO). 
 
  IC50 (nM)  
 OVSAHO OVCAR4 OVCAR8 
Verticillin A 60 47 45 
Taxol 80 113 6 
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 In order to determine whether the growth inhibition effects exerted by verticillin 
A, a 2D foci assay was performed. Cells were treated with verticillin A for 8 hrs and foci 
were allowed to form for 2 weeks. Treatment with verticillin A completely abrogated foci 
formation in OVCAR4 and OVCAR8 cells (Figure S74) compared to vehicle control 
suggesting a cytotoxic effect and not a cytostatic effect.  
Verticillin A encapsulated nanoparticles demonstrated reduced liver toxicity 
relative to free drug 
To determine whether verticillin A affected tumor burden in vivo, OVCAR8-RFP 
cells were xenografted IP into female athymic nude mice. Tumors were allowed to form 
for 4 weeks and once all the mice displayed detectable tumors, the animals were treated 
with verticillin A and vehicle control (Cremophor EL/EtOH). However, animals treated 
with verticillin A showed significant gross morphological liver damage at the time of 
sacrifice (Figure 13). These observations suggested that verticillin A exerted a non-





Figure 13. Representative Images Show Liver Damage in Verticillin A Treated 
Animals. OVCAR8-RFP cells were xenografted IP to form tumors. Mice were dosed 




To confirm this, dose response curves were performed using two non-cancerous 
cell lines. Human ovarian surface epithelial cells IOSE80 and human fallopian tube 
epithelial secretory cells FT33 were treated with verticillin A and vehicle control 
(DMSO) for 3 days. Verticillin A inhibited growth of both cancerous and non-cancerous 
cells indicating a non-specific cytotoxic effect (Figure S75).  
To improve the drug specificity towards tumor cells, verticillin A was 
encapsulated in expansile nanoparticles (verticillin A-eNPs) that have been shown to, 
following IP administration, localize to IP tumors of ovarian, mesothelial and pancreatic 





to tumors via materials-based targeting and, following internalization via 
macropinocytosis, release the encapsulated verticillin A upon encountering the acidic late 
endosome, thus reducing non-specific toxicity and increasing drug delivery to the 
tumor.209, 211 To determine whether verticillin A loaded nanoparticles were still active, 
verticillin A-eNPs and eNPs were evaluated in an in vitro cytotoxicity assay using 3 
HGSOC cell lines (OVSAHO, OVCAR4 and OVCAR8). Verticillin A-eNPs showed 
potent cytotoxicity with IC50 values of 44 nM, 29 nM and 32 nM in OVSAHO, OVCAR4 
and OVCAR8 cells respectively (Table 7). Interestingly, IC50 values of verticillin A-eNPs 
were similar to free compound in all three HGSOC cell lines tested, confirming that 
encapsulation in nanoparticles did not reduce the activity and potency of verticillin A. 
Unloaded-eNPs did not exert a cytotoxic effect on any of the cell lines. 
 
Table 7. Cytotoxicity Results of Verticillin A Encapsulated Nanoparticles (eNP-VA). 
OVSAHO, OVCAR4 and OVCAR8 cells were treated with verticillin A and empty 
nanoparticles (eNP) for 72 hrs. 
 
 IC50 (nM) 
 OVSAHO OVCAR4 OVCAR8 
Verticillin A-eNPs 44 29 32 
 
 
Verticillin A reduces tumor burden in vivo  
To evaluate the ability of verticillin A-eNPs to reduce in vivo tumor burden, 
OVCAR8-RFP cells were xenografted IP in athymic nude mice and tumors were allowed 
to form for 4 weeks. The mice were treated with unloaded-eNPs and verticillin A-eNPs 
every other day for 12 days at a dose of 0.5 mg/kg. Animals treated with verticillin A-
eNPs had significantly less tumor burden based on average radiant efficiency measured 
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with IVIS and had no measurable change in body weight (Figure 14). Interestingly, eNPs 
and verticillin A-eNPs did not cause the same gross morphological liver damage that was 
seen in mice treated with free verticillin A suggesting that encapsulation into the eNPs 




Figure 14. IVIS Images of Tumors in Mice on Days 0, 4, 8 and 12 of Drug 
Treatment. OVCAR8-RFP cells were xenografted IP to form tumors. Mice were dosed 




New therapies are needed to treat HGSOC and metastasis related lethality from 
the disease. Nearly 60% of all FDA approved anti-cancer drugs are derived from nature, 
and it remains a promising source for new drug leads, particularly due to the chemical 
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diversity.10, 14 This study found that verticillin A, a fungal metabolite, caused cytotoxicity 
in HGSOC. Encapsulation of verticillin A in eNPs also improved drug specificity, 
reduced toxicity and, more importantly, caused a significant reduction of tumor burden in 
vivo.  
A challenge with chemotherapeutic agents, particularly hydrophobic ones derived 
from nature, is to identify a delivery method that enables drug to accumulate therapeutic 
concentrations within the target tissue while minimizing, or averting altogether, adverse 
systemic toxicities. For example, taxol, which was first reported in 1971, was not 
considered a promising drug in terms of solubility, toxicity and large-scale production.179, 
182, 216 However, tremendous progress has been made in the past four decades making 
taxol one of the most effective chemotherapeutic drugs, particularly in frontline therapy 
for ovarian cancer.217-218 IP administration of free verticillin A, solubilized in Cremophor 
EL/EtOH as a means to address its low solubility, resulted in liver toxicity. Shorter 
studies using verticillin A IP did not report significant liver toxicity, nevertheless, studies 
performed using peripheral nerve sheath tumor cells report it.30, 35 To overcome the toxic 
effects induced by verticillin A, and to enhance solubility, a well-characterized 
nanoparticle-based drug delivery system, the eNP was used.209, 211, 219 Previously, eNPs 
have been used to deliver other cytotoxic natural products (e.g., taxol) with high 
specificity to peritoneal tumors. As a result of their unique materials-based targeting 
mechanism, eNPs afford 10 to 100-fold higher intratumoral drug concentrations than are 
achieved with free drug and show remarkable efficacy (e.g., doubling of survival 
compared to free drug controls).211  
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In conclusion, encapsulation of verticillin A in an eNP improves drug efficacy, 
reduces toxicity and highlights the advantages of marrying natural products/anti-cancer 
research with nanoparticle drug delivery systems to address a clinical challenge. 
Continued investigation of verticillin A, verticillin analogs, and the eNP delivery system 
will provide key data for preparing an optimized efficacious formulation worthy of large 
animal pharmacokinetic studies and bring us one step closer to a promising therapy for 
ovarian cancer patients. 
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DROPLET PROBE: COUPLING CHROMATOGRAPHY TO THE IN SITU 
EVALUATION OF THE CHEMISTRY OF NATURE 
This chapter has been modified from the review paper accepted for publication in 
Natural Product Reports and is presented in that style. Coauthors include 




The chemistry of nature can be beautiful, inspiring, beneficial and poisonous, 
deepening on perspective. Since the isolation of the first secondary metabolites roughly 
two centuries ago220, much of the chemical research on natural products has been both 
reductionist and static.221 Typically, compounds were isolated and characterized from the 
extract of an entire organism from a single time point. While there could be subtexts to 
that approach, the general premise has been to determine the chemistry with very little in 
the way of tools to differentiate spatial and/or temporal changes in secondary metabolite 
profiles.222 However, the past decade has seen exponential advances in our ability to 
observe, measure, and visualize the chemistry of nature in situ.105-106  
In many ways, this review on the droplet-liquid microjunction-surface sampling 
probe (droplet probe) originates in attempting to carry out similar in situ chemistry 
experiments but on fungal cultures. We believe that the process of studying the chemistry 
of nature in situ is here to stay, and most likely, it will only become both more powerful 
and more accessible in the future. Quite simply, the ability to probe research questions 
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that address the timing and/or spatial distribution of natural products are both too 
tempting and too important to ignore.  
Optimized Production of Fungal Metabolites on the Lab Scale 
It has long been known that media studies can be used to optimize the production 
of fungal metabolites, sometimes codified as an OSMAC (one strain, many cultures) 
approach.223-224 However, how one goes about that can be quite variable, and we have 
found that evaluating the chemistry of fungal cultures in situ via droplet probe enables 
scouting growth conditions rapidly, especially when spatial and temporal studies are 
taken into consideration.  
Mevalocidin (spatial considerations) 
Mevalocidin225-226 is a unique phytotoxin that exhibits broad spectrum post 
emergent herbicidal properties. Since there are no organic herbicides on the market, it is 
currently being considered for development. As part of a study to improve the production 
of this compound via fermentation on the laboratory scale, in situ sampling via droplet 
probe permitted a better understanding of the distribution of this herbicidal secondary 
metabolite in the fungal culture.227 In addition to the pragmatic goal of increasing yield, 
what the fungus did with mevalocidin was of interest from a chemical ecology 
perspective. 
The droplet probe facilitated in situ sampling of the fungal chemistry on the 
surface of the cultures (mycelium, guttates, and surrounding agar), which would be 
challenging to accomplish via traditional natural product extraction methods (Figure. 15). 
The use of droplet probe was important in understanding that both strains of 
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Coniolariella sp. (strains MSX56446 and MSX92917) released mevalocidin into their 
surroundings via guttates (exudates or liquid droplets), where the highest concentration of 
this secondary metabolite was mapped. Similarly, mevalocidin was also detected in the 
surrounding agar but not on the surface of the mycelium. Since the fungi that 
biosynthesize it are both saprobes (i.e. decomposers of dead organic matter), it was 
fascinating to map that the fungi seem to concentrate mevalocidin in this fashion, so as to 
exude the phytotoxic compound into their surroundings.227 Extrapolating, we 
hypothesized that this imparts an advantage to the fungus, potentially killing (or at least 
weakening) surrounding plant material, so that the fungus can utilize the dead organic 
matter for growth and reproduction. Such information could not be obtained without 
instruments that sampled chemistry in situ in this manner.  
This general approach has been used several times, where it has been interesting 
to see where fungal secondary metabolites are concentrated.228-229 Based on additional 
literature,119, 230-232 we suspect that guttates may be a common place for such compounds 
to be localized.  
Verticillins (spatial and temporal considerations) 
One of the more prominent examples of using the droplet probe to scout for 
optimized fermentation conditions comes via our studies on verticillins.233 This class of 
compounds (epipolythiodioxopiperazine alkaloids) has been in the literature since the 
early 1970s.234 While they have been studied by prominent organic chemists,65-66, 235 a 
scalable total synthesis has yet to be reported. Recently, a series of studies on the 
anticancer activity of the verticillins have been published,236-240 and there is growing 
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interest in their potential as selective histone methyl transferase inhibitors. This 
stimulated several in vivo studies,31, 239-241 and it became obvious that if future progress 
was to be made, an amplified supply of verticillins was needed. However, based on the 
initial growth parameters using a rice-based substrate,236 we found it challenging to scale 




Figure. 15. The Fermentation Conditions Optimized for the Production of 
Verticillin A and Verticillin H. This was through both strain and media optimization via 
an OSMAC approach, where the droplet probe played an instrumental role. An average 
growth of strain MSX59553 yielded about 3 g of extract per flask in the lab. The data in 
orange are from three biological replicates (+/- SD), indicating about 10 mg of each 
compound per gram of extract (or 30 mg per flask). Initially, the cultures were generating 




Fungal cultures that produced verticillins were examined in situ via droplet probe 
on a suite of different media (Figure. 15), ranging from both rich (i.e. those based on 
extracts of potatoes, yeast, etc.) and defined (i.e. those that are made via a specific 
recipe).233 We were pleased that fermentation on oatmeal-based medium seemed to 
produce the highest yield of verticillins, a fact that could only be discerned empirically. 
This observation was then tested in scaled up cultures (including three biological 
replicates), using a traditional natural products approach to validate the measurements 
from in situ analysis. Not only did the in situ results translate well to the pragmatic need 
for isolating more of the verticillins, but also, a timing study noted their peak production 
from 7 to 22 days, meaning that cultures could be processed on a weekly to biweekly 
basis.233 All told, we went from a challenging provision of a few mg of verticillins to a 
steady state production of 50 to 100 mg monthly (Figure. 15). Importantly, those 
materials are now being used in a suite of further studies, including in vivo 
pharmacology, in vivo pharmacokinetics, and semi-synthesis; none of those would be 
possible without the enhanced supply.  
Conclusion 
In general, the advent of ambient ionization mass spectrometry techniques has 
made an enormous impact on natural products research, since organisms can be examined 
in situ with limited sample preparation.242 When it comes to the droplet probe, and with 
the caveat that we may be biased based on our mycological research, fungi represent 
ideal candidates for in situ mass spectrometry mapping experiments. Compared to plants, 
microorganisms respond quickly to changes in environment (i.e. media)243-244 or by the 
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introduction of other organisms (i.e. co-cultures),223, 245 thus creating unique profiles of 
their biosynthesized secondary metabolites. Furthermore, as opposed to many bacteria, 
fungi are morphologically diverse and often develop unique physical characteristics as 
the culture grows. The presence of stroma (finger–like projections),246-247 guttates or 
liquid exudates 119, 230-231, 248 and mycelium color changes/gradients give rise to several 
questions about the spatial distribution of the metabolites associated with such features. 
Once the droplet probe has sampled the surface of an organism, that extract can 
then be interfaced with a wide range of analytical tools that are common to natural 
products laboratories. Chromatographic separation is the most unique aspect, as that is 
how it differs from the range of ambient ionization techniques that are also used to study 
the chemistry of nature in situ. In turn, chromatographic resolution of the extract from in 
situ sampling via droplet probe serves to enhance the measurements from any detectors 
added post column, including UV/Vis and HRMS/tandem mass spectrometry.  
We have found that it is a great tool for determining ways to enhance the 
production of secondary metabolites, to probe conditions for the biosynthesis of non-
natural natural products, and to examine the generation of new chemical diversity via co-
culturing. Opportunities to study the chemistry of a range of materials in situ abound, and 
only time will tell what other questions can be analysed using the droplet probe. 
Acknowledgements 
SLK and DK were supported by the National Center for Complementary and 
Integrative Health/National Institutes of Health (NIH), under award numbers T32 
AT008938 and F31 AT009264, respectively. VK was supported by the U. S. Department 
 
108 
of Energy, Office of Science, Basic Energy Sciences, Chemical Sciences, Geosciences, 
and Biosciences Division. Research on bioactive fungal metabolites in NHO’s lab is 




  (1)  Miller, K., D.; Siegel, R., L.; Lin, C., C.; Mariotto, A., B.; Kramer, J., L.; Rowland, 
J., H.; Stein, K., D.; Alteri, R., Jemal, A., Ca-Cancer J. Clin. 2016, 66, 271. 
  (2)  Siegel, R. L.; Miller, K. D., Jemal, A., Ca-Cancer J. Clin. 2019, 69, 7. 
  (3)  Agarwal, R., Kaye, S., B., Nat. Rev. Cancer 2003, 3, 502. 
  (4)  Whiteside, T., Oncogene 2008, 27, 5904. 
  (5)  Rueff, J., Rodrigues A, S.,Cancer Drug Resist.; Humana Press, 2016, p. 1. 
  (6)  Lin, J. H., Biopolymers 2016, 105, 2. 
  (7)  Holohan, C.; Van Schaeybroeck, S.; Longley, D. B., Johnston, P. G., Nat. Rev. Cancer 
2013, 13, 714. 
  (8)  Newman, D., J., Cragg, G., M., J. Nat. Prod. 2007, 70, 461. 
  (9)  Salim, A., A.; Chin, Y., W., Kinghorn, A., D. ,Bioactive molecules and medicinal 
plants; Springer-Verlag Berlin Heidelberg, 2008, p. XXIII. 
  (10)  Newman, D., J., Cragg, G., M., J. Nat. Prod. 2016, 79, 629. 
  (11)  Kinghorn, A. D.; Carcache De Blanco, E. J.; Lucas, D. M.; Rakotondraibe, H. L.; 
Orjala, J.; Soejarto, D. D.; Oberlies, N. H.; Pearce, C. J.; Wani, M. C.; Stockwell, B. R.; 
Burdette, J. E.; Swanson, S. M.; Fuchs, J. R.; Phelps, M. A.; Xu, L.; Zhang, X., Shen, Y. 
Y., Anticancer Res. 2016, 36, 5623. 
  (12)  González-Medina, M.; Owen, J. R.; El-Elimat, T.; Pearce, C. J.; Oberlies, N. H.; 
Figueroa, M., Medina-Franco, J. L., Front. Pharmacol. 2017, 8, DOI: 
10.3389/fphar.2017.00180. 
  (13)  González-Medina, M.; Prieto-Martínez, F. D.; Naveja, J. J.; Méndez-Lucio, O.; El-
Elimat, T.; Pearce, C. J.; Oberlies, N. H.; Figueroa, M., Medina-Franco, J. L., Future Med. 
Chem. 2016, 8, 1399. 
  (14)  El-Elimat, T.; Zhang, X.; Jarjoura, D.; Moy, F. J.; Orjala, J.; Kinghorn, A. D.; Pearce, 
C. J., Oberlies, N. H., ACS Med. Chem. Lett. 2012, 3, 645. 
  (15)  Andersen, S., Frisvad, J., J. Appl. Microbiol. 1994, 19, 486. 
  (16)  Ligon, B. L., in Seminars in pediatric infectious diseases, Vol. 15, Elsevier, 2004, 
p. 52. 
  (17)  Hendrik, G.; Ietida, M.; Pontius, A.; Kehraus, S.; Gross, H., König, G., Phytochem. 
Rev. 2010, 9, 537. 
  (18)  Blackwell, M., Am. J. Bot. 2011, 98, 426. 
  (19)  Hawksworth, D. L., Lücking, R., Microbiol. Spectrum 2017, 5. 
  (20)  Hibbett, D.; Abarenkov, K.; Kõljalg, U.; Öpik, M.; Chai, B.; Cole, J.; Wang, Q.; 
Crous, P.; Robert, V., Helgason, T., Mycologia 2016, 108, 1049. 
  (21)  Bills, G. F., Gloer, J. B., Microbiol. Spectrum 2016, 4, DOI: 
10.1128/microbiolspec.FUNK. 




  (23)  Evidente, A.; Kornienko, A.; Cimmino, A.; Andolfi, A.; Lefranc, F.; Mathieu, V., 
R., Kiss, R., Nat. Prod. Rep. 2014, 31, 617. 
  (24)  Iwasa , E.; Hamashima , Y., Sodeoka , M., Isr. J. Chem. 2011, 51, 420. 
  (25)  Jiang, C. S., Guo, Y. W., Mini-Reviews in Medicinal Chemistry 2011, 11, 728. 
  (26)  Gardiner, D. M.; Waring, P., Howlett, B. J., Microbiology 2005, 151, 1021. 
  (27)  Liu., F.; Liu., Q.; Yang., D.; Bollag., W. B.; Robertson., K.; Wu., P., Liu., K., Cancer 
Res. 2011, 71, 6807. 
  (28)  Feiyan, L.; Ping, W., Kebin, L., in United States Patent Application, Vol. US 
20140161785A1, Zhejiang UniversityAugusta University Research Institute Inc United 
States, 2014, p. 15. 
  (29)  Niu, S.; Yuan, D.; Jiang, X., Che, Y., Protein Cell 2014, 5, 945. 
  (30)  Zewdu, A.; Lopez, G.; Braggio, D.; Kenny, C.; Constantino, D.; Bid, H. K.; Batte, 
K.; Iwenofu, O. H.; Oberlies, N. H.; Pearce, C. J.; Strohecker, A. M.; Lev, D., Pollock, R. 
E., Clin. Exp. Pharmacol. 2016, 6, 221. 
  (31)  Wang, J.; Zhu, X.; Kolli, S.; Wang, H.; Pearce, C. J.; Oberlies, N. H., Phelps, M. A., 
J. Pharm. Biomed. Anal. 2017, 139, 187. 
  (32)  Wang, Y.; Hu, P.; Pan, Y.; Zhu, Y.; Liu, X.; Che, Y., Liu, G., Fungal Genet. Biol. 
2017, 103, 25. 
  (33)  Amrine, C. S. M.; Raja, H. A.; Darveaux, B. A.; Pearce, C. J., Oberlies, N. H., J. 
Ind. Microbiol. Biotechnol. 2018, 45, 1053. 
  (34)  Figueroa, M.; Graf, T. N.; Ayers, S.; Adcock, A. F.; Kroll, D. J.; Yang, J.; Swanson, 
S. M.; Munoz-Acuna, U.; Carcache de Blanco, E. J.; Agrawal, R.; Wani, M. C.; Darveaux, 
B. A.; Pearce, C. J., Oberlies, N. H., J. Antibiot. 2012, 65, 559. 
  (35)  Paschall, A. V.; Yang, D.; Lu, C.; Choi, J.-H.; Li, X.; Liu, F.; Figueroa, M.; Oberlies, 
N. H.; Pearce, C.; Bollag, W. B.; Nayak-Kapoor, A., Liu, K., J. Immunol. 2015, 195, 1868. 
  (36)  Lu, C., Liu, K., Transl. Cancer Res. 2017, 6, S652. 
  (37)  Lu, C.; Yang, D.; Sabbatini, M. E.; Colby, A. H.; Grinstaff, M. W.; Oberlies, N. H.; 
Pearce, C., Liu, K., BMC Cancer 2018, 18, 149. 
  (38)  Jordan, T. W., Cordiner, S. J., Trends Pharmacol. Sci. 1987, 8, 144. 
  (39)  Liu, F.; Wu, S.; Chen, Y.; Yang, L., Wu, P., Acta Crystallogr., Sect. E: Struct. Rep. 
Online 2006, 62, 974. 
  (40)  Katagiri, K.; Sato, K.; Hayakawa, S.; Matsushima, T., Minato, H., J. Antibiot. 1970, 
23, 420. 
  (41)  Joshi, B. K.; Gloer, J. B., Wicklow, D. T., J. Nat. Prod. 1999, 62, 730. 
  (42)  Fox, E. M., Howlett, B. J., Mycol. Res. 2008, 112, 162. 
  (43)  Minato, H.; Matsumoto, M., Katayama , T., J. Chem. Soc. D 1971, 0, 44. 
  (44)  Minato, H.; Matsumoto, M., Katayama , T., J. Chem. Soc., Perkin Trans. 1 1973, 
17, 1819. 
  (45)  Chu, M.; Truumees, I.; Rothofsky, M. L.; Patel, M. G.; Gentile, F.; Das, P. R., Puar, 
M. S., J. Antibiot. 1995, 48, 1440. 
  (46)  Son, W. B.; Jensen, R. P.; Kauffman, C. A., Fenical, W., Nat. Prod. Lett. 1999, 13, 
213. 
  (47)  Yoshihide, U.; Junko, Y., Atsushi, N., Heterocycles 2004, 63, 1123. 
 
111 
  (48)  Dong, J.; He, H.; Shen, Y., Zhang, K., J. Nat. Prod. 2005, 68, 1510. 
  (49)  Zheng, C. J.; Kim, C. J.; Bae, K. S.; Kim, Y. H., Kim, W. G., J. Nat. Prod. 2006, 
69, 1816. 
  (50)  Jin-Yan, D.; Wei, Z.; Lei, L.; Guo-Hong, L.; Ya-Jun, L., Ke-Qing, Z., Chin. Chem. 
Lett. 2006, 17, 922. 
  (51)  Zheng, C. J.; Park, S. H.; Koshino, H.; Kim, Y. H., Kim, W. G., J. Antibiot. 2007, 
60, 61. 
  (52)  Chen, Y.; Guo, H.; Du, Z.; Liu, X. Z.; Che, Y., Ye, X., Cell Proliferation 2009, 42, 
838. 
  (53)  Xingzhong, L.; Shuchun, L.; Che, Y. Y.; sheng, Y.; Huijuan, G., Yali, C., Vol. CN 
200910077302 (Ed.: Institute of Microbiology, C. A. o. S.), Chinese Academy of Sciences, 
Peop. Rep. China, 2009. 
  (54)  Dirk, S.; Böttcher, C.; Lee, J., Scheel, D., J. Antibiot. 2011, 64, 523. 
  (55)  Suhadolnik, R. J., Chenoweth, R. G., J. Am. Chem. Soc. 1958, 80, 4391. 
  (56)  Winstead, J. A., Suhadolnik, R. J., J. Am. Chem. Soc. 1960, 82, 1644. 
  (57)  Kirby, W., Robins, J., Academic Press, New York, 1980, p. 301-326. 
  (58)  Mootz, H., D., Marahiel, M., A., Curr. Opin. Chem. Biol. 1997, 1, 543. 
  (59)  Marion, A.; Groll, M.; Scharf, D. H.; Scherlach, K.; Glaser, M.; Sievers, H.; 
Schuster, M.; Hertweck, C.; Brakhage, A. A.; Antes, I., Huber, E. M., ACS Chem. Biol. 
2017, 12, 1874. 
  (60)  Scharf, D. H.; Heinekamp, T.; Remme, N.; Hortschansky, P.; Brakhage, A. A., 
Hertweck, C., Appl. Microbiol. Biotechnol. 2012, 93, 467. 
  (61)  Dolan, S. K.; O’Keeffe, G.; Jones, G. W., Doyle, S., Trends Microbiol. 2015, 23, 
419. 
  (62)  Kim, J.; Ashenhurst, J. A., Movassaghi, M., Science 2009, 324, 238. 
  (63)  Kim, J., Movassaghi, M., Chem. Soc. Rev. 2009, 38, 3035. 
  (64)  Overman, L. E., Shin, Y., Org. Lett. 2007, 9, 339. 
  (65)  Boyer, N.; Morrison, K. C.; Kim, J.; Hergenrother, P. J., Movassaghi, M., Chem. 
Sci. 2013, 4, 1646. 
  (66)  Kim, J., Movassaghi, M., Acc. Chem. Res. 2015, 48, 1159. 
  (67)  Rodriguez, P., L., Carrasco, L., J. Virol. 1992, 66, 1971. 
  (68)  He, J.-S.; Gong, D.-E., Ostergaard, H. L., J. Immunol. 2010, 184, 555. 
  (69)  Koncz, G.; Hancz, A.; Chakrabandhu, K.; Gogolák, P.; Kerekes, K.; Rajnavölgyi, 
É., Hueber, A.-O., J. Immunol. 2012. 
  (70)  Lu, C.; Paschall, A. V.; Shi, H.; Savage, N.; Waller, J. L.; Sabbatini, M. E.; Oberlies, 
N. H.; Pearce, C., Liu, K., J. Natl. Cancer Inst. 2017, 109, djw283. 
  (71)  O'Hara, B., M.; Klinger, H., P.; Curran, T.; Zhang, Y., D., Blair, D., G., Mol. Cell. 
Biol. 1987, 7, 2941. 
  (72)  Scott, R., E., Pharmacol. Ther. 1997, 73, 51. 
  (73)  Erkel, G.; Gehrt, A.; Anke, T., Sterner, O., Z. Naturforsch. C 2002, 57, 759. 
  (74)  Zhang, Y.; Chen, Y.; Guo, X.; Zhang, X.; Zhao, W.; Zhong, L.; Zhou, J.; Xi, Y.; 
Lin, Z., Ding, J., Anti-Cancer Drugs 2005, 16, 515. 
  (75)  Chen, Y.; Miao, Z.; Zhao, W., Ding, J., FEBS Lett. 2005, 579, 3683. 
 
112 
  (76)  Chen, Y.; Zhang, Y.; Li, M.; Zhao, W.; Shi, Y.; Miao, Z.; Zhang, X.; Lin, L., Ding, 
J., Biochem. Biophys. Res. Commun. 2005, 329, 1334. 
  (77)  Zheng, L., J. Natl. Cancer Inst. Monogr. 2017, 109, djw304. 
  (78)  Brahmer , J.; Tykodi , S.; Chow , L.; Hwu , W.-J.; Topalian , S.; Hwu , P.; Drake , 
C.; Camacho , L.; Kauh , J.; Odunsi , K.; Pitot , H.; Hamid , O.; Bhatia , S.; Martins , R.; 
Eaton , K.; Chen , S.; Salay , T.; Alaparthy , S.; Grosso , J.; Korman , A.; Parker , S.; 
Agrawal , S.; Goldberg , S.; Pardoll , D.; Gupta , A., Wigginton , J., N. Engl. J. Med. 2012, 
366, 2455. 
  (79)  Siegel, R. L.; Miller, K. D., Jemal, A., Ca-Cancer J. Clin. 2016, 66, 7. 
  (80)  Orjala, J.; Oberlies, N. H.; Pearce, C. J.; Swanson, S. M., Kinghorn, A. D.,Bioactive 
Compounds from Natural Sources, Second Edition; CRC Press, 2011, p. 37. 
  (81)  Koncz, G.; Hancz, A.; Chakrabandhu, K.; Gogolák, P.; Kerekes, K.; Rajnavölgyi, 
É., Hueber, A.-O., J. Immunol. 2012, 189, 2815. 
  (82)  Bennett, J. W., Ciegler, A., M. Dekker, New York, 1983, p. xii- 478. 
  (83)  Bunch, A. W., Harris, R. E., Biotechnol. Genet. Eng. Rev. 1986, 4, 117. 
  (84)  Meletiadis, J.; Meis, J. F.; Mouton, J. W., Verweij, P. E., J. Clin. Microbiol. 2001, 
39, 478. 
  (85)  Lilly, V. G., Barnett, H. L., 1 ed., McGraw-Hill Book Company, Inc., New York, 
1951, p. xii - 464  
  (86)  Hewage, R. T.; Aree, T.; Mahidol, C.; Ruchirawat, S., Kittakoop, P., Phytochemistry 
2014, 108, 87. 
  (87)  Hemphill, C. F. P.; Sureechatchaiyan, P.; Kassack, M. U.; Orfali, R. S.; Lin, W.; 
Daletos, G., Proksch, P., J. Antibiot. 2017, 70, 726. 
  (88)  Kertesz, V.; Weiskittel, T. M., Van Berkel, G. J., Anal. Bioanal. Chem. 2015, 407, 
2117. 
  (89)  Sica, V. P.; Raja, H. A.; El-Elimat, T.; Kertesz, V.; Van Berkel, G. J.; Pearce, C. J., 
Oberlies, N. H., J. Nat. Prod. 2015, 78, 1926. 
  (90)  Paguigan, N. D.; El-Elimat, T.; Kao, D.; Raja, H. A.; Pearce, C. J., Oberlies, N. H., 
J. Antibiot. 2017, 70, 553. 
  (91)  El-Elimat, T.; Figueroa, M.; Ehrmann, B. M.; Cech, N. B.; Pearce, C. J., Oberlies, 
N. H., J. Nat. Prod. 2013, 76, 1709. 
  (92)  White, T. J.; Bruns, T.; Lee, S. H., Taylor, J. W., Academic Press, San Diego, 
California, 1990, p. 315-322. 
  (93)  Gardes, M.; White, T. J.; Fortin, J. A.; Bruns, T. D., Taylor, J. W., Canadian Journal 
of Botany 1991, 69, 180. 
  (94)  Raja, H. A.; Miller, A. N.; Pearce, C. J., Oberlies, N. H., J. Nat. Prod. 2017, 80, 756. 
  (95)  Abreu, L. M.; Moreira, G. M.; Ferreira, D.; Rodrigues-Filho, E., Pfenning, L. H., 
Fungal Biol 2014, 118, 1004. 
  (96)  Schroers, H.-J., Vol. Studies in mycology, Centraalbureau voor Schimmelcultures, 
Utrecht, The Netherlands. , 2001. 
  (97)  Hongsanan, S.; Jeewon, R.; Purahong, W.; Xie, N.; Liu, J.-K.; Jayawardena, R. S.; 
Ekanayaka, A. H.; Dissanayake, A.; Raspé, O.; Hyde, K. D.; Stadler, M., Peršoh, D., 
Fungal Divers. 2018, 1. 
 
113 
  (98)  Moreira, G. M.; Abreu, L. M.; Carvalho, V. G.; Schroers, H.-J., Pfenning, L. H., 
Mycol. Prog. 2016, 15, 1031. 
  (99)  Taylor, J. W., IMA Fungus 2011, 2, 113. 
  (100)  Hawksworth, D. L.; Crous, P. W.; Redhead, S. A.; Reynolds, D. R.; Samson, R. 
A.; Seifert, K. A.; Taylor, J. W.; Wingfield, M. J.; Abaci, Ö.; Aime, C.; Asan, A.; Bai, F.-
Y.; de Beer, Z. W.; Begerow, D.; Berikten, D.; Boekhout, T.; Buchanan, P. K.; Burgess, 
T.; Buzina, W.; Cai, L.; Cannon, P. F.; Crane, J. L.; Damm, U.; Daniel, H.-M.; van 
Diepeningen, A. D.; Druzhinina, I.; Dyer, P. S.; Eberhardt, U.; Fell, J. W.; Frisvad, J. C.; 
Geiser, D. M.; Geml, J.; Glienke, C.; Gräfenhan, T.; Groenewald, J. Z.; Groenewald, M.; 
de Gruyter, J.; Guého-Kellermann, E.; Guo, L.-D.; Hibbett, D. S.; Hong, S.-B.; de Hoog, 
G. S.; Houbraken, J.; Huhndorf, S. M.; Hyde, K. D.; Ismail, A.; Johnston, P. R.; 
Kadaifciler, D. G.; Kirk, P. M.; Kõljalg, U.; Kurtzman, C. P.; Lagneau, P.-E.; Lévesque, 
C. A.; Liu, X.; Lombard, L.; Meyer, W.; Miller, A.; Minter, D. W.; Najafzadeh, M. J.; 
Norvell, L.; Ozerskaya, S. M.; Öziç, R.; Pennycook, S. R.; Peterson, S. W.; Pettersson, O. 
V.; Quaedvlieg, W.; Robert, V. A.; Ruibal, C.; Schnürer, J.; Schroers, H.-J.; Shivas, R.; 
Slippers, B.; Spierenburg, H.; Takashima, M.; Taşkın, E.; Thines, M.; Thrane, U.; Uztan, 
A. H.; van Raak, M.; Varga, J.; Vasco, A.; Verkley, G.; Videira, S. I. R.; de Vries, R. P.; 
Weir, B. S.; Yilmaz, N.; Yurkov, A., Zhang, N., IMA Fungus 2011, 2, 105. 
  (101)  Rossman, A. Y.; Seifert, K. A.; Samuels, G. J.; Minnis, A. M.; Schroers, H.-J.; 
Lombard, L.; Crous, P. W.; Põldmaa, K.; Cannon, P. F.; Summerbell, R. C.; Geiser, D. M.; 
Zhuang, W.-y.; Hirooka, Y.; Herrera, C.; Salgado-Salazar, C., Chaverri, P., IMA Fungus 
2013, 4, 41. 
  (102)  Perdomo, H.; Cano, J.; Gené, J.; García, D.; Hernández, M., Guarro, J., Mycologia 
2013, 105, 151. 
  (103)  Sica, V. P.; Figueroa, M.; Raja, H. A.; El-Elimat, T.; Darveaux, B. A.; Pearce, C. 
J., Oberlies, N. H., J. Ind. Microbiol. Biotechnol. 2016, 43, 1149. 
  (104)  Sica, V. P.; Rees, E. R.; Raja, H. A.; Rivera-Chávez, J.; Burdette, J. E.; Pearce, C. 
J., Oberlies, N. H., Phytochemistry 2017, 143, 45. 
  (105)  Sica, V. P.; El-Elimat, T., Oberlies, N. H., Anal. Methods 2016, 8, 6143. 
  (106)  Sica, V. P.; Rees, E. R.; Tchegnon, E.; Bardsley, R. H.; Raja, H. A., Oberlies, N. 
H., Front. Microbiol. 2016, 7, DOI: 10.3389/fmicb.2016.00544. 
  (107)  Paguigan, N. D.; Raja, H. A.; Day, C. S., Oberlies, N. H., Phytochemistry 2016, 
126, 59. 
  (108)  Kertesz, V., Van Berkel, G. J., Anal. Chem. 2010, 82, 5917. 
  (109)  Kertesz, V., Berkel, G. J. V., Rapid Commun. Mass Spectrom. 2014, 28, 1553. 
  (110)  Khanna, S., Srivastava, A. K., Process Biochem. 2005, 40, 2173. 
  (111)  Yang, L. H.; Miao, L.; Lee, O. O.; Li, X.; Xiong, H.; Pang, K.; Vrijmoed, L., Qian, 
P., Appl. Microbiol. Biotechnol. 2007, 74, 1221. 
  (112)  Fuchser, J., Zeeck, A., Liebigs Ann. 1997, 1997, 87. 
  (113)  Espeso, E. A.; Tilburn, J.; Arst Jr, H., Penalva, M., EMBO J. 1993, 12, 3947. 
  (114)  Miao, L.; Kwong, T. F., Qian, P.-Y., Appl. Microbiol. Biotechnol. 2006, 72, 1063. 
  (115)  Bode, H. B.; Bethe, B.; Höfs, R., Zeeck, A., ChemBioChem 2002, 3, 619. 
  (116)  Barrios-González, J.; Castillo, T. E., Mejía, A., Biotechnol Adv. 1993, 11, 525. 
 
114 
  (117)  Pfefferle, C.; Theobald, U.; Gürtler, H., Fiedler, H.-P., J. Biotechnol 2000, 80, 135. 
  (118)  Soltero, F. V., Johnson, M. J., Appl Microbiol. 1953, 1, 52. 
  (119)  Hutwimmer, S.; Wang, H.; Strasser, H., Burgstaller, W., Mycologia 2010, 102, 1. 
  (120)  Gareis, M., Gareis, E.-M., Mycopathologia 2007, 163, 207. 
  (121)  Wang, X.; Sena Filho, J. G.; Hoover, A. R.; King, J. B.; Ellis, T. K.; Powell, D. R., 
Cichewicz, R. H., J. Nat. Prod. 2010, 73, 942. 
  (122)  Mascarin, G. M.; Jackson, M. A.; Kobori, N. N.; Behle, R. W.; Dunlap, C. A., 
Júnior, Í. D., Appl. Microbiol. Biotechnol. 2015, 99, 6653. 
  (123)  Robinson, T.; Singh, D., Nigam, P., Appl. Microbiol. Biotechnol. 2001, 55, 284. 
  (124)  Elibol, M., Mavituna, F., Process Biochem. 1997, 32, 417. 
  (125)  Barrios-González, J.; Rodríguez, G. M., Tomasini, A., J. Ferment. Bioeng. 1990, 
70, 329. 
  (126)  Lindenfelser, L., Ciegler, A., Appl Microbiol. 1975, 29, 323. 
  (127)  Hölker, U., Lenz, J., Curr. Opin. Microbiol. 2005, 8, 301. 
  (128)  VanderMolen, K. M.; Raja, H. A.; El-Elimat, T., Oberlies, N. H., AMB Express 
2013, 3, 71. 
  (129)  Bills, G. F.; Dombrowski, A. W., Goetz, M. A.,Fungal Secondary Metabolism: 
Methods and Protocols; Humana Press: New Jersey, 2012, p. 79. 
  (130)  Hölker, U.; Höfer, M., Lenz, J., Appl. Microbiol. Biotechnol. 2004, 64, 175. 
  (131)  Yamazaki, T.; Taguchi, T., Ojima, I.,Fluorine in medicinal chemistry and chemical 
biology; John Wiley & Sons: Wiltshire Great Britain, 2009, p. 3. 
  (132)  O’Hagan, D., Deng, H., Chem. Rev. 2015, 115, 634. 
  (133)  Boland, E. W., Ann. N. Y. Acad. Sci. 1959, 82, 887. 
  (134)  Cohen, S. S.; Flaks, J. G.; Barner, H. D.; Loeb, M. R., Lichtenstein, J., Proc. Natl. 
Acad. Sci. 1958, 44, 1004. 
  (135)  Duschinsky, R.; Pleven, E., Heidelberger, C., J. Am. Chem. Soc. 1957, 79, 4559. 
  (136)  Gillis, E. P.; Eastman, K. J.; Hill, M. D.; Donnelly, D. J., Meanwell, N. A., J. Med. 
Chem. 2015, 58, 8315. 
  (137)  Purser, S.; Moore, P. R.; Swallow, S., Gouverneur, V., Chem. Soc. Rev. 2008, 37, 
320. 
  (138)  Müller, K.; Faeh, C., Diederich, F., Science 2007, 317, 1881. 
  (139)  Meanwell, N. A., J. Med. Chem. 2018, 61, 5822. 
  (140)  Wang, J.; Sánchez-Roselló, M.; Aceña, J. L.; del Pozo, C.; Sorochinsky, A. E.; 
Fustero, S.; Soloshonok, V. A., Liu, H., Chem. Rev. 2014, 114, 2432. 
  (141)  Wong, D. T.; Perry, K. W., Bymaster, F. P., Nat. Rev. Drug Discovery 2005, 4, 
764. 
  (142)  Chin, N.-X., Neu, H. C., Antimicrob. Agents Chemother. 1984, 25, 319. 
  (143)  Sharma, P. C.; Jain, A.; Jain, S.; Pahwa, R., Yar, M. S., J. Enzyme Inhib. Med. 
Chem. 2010, 25, 577. 
  (144)  Kim, D.; Wang, L.; Beconi, M.; Eiermann, G. J.; Fisher, M. H.; He, H.; Hickey, G. 
J.; Kowalchick, J. E.; Leiting, B.; Lyons, K.; Marsilio, F.; McCann, M. E.; Patel, R. A.; 
Petrov, A.; Scapin, G.; Patel, S. B.; Roy, R. S.; Wu, J. K.; Wyvratt, M. J.; Zhang, B. B.; 
Zhu, L.; Thornberry, N. A., Weber, A. E., J. Med. Chem. 2005, 48, 141. 
 
115 
  (145)  Zhou, Y.; Wang, J.; Gu, Z.; Wang, S.; Zhu, W.; Aceña, J. L.; Soloshonok, V. A.; 
Izawa, K., Liu, H., Chem. Rev. 2016, 116, 422. 
  (146)  Kirk, K. L., Org. Process Res. Dev. 2008, 12, 305. 
  (147)  Romanov‐Michailidis, F.; Guenee, L., Alexakis, A., Angew. Chem. Int. Ed 2013, 
125, 9436. 
  (148)  Halperin, S. D.; Kwon, D.; Holmes, M.; Regalado, E. L.; Campeau, L.-C.; 
DiRocco, D. A., Britton, R., Org. Lett. 2015, 17, 5200. 
  (149)  Walker, M. C., Chang, M. C., Chem. Soc. Rev. 2014, 43, 6527. 
  (150)  Nilanonta, C.; Isaka, M.; Kittakoop, P.; Trakulnaleamsai, S.; Tanticharoen, M., 
Thebtaranonth, Y., Tetrahedron 2002, 58, 3355. 
  (151)  Thiericke, R., Rohr, J., Nat. Prod. Rep. 1993, 10, 265. 
  (152)  Xu, Y.; Zhan, J.; Wijeratne, E. K.; Burns, A. M.; Gunatilaka, A. L., Molnár, I., J. 
Nat. Prod. 2007, 70, 1467. 
  (153)  Saverino, D.; Debbia, E. A.; Pesce, A.; Lepore, A. M., Schito, G. C., J. Antimicrob. 
Chemother. 1992, 30, 261. 
  (154)  Toscano, L.; Fioriello, G.; Spagnoli, R.; Cappelletti, L., Zanuso, G., J. Antibiot. 
1983, 36, 1439. 
  (155)  Rivera-Chávez, J.; Raja, H. A.; Graf, T. N.; Burdette, J. E.; Pearce, C. J., Oberlies, 
N. H., J. Nat. Prod. 2017, 80, 1883. 
  (156)  Süssmuth, R. D., Mainz, A., Angew. Chem. Int. Ed 2017, 56, 3770. 
  (157)  McAlpine, J. B.; Chen, S.-N.; Kutateladze, A.; MacMillan, J. B.; Appendino, G.; 
Barison, A.; Beniddir, M. A.; Biavatti, M. W.; Bluml, S.; Boufridi, A.; Butler, M. S.; 
Capon, R. J.; Choi, Y. H.; Coppage, D.; Crews, P.; Crimmins, M. T.; Csete, M.; Dewapriya, 
P.; Egan, J. M.; Garson, M. J.; Genta-Jouve, G.; Gerwick, W. H.; Gross, H.; Harper, M. 
K.; Hermanto, P.; Hook, J. M.; Hunter, L.; Jeannerat, D.; Ji, N.-Y.; Johnson, T. A.; 
Kingston, D. G. I.; Koshino, H.; Lee, H.-W.; Lewin, G.; Li, J.; Linington, R. G.; Liu, M.; 
McPhail, K. L.; Molinski, T. F.; Moore, B. S.; Nam, J.-W.; Neupane, R. P.; Niemitz, M.; 
Nuzillard, J.-M.; Oberlies, N. H.; Ocampos, F. M. M.; Pan, G.; Quinn, R. J.; Reddy, D. S.; 
Renault, J.-H.; Rivera-Chávez, J.; Robien, W.; Saunders, C. M.; Schmidt, T. J.; Seger, C.; 
Shen, B.; Steinbeck, C.; Stuppner, H.; Sturm, S.; Taglialatela-Scafati, O.; Tantillo, D. J.; 
Verpoorte, R.; Wang, B.-G.; Williams, C. M.; Williams, P. G.; Wist, J.; Yue, J.-M.; Zhang, 
C.; Xu, Z.; Simmler, C.; Lankin, D. C.; Bisson, J., Pauli, G. F., Nat. Prod. Rep. 2019, DOI: 
10.1039/C8NP90041H. 
  (158)  Kim, W. E.; Patel, A.; Hur, G. H.; Tufar, P.; Wuo, M. G.; McCammon, J. A., 
Burkart, M. D., ChemBioChem 2019, 20, 147. 
  (159)  Tanner, M. E., Acc. Chem. Res. 2002, 35, 237. 
  (160)  Gu, B.; He, S.; Yan, X., Zhang, L., Appl. Microbiol. Biotechnol. 2013, 97, 8439. 
  (161)  Guo, C.-J.; Yeh, H.-H.; Chiang, Y.-M.; Sanchez, J. F.; Chang, S.-L.; Bruno, K. S., 
Wang, C. C. C., J. Am. Chem. Soc. 2013, 135, 7205. 
  (162)  El‐Elimat, T.; Figueroa, M.; Raja, H. A.; Graf, T. N.; Swanson, S. M.; Falkinham 
III, J. O.; Wani, M. C.; Pearce, C. J., Oberlies, N. H., Eur. J. Org. Chem 2015, 2015, 109. 
  (163)  El-Elimat, T.; Raja, H. A.; Day, C. S.; Chen, W.-L.; Swanson, S. M., Oberlies, N. 
H., J. Nat. Prod. 2014, 77, 2088. 
 
116 
  (164)  Harrison, C., Nat. Biotechnol. 2014, 32, 403. 
  (165)  Society, A. C., Atlanta, Ga: American Cancer Society 2019. 
  (166)  Cragg, G. M., Newman, D. J.,Natural Products as Source of Molecules with 
Therapeutic Potential; Springer, 2018, p. 309. 
  (167)  Fakhouri, L.; El-Elimat, T.; Hurst, D. P.; Reggio, P. H.; Pearce, C. J.; Oberlies, N. 
H., Croatt, M. P., Bioorg. Med. Chem. 2015, 23, 6993. 
  (168)  Altmann, K.-H.; Gaugaz, F. Z., Schiess, R., Mol. Divers. 2011, 15, 383. 
  (169)  Nicolaou, K.; Pfefferkorn, J.; Roecker, A.; Cao, G.-Q.; Barluenga, S., Mitchell, H., 
J. Am. Chem. Soc. 2000, 122, 9939. 
  (170)  Harvey, A. L.; Clark, R. L.; Mackay, S. P., Johnston, B. F., Expert Opin. Drug 
Discov. 2010, 5, 559. 
  (171)  Yoshioka, T.; Murakami, K.; Ido, K.; Hanaki, M.; Yamaguchi, K.; Midorikawa, 
S.; Taniwaki, S.; Gunji, H., Irie, K., J. Nat. Prod. 2016, 79, 2521. 
  (172)  Bian, L.; Cao, S.; Cheng, L.; Nakazaki, A.; Nishikawa, T., Qi, J., ChemMedChem 
2018, 13, 1972. 
  (173)  Xu, H.; Wang, J.; Sun, H.; Lv, M.; Tian, X.; Yao, X., Zhang, X., J. Agric. Food 
Chem. 2009, 57, 7919. 
  (174)  Lee, R. E.; Hurdle, J. G.; Liu, J.; Bruhn, D. F.; Matt, T.; Scherman, M. S.; Vaddady, 
P. K.; Zheng, Z.; Qi, J., Akbergenov, R., Nat. Med. 2014, 20, 152. 
  (175)  Patridge, E.; Gareiss, P.; Kinch, M. S., Hoyer, D., Drug Discov. Today 2016, 21, 
204. 
  (176)  Newman, D. J., Pharmacol. Ther. 2016, 162, 1. 
  (177)  Kung, S. H.; Lund, S.; Murarka, A.; McPhee, D., Paddon, C. J., Front. Plant Sci. 
2018, 9, 87. 
  (178)  McElroy, C., Jennewein, S.,Biotechnology of Natural Products; Springer, 2018, p. 
145. 
  (179)  Oberlies, N. H., Kroll, D. J., J. Nat. Prod. 2004, 67, 129. 
  (180)  Ringel, I., Horwitz, S. B., J. Natl. Cancer Inst. Monogr. 1991, 83, 288. 
  (181)  Guenard, D.; Gueritte-Voegelein, F., Potier, P., Acc. Chem. Res. 1993, 26, 160. 
  (182)  Wani, M. C.; Taylor, H. L.; Wall, M. E.; Coggon, P., McPhail, A. T., J. Am. Chem. 
Soc. 1971, 93, 2325. 
  (183)  Commercon, A.; Bezard, D.; Bernard, F., Bourzat, J., Tetrahedron Lett. 1992, 33, 
5185. 
  (184)  Greenwald, R. B.; Pendri, A., Bolikal, D., J. Org. Chem. 1995, 60, 331. 
  (185)  Mellado, W.; Magri, N. F.; Kingston, D. G.; Garcia-Arenas, R.; Orr, G. A., 
Horwitz, S. B., Biochem. Biophys. Res. Commun. 1984, 124, 329. 
  (186)  Magri, N. F., Kingston, D. G., J. Nat. Prod. 1988, 51, 298. 
  (187)  Vyas, D. M.; Wong, H.; Crosswell, A. R.; Casazza, A. M.; Knipe, J. O.; Mamber, 
S. W., Doyle, T. W., Bioorg. Med. Chem. Lett. 1993, 3, 1357. 
  (188)  Wall, M. E.; Wani, M.; Cook, C.; Palmer, K. H.; McPhail, A. a., Sim, G., J. Am. 
Chem. Soc. 1966, 88, 3888. 
  (189)  O’Leary, J., Muggia, F., Eur. J. Cancer 1998, 34, 1500. 
 
117 
  (190)  Tsuruo, T.; Matsuzaki, T.; Matsushita, M.; Saito, H., Yokokura, T., Cancer 
Chemother. Pharmacol 1988, 21, 71. 
  (191)  Kawato, Y.; Furuta, T.; Aonuma, M.; Yasuoka, M.; Yokokura, T., Matsumoto, K., 
Cancer Chemother. Pharmacol 1991, 28, 192. 
  (192)  Oncology (Williston Park, N.Y.) 2000, 14, 652. 
  (193)  Kingsbury, W. D.; Boehm, J. C.; Jakas, D. R.; Holden, K. G.; Hecht, S. M.; 
Gallagher, G.; Caranfa, M. J.; McCabe, F. L.; Faucette, L. F., Johnson, R. K., J. Med. 
Chem. 1991, 34, 98. 
  (194)  Takimoto, C. H., Arbuck, S. G., Oncology 1997, 11, 1635. 
  (195)  Ulukan, H., Swaan, P. W., Drugs 2002, 62, 2039. 
  (196)  Walko, C. M., Lindley, C., Clin. Ther. 2005, 27, 23. 
  (197)  Puhalla, S., Brufsky, A., Biol.: Targets Ther. 2008, 2, 505. 
  (198)  Fumoleau, P.; Coudert, B.; Isambert, N., Ferrant, E., Ann. Oncol. 2007, 18, v9. 
  (199)  Rannard, S. P., Davis, N. J., Org. Lett. 2000, 2, 2117. 
  (200)  Siegel, R. L.; Miller, K. D., Jemal, A., Ca-Cancer J. Clin. 2017, 67, 7. 
  (201)  Bowtell, D. D.; Böhm, S.; Ahmed, A. A.; Aspuria, P.-J.; Bast Jr, R. C.; Beral, V.; 
Berek, J. S.; Birrer, M. J.; Blagden, S., Bookman, M. A., Nat. Rev. Cancer 2015, 15, 668. 
  (202)  Korkmaz, T.; Seber, S., Basaran, G., Crit Rev Oncol Hematol. 2016, 98, 180. 
  (203)  Bitler, B. G.; Watson, Z. L.; Wheeler, L. J., Behbakht, K., Gynecol Oncol. 2017, 
147, 695. 
  (204)  Herzog, T. J., Monk, B. J., Gynecol Oncol Res Pract. 2017, 4, 13. 
  (205)  Moses, M., A.; Brem, H., Langer, R., Cancer Cell 2003, 4, 337. 
  (206)  Shukla, S., Steinmetz, N. F., Experimental Biology and Medicine 2016, 241, 1116. 
  (207)  Farokhzad, O. C., Langer, R., Advanced Drug Delivery Reviews 2006, 58, 1456. 
  (208)  Colby, A. H.; Colson, Y. L., Grinstaff, M. W., Nanoscale 2013, 5, 3496. 
  (209)  Liu, R.; Colby, A. H.; Gilmore, D.; Schulz, M.; Zeng, J.; Padera, R. F.; Shirihai, 
O.; Grinstaff, M. W., Colson, Y. L., Biomaterials 2016, 102, 175. 
  (210)  Zubris, K. A. V.; Liu, R.; Colby, A.; Schulz, M. D.; Colson, Y. L., Grinstaff, M. 
W., Biomacromolecules 2013, 14, 2074. 
  (211)  Colby, A. H.; Oberlies, N. H.; Pearce, C. J.; Herrera, V. L.; Colson, Y. L., Grinstaff, 
M. W., Wiley Interdiscip Rev Nanomed Nanobiotechnol 2017, 9, e1451. 
  (212)  Lewellen, K. A.; Metzinger, M. N.; Liu, Y., Stack, M. S., J. Vis. Exp. 2016, e53316. 
  (213)  Colby, A. H.; Berry, S. M.; Moran, A. M.; Pasion, K. A.; Liu, R.; Colson, Y. L.; 
Ruiz-Opazo, N.; Grinstaff, M. W., Herrera, V. L., ACS Nano 2017, 11, 1466. 
  (214)  Herrera, V. L.; Colby, A. H.; Tan, G. A.; Moran, A. M.; O’Brien, M. J.; Colson, 
Y. L.; Ruiz-Opazo, N., Grinstaff, M. W., Nanomedicine 2016, 11, 1001. 
  (215)  Gilmore, D.; Schulz, M.; Liu, R.; Zubris, K. A. V.; Padera, R. F.; Catalano, P. J.; 
Grinstaff, M. W., Colson, Y. L., Ann. Surg. Oncol. 2013, 20, 1684. 
  (216)  Weaver, B. A., Mol. Biol. Cell 2014, 25, 2677. 
  (217)  Goldhirsch, A.; Francis, P.; Castiglione-Gertsch, M.; Gelber, R. D., Coates, A. S., 
Lancet 2000, 356, 507. 
  (218)  Tuma, R. S., Oncology Times 2003, 25, 52. 
 
118 
  (219)  Griset, A. P.; Walpole, J.; Liu, R.; Gaffey, A.; Colson, Y. L., Grinstaff, M. W., J. 
Am. Chem. Soc. 2009, 131, 2469. 
  (220)  Dias, D. A.; Urban, S., Roessner, U., Metabolites 2012, 2, 303. 
  (221)  Schmidt, B.; Ribnicky, D. M.; Poulev, A.; Logendra, S.; Cefalu, W. T., Raskin, I., 
Metabolism 2008, 57, S3. 
  (222)  Jones, W. P., Kinghorn, A. D.,Natural products isolation; Springer, 2006, p. 323. 
  (223)  Hewage, R. T.; Aree, T.; Mahidol, C.; Ruchirawat, S., Kittakoop, P., 
Phytochemistry 2014, 108, 87. 
  (224)  Hemphill, C. F. P.; Sureechatchaiyan, P.; Kassack, M. U.; Orfali, R. S.; Lin, W.; 
Daletos, G., Proksch, P., J. Antibiot. 2017, 70, 726. 
  (225)  Gerwick, B. C.; Brewster, W. K.; Fields, S. C.; Graupner, P. R.; Hahn, D. R.; 
Pearce, C. J.; Schmitzer, P. R., Webster, J. D., J. Chem. Ecol. 2013, 39, 253. 
  (226)  Gerwick III, B. C.; Graupner, P. R.; Fields, S. C.; Schmitzer, P. R., Brewster, W. 
K., Google Patents, USA, 2008, p. 12. 
  (227)  Sica, V. P.; Figueroa, M.; Raja, H. A.; El-Elimat, T.; Darveaux, B. A.; Pearce, C. 
J., Oberlies, N. H., J. Ind. Microbiol. Biotechnol. 2016, 43, 1149. 
  (228)  Paguigan, N. D.; Raja, H. A.; Day, C. S., Oberlies, N. H., Phytochemistry 2016, 
126, 59. 
  (229)  Raja, H. A.; Paguigan, N. D.; Fournier, J., Oberlies, N. H., Mycol. Prog. 2017, 16, 
535. 
  (230)  Koulman, A.; Lane, G. A.; Christensen, M. J.; Fraser, K., Tapper, B. A., 
Phytochemistry 2007, 68, 355. 
  (231)  Wang, X.; Sena Filho, J. G.; Hoover, A. R.; King, J. B.; Ellis, T. K.; Powell, D. R., 
Cichewicz, R. H., J. Nat. Prod. 2010, 73, 942. 
  (232)  Gardes, M., Bruns, T. D., Mol. Ecol. 1993, 2, 113. 
  (233)  Amrine, C. S. M.; Raja, H. A.; Darveaux, B. A.; Pearce, C. J., Oberlies, N. H., J. 
Ind. Microbiol. Biotechnol. 2018, 45, 1053. 
  (234)  Katagiri, K.; Sato, K.; Hayakawa, S.; Matsushima, T., Minato, H., J. Antibiot. 1970, 
23, 420. 
  (235)  Kim, J.; Ashenhurst, J. A., Movassaghi, M., Science 2009, 324, 238. 
  (236)  Figueroa, M.; Graf, T. N.; Ayers, S.; Adcock, A. F.; Kroll, D. J.; Yang, J.; Swanson, 
S. M.; Munoz-Acuna, U.; De Blanco, E. J. C., Agrawal, R., J. Antibiot. 2012, 65, 559. 
  (237)  Liu, F.; Liu, Q.; Yang, D.; Bollag, W. B.; Robertson, K.; Wu, P., Liu, K., Cancer 
Res. 2011. 
  (238)  Lu, C.; Yang, D.; Sabbatini, M. E.; Colby, A. H.; Grinstaff, M. W.; Oberlies, N. 
H.; Pearce, C., Liu, K., BMC cancer 2018, 18, 149. 
  (239)  Lu, C.; Paschall, A. V.; Shi, H.; Savage, N.; Waller, J. L.; Sabbatini, M. E.; 
Oberlies, N. H.; Pearce, C., Liu, K., J. Natl. Cancer Inst. 2017, 109. 
  (240)  Paschall, A. V.; Yang, D.; Lu, C.; Choi, J.-H.; Li, X.; Liu, F.; Figueroa, M.; 
Oberlies, N. H.; Pearce, C., Bollag, W. B., J. Immunol. 2015, 195, 1868. 
  (241)  Zewdu, A.; Lopez, G.; Braggio, D.; Kenny, C.; Constantino, D.; Bid, H.; Batte, K.; 
Iwenofu, O.; Oberlies, N., Pearce, C., Clin. Exp. Pharmacol. 2016, 6, 221. 
  (242)  Cooks, R. G.; Ouyang, Z.; Takats, Z., Wiseman, J. M., Science 2006, 311, 1566. 
 
119 
  (243)  VanderMolen, K. M.; Darveaux, B. A.; Chen, W.-L.; Swanson, S. M.; Pearce, C. 
J., Oberlies, N. H., RSC Adv. 2014, 4, 18329. 
  (244)  Bills, G. F.; Platas, G.; Fillola, A.; Jiménez, M. R.; Collado, J.; Vicente, F.; Martín, 
J.; González, A.; Bur-Zimmermann, J.; Tormo, J. R., Peláez, F., J. Appl. Microbiol. 2008, 
104, 1644. 
  (245)  Wei, H.; Lin, Z.; Li, D.; Gu, Q., Zhu, T., Acta Microbiol. Sin. 2010, 50, 701. 
  (246)  Kuhnert, E.; Heitkämper, S.; Fournier, J.; Surup, F., Stadler, M., Fungal Biol. 2014, 
118, 242. 
  (247)  Stadler, M., Cur. Res. Env. App. Microbiol. 2011, 1, 75. 
  (248)  Figueroa, M.; Jarmusch, A. K.; Raja, H. A.; El-Elimat, T.; Kavanaugh, J. S.; 






Table S1. Composition of the Various Agar Media Evaluated in the Current Study. 
Table S2. Verticillin Analogues Observed via LC-HRMS Dereplication in a  
Panel of Fungal Strains from the Mycosynthetix Library (MSX).  
Table S3. 1H and 13C NMR Data for Verticillin H (1) in CDCl3. 
Table S4. 1H and 13C NMR Data for Sch 52901 (2) in CDCl3. 
Table S5. 1H and 13C NMR Data for Verticillin A (3) in CDCl3. 
Table S6. 1H, 13C and HMBC NMR Data for 9-F-Verticillin H (4) in CDCl3. 
Table S7. 1H, 13C and HMBC NMR Data for 9-F-Sch 52901 (5) in CDCl3. 
Table S8. 1H, 13C and HMBC NMR Data for 9ʹ-F-Sch 52901 (6) in CDCl3. 
Table S9. 1H, 13C and HMBC NMR Data for 9-F-Verticillin A (7) in CDCl3. 
Table S10. 1H, 13C and HMBC NMR Data for 9,9ʹ-di F-Verticillin A (8) in CDCl3. 
Table S11. 1H and HMBC NMR Data for 9,9ʹ-di F-Verticillin H (9) in CDCl3. 




Table S1. Composition of the Various Agar Media Evaluated in the Current Study. 
 
  
Name Abbreviation  
 
Composition per 1000 mL Deionized water 
(DI-H2O) 
Malt extract agar MEA 
12.75 g maltose, 2.75 g dextrin, 2.35 g 
glycerol, 0.78 g gelatin peptone, 15.0 g 
agar. 
Potato dextrose agar PDA 4 g potato starch, 20 g dextrose, 15 g agar. 
Yeast extract 
dextrose agar YESDA 
10 g yeast extract, 20 g soy peptone, 20 g 
dextrose, 15 g agar. 
Spezieller 
Nahrstoffarmer agar SNA 
1 g KH2PO4, 1 g KNO3, 0.5 g 
MgSO4.7H2O, 0.5 g KCl, 0.2 g glucose, 0.2 
g sucrose, 20 g agar. 
Sabouraud dextrose 
agar SDA 
5 g peptic digest of animal tissue, 5 g 
pancreatic digest of casein, 20 g dextrose, 





4 g potato starch, 20 g dextrose, 15 g agar, 
sterilized pieces of Leucoagaricus sp. 
mushroom. 
Oatmeal agar Oat-A 60 g oatmeal, 12.5 g agar. 
 
122 
Table S2. Verticillin Analogues Observed via LC-HRMS Dereplication in a Panel of 
Fungal Strains from the Mycosynthetix Library (MSX), all of which were grown on a 
rice based medium. Strains MSX59553 and MSX79542 were chosen for further 
optimization due to their biosynthetic potential to yield a wide variety of desirable 
analogues. 
.
Strain ID Verticillin analogues matched via LC-HRMS dereplication 
MSX74391 Sch52900, Gliocladicillin A, Verticillin A, Verticillin H, Sch52901 
MSX71844 Verticillin A, Sch52900 
MSX58124 Verticillin H, Sch52901, Gliocladicillin C, Sch52900 
MSX75296 Verticillin D 
MSX75281 Verticillin D 
MSX45374 11-Deoxyverticillin A, Gliocladicillin, Verticillin H, Sch52901, 
Gliocladicillin C, Sch52900 
MSX70777 11-Deoxyverticillin A, Sch52900, Sch52901, Verticillin A, 
Gliocladicillin A, Gliocladicillin C 
MSX59553 Verticillin A,  Verticillin H,  11-Deoxyverticillin A,  Gliocladicillin C,  
Sch52900,  Sch52901 
MSX79542 Verticillin A, Verticillin H, 11-Deoxyverticillin A,  Gliocladicillin C,  













































Table S3. 1H and 13C NMR Data for Verticillin H (1) in CDCl3. [500 MHz for 1H and 
125 MHz for 13C]. 
 
Position δC δH, mult (J in Hz) 
1, 1ʹ 167.4 - 
3, 3ʹ 77.5 - 
4, 4ʹ 161.6 - 
5a, 5aʹ 82.1 5.73, s 
6a, 6aʹ 148.9 - 
7, 7ʹ 110.9 6.64, dd (7.8, 0.9) 
8, 8ʹ 130.1 7.14, td (7.8, 1.1) 
9, 9ʹ 120.6 6.83, td (7.8, 0.9) 
10, 10ʹ 128.3 7.84, dd (7.8, 1.1) 
10a, 10aʹ 129.5 - 
10b, 10bʹ 65.8 - 
11, 11ʹ 83.3 5.14, s 
11a, 11aʹ 76.9 - 
12, 12ʹ 28.1 3.01, s 
13, 13ʹ 24.7 2.16, m 
2.37, m 
14, 14ʹ 9.9 1.21, t (7.2) 













































Table S4. 1H and 13C NMR Data for Sch 52901 (2) in CDCl3. [500 MHz for 1H and 125 MHz for 13C]. 
 
Position δC δH, mult (J in Hz) Position δC δH, mult (J in Hz) 
1 162.5a - 1ʹ 161.5a - 
3 77.5a - 3ʹ 76.6a - 
4 167.3a - 4ʹ 166.3a - 
5a 82.1 5.73, s 5aʹ 82.1 5.73, s 
6a 148.8 - 6aʹ 148.8 - 
7 111.0 6.65, dd (7.6, 1.0) 7ʹ 111.0 6.65, dd (7.3, 1.0) 
8 128.3 7.15, ddd (7.6, 7.4, 1.1) 8ʹ 128.3 7.13, ddd (7.6, 7.3, 1.1) 
9 120.6 6.84, ddd (7.8, 7.4, 1.0) 9ʹ 120.6 6.81, ddd (7.8, 7.6, 1.0) 
10 129.5 7.84, dd (7.8, 1.1) 10ʹ 129.5 7.82, dd (7.8, 1.1) 
10a 130.1 - 10aʹ 130.1 - 
10b 66.0a - 10bʹ 65.8a - 
11 83.3a 5.15, s 11ʹ 83.1 5.15, s 
11a 73.0 - 11aʹ 73.0a - 
12 28.1a 3.01a, s  12ʹ 27.3a 2.99a, s  
13 17.6 2.16, m 
2.36, m 
13ʹ 24.7 1.89, s 
14 9.9 1.22, t (7.1) - - - 
6-NH - 5.09b, s 6ʹ-NH - 5.14b, s 
11-OH - 5.56b, s 11ʹ-OH - 5.67b, s 





Table S5. 1H and 13C NMR Data for Verticillin A (3) in CDCl3. [500 MHz for 1H and 
125 MHz for 13C]. 
 
Position δC δH, mult (J in Hz) 
1, 1ʹ 162.5 - 
3, 3ʹ 76.6 - 
4, 4ʹ 166.3 - 
5a, 5aʹ 82.1 5.72, s 
6a, 6aʹ 148.8 - 
7, 7ʹ 111.0 6.66, dd (7.8, 0.9) 
8, 8ʹ 128.3 7.14, td (7.8, 1.1) 
9, 9ʹ 120.6 6.82, td (7.8, 0.9) 
10, 10ʹ 130.1 7.83, dd (7.8, 1.1) 
10a, 10aʹ 129.5 - 
10b, 10bʹ 66.0 - 
11, 11ʹ 83.1 5.14, s 
11a, 11aʹ 73.0 - 
12, 12ʹ 27.3 2.99, s 
13, 13ʹ 17.6 1.89, s 
6-NH, 6ʹ-NH - 5.09a, s  
11-OH, 11ʹ-OH - 5.66a, s  

























































































Table S6. 1H, 13C and HMBC NMR Data for 9-F-Verticillin H (4) in CDCl3. [700 MHz for 1H and 175 MHz for 13C]. 
 
Position δC, mult (J in Hz) δH, mult (J in Hz) HMBC (1H    13C) Position δC, mult δH, mult (J in Hz) HMBC (1H    13C) 
1  167.1 -  1ʹ 167.1 -  
3 77.4a -  3ʹ 77.5 a -  
4 161.4 -  4ʹ 161.4 -  
5a 82.0 5.68, s 4, 10a, 10b, 11, 
11a 
5aʹ 81.9 5.70, s 4ʹ, 10aʹ, 10bʹ, 11ʹ, 
11aʹ 
6a 144.9, d (1.3) -  6aʹ 148.8 -  
7 111.1, d (8.5) 6.58, dd (8.6, 4.4) 9, 10a 7ʹ 110.8 6.65, dd (7.6, 1.0) 9ʹ, 10aʹ 
8 116.6, d (24.5) 6.86, td (8.6, 2.7) 6a, 9, 10 8ʹ 130.1 7.15, td (7.6, 1.2) 6aʹ, 10ʹ 
9 157.6, d (235.6) -  9ʹ 120.5 6.83, td (7.6, 1.0) 7ʹ, 10aʹ 
10 115.5, d (25.4) 7.63, dd (9.4, 2.7) 6a, 8, 9, 10a, 10b 10ʹ 128.2 7.83, dd (7.6, 1.2) 6aʹ, 8ʹ, 10bʹ 
10a 130.8, d (8.5) -  10aʹ 128.9 -  
10b 65.9, d (1.9) -  10bʹ 65.5 -  
11 83.8 5.16, s 6a, 10a, 11a 11ʹ 83.0 5.14, s 6aʹ, 11aʹ  
11a 76.6 -  11aʹ 76.7 -  
12 28.0 3.02a, s  1, 3 12ʹ 28.0 3.03a, s  1ʹ, 3ʹ 
13 24.6 a 2.17, m, 2.38, m 3, 4, 14 13ʹ 24.5 a 2.17, m, 2.38, m  3ʹ, 4ʹ, 14ʹ 
14 9.9 a 1.25b, t (7.2) 3, 13 14ʹ 9.8 a 1.22b, t (7.2) 3ʹ,13ʹ 
6-NH - 5.05, s 6a, 7, 10a, 10b 6ʹ-NH - 5.15, s 6aʹ, 7ʹ, 10aʹ, 10bʹ 
11-OH - 5.59, s 10a, 10b, 11a 11ʹ-OH - 5.64, s 10aʹ, 10bʹ, 11aʹ 











































Table S7. 1H, 13C and HMBC NMR Data for 9-F-Sch 52901 (5) in CDCl3. [700 MHz for 1H and 175 MHz for 13C]. 
 
Position δC, mult (J in Hz) δH, mult (J in Hz) HMBC (1H    13C) Position δC,  δH, mult (J in Hz) HMBC (1H    13C) 
1 167.1 -  1ʹ 166.1 -  
3 77.5 -  3ʹ 72.9 -  
4 161.4 -  4ʹ 162.3 -  
5a 82.0 5.67, s 4, 10a, 10b, 11, 11a 5aʹ 81.9 5.70, s 4ʹ, 10aʹ, 10b ʹ, 11ʹ, 
11aʹ 
6a 144.9, d (1.1) -  6aʹ 148.7 -  
7 111.1, d (8.5) 6.58, dd (8.6, 4.4) 9, 10a 7ʹ 110.8 6.66, dd (7.7, 1.0) 9ʹ, 10aʹ 
8 116.6, d (23.6) 6.86, td (8.6, 2.7) 6a, 9, 10 8ʹ 130.2 7.15, td (7.7, 1.2) 6aʹ, 10ʹ 
9 157.6, d (236.3) -  9ʹ 120.5 6.84, td (7.7, 1.0) 7ʹ, 10aʹ 
10 115.5, d (25.7) 7.61, dd (9.4, 2.7) 6a, 8, 9, 10a, 10b 10ʹ 128.3 7.84, dd (7.7, 1.2) 6aʹ, 8ʹ, 10bʹ 
10a 130.8, d (8.6) -  10aʹ 128.9 -  
10b 65.9, d (1.9) -  10bʹ 65.6 -  
11 83.7 5.15, s 6a, 10a, 10b, 11a 11ʹ 82.8 5.13, s 6aʹ, 10aʹ, 10bʹ, 11aʹ 
11a 76.6 -  11aʹ 76.4 -  
12 28.0 3.02, s 
3.01, s 
1, 3 12ʹ 27.2 3.01, s 1ʹ, 3ʹ 
13 24.5 2.17, m 
2.37, m 
3, 4, 14 13ʹ 17.5 1.90, s 3ʹ, 4ʹ 
14 9.8 1.22, t (7.2) 3, 13     
6-NH - 5.05, s 5a, 6a, 7, 10a, 10b 6ʹ-NH - 5.10, s 5aʹ, 7ʹ, 10bʹ 














































Table S8. 1H, 13C and HMBC NMR Data for 9ʹ-F-Sch 52901 (6) in CDCl3. [700 MHz for 1H and 175 MHz for 13C]. 
 
Position δC,  δH, mult (J in Hz) HMBC (1H    13C) Position δC, mult (J in Hz) δH, mult (J in Hz) HMBC (1H    13C) 
1 167.1 -  1ʹ 166.1 -  
3 77.4 -  3ʹ 73.0 -  
4 161.4 -  4ʹ 162.3 -  
5a 81.9 5.70, s 10a, 10b, 11 5aʹ 82.0 5.68, s 10aʹ, 10bʹ, 11ʹ 
6a 148.7 -  6aʹ 144.8, d (1.4) -  
7 110.8 6.65, dd (7.7, 1.0) 9, 10a 7ʹ 111.2, d (8.5) 6.58, dd (4.4, 8.6) 9ʹ, 10aʹ 
8 130.1 7.13, td (7.7, 1.3) 6a, 10 8ʹ 116.6, d (23.8) 6.87, td (8.6, 2.7) 6aʹ, 9ʹ,10ʹ 
9 120.5 6.81, td (7.7, 1.0) 10a 9ʹ 157.6, d (236.0) -  
10 128.2 7.81, dd (7.7, 1.3) 6a, 8, 10a, 10b 10ʹ 115.6, d (25.5) 7.64, dd (9.4, 2.7) 6aʹ, 8ʹ, 9ʹ, 10aʹ, 10bʹ 
10a 128.9 -  10aʹ 130.8, d (8.6) -  
10b 65.6 -  10bʹ 66.0 d (1.9) -  
11 83.0 5.15, s 6a, 10a, 11a 11ʹ 83.6 5.13, s 6aʹ, 10aʹ, 11aʹ  
11a 76.7 -  11aʹ 76.3 -  
12 28.0 3.03, s 1, 3 12ʹ 27.2 2.99, s 1ʹ, 3ʹ 
13 24.6 2.18, m 
2.39, m 
3, 4 13ʹ 17.5 1.89, s 3ʹ, 4ʹ 
14 9.8 1.25, t (7.2) 3     
6-NH - 5.15, s 10a, 10b 6ʹ-NH - 4.99, s 10aʹ, 10bʹ 











































Table S9. 1H, 13C and HMBC NMR Data for 9-F-Verticillin A (7) in CDCl3. [700 MHz for 1H and 175 MHz for 13C]. 
 
Position δC, mult (J in Hz) δH, mult (J in Hz) HMBC (1H     13C) Position δC, mult  δH, mult (J in Hz) HMBC (1H    13C) 
1 166.1 -  1ʹ 166.1 -  
3 73.0a -  3ʹ 72.9 a -  
4 162.2 -  4ʹ 162.3 -  
5a 82.0 5.67, s 4, 10a, 10b, 11, 11a 5aʹ 81.9 5.69, s 4ʹ, 10aʹ, 10bʹ, 11ʹ, 
11aʹ 
6a 144.8, d (1.2) -  6aʹ 148.6 -  
7 111.2, d (8.6) 6.58, dd (8.6, 4.4) 9, 10a 7ʹ 110.8 6.65, dd (7.7, 1.0) 9ʹ, 10aʹ 
8 116.6, d (24.7) 6.86, td (8.6, 2.7) 6a, 9, 10 8ʹ 130.1 7.14, td (7.7, 0.9) 6aʹ, 10ʹ 
9 157.6, d (236.2) -  9ʹ 120.5 6.82, td (7.7, 1.0) 7ʹ, 10aʹ 
10 115.5, d (25.5) 7.61, dd (9.4, 2.7) 6a, 8, 9, 10b 10ʹ 128.2 7.82, dd (7.7, 0.9) 6aʹ, 8ʹ, 10bʹ 
10a 130.8, d (8.6) -  10aʹ 128.9 -  
10b 66.0, d (1.6) -  10bʹ 65.7 -  
11 83.6 5.14, s 6a, 10a, 10b, 11a 11ʹ 82.8 5.12, s 6aʹ, 10aʹ, 10bʹ, 11aʹ 
11a 76.4 -  11aʹ 76.3 -  
12 27.20 a 3.01a, s  1, 3 12ʹ 27.18 a 2.99a, s  1ʹ, 3ʹ 
13 17.4 1.88, s, 1.90, s 3, 4 13ʹ 17.4 1.88, s, 1.90, s 3ʹ, 4ʹ 
6-NH - 4.99, s 6a, 7, 10a, 10b 6ʹ-NH - 5.10, s 6aʹ, 7ʹ, 10aʹ, 10bʹ 
11-OH - 5.69, s 10a, 10b 11ʹ-OH - 5.73, s 10aʹ, 10bʹ 












































Table S10. 1H, 13C and HMBC NMR Data for 9,9ʹ-di F-Verticillin A (8) in CDCl3. 
[700 MHz for 1H and 175 MHz for 13C]. 
 
Position δC, mult (J in Hz) δH, mult (J in Hz) HMBC (1H    13C) 
1, 1ʹ 166.0 -  
3, 3ʹ 73.0 -  
4, 4ʹ 162.3 -  
5a, 5aʹ 81.9 5.65, s 4, 4ʹ, 10a, 10aʹ, 10b, 10bʹ, 
11, 11ʹ, 11a, 11aʹ 
6a, 6aʹ 144.8 -  
7, 7ʹ 111.3, d (8.3) 6.59, dd (8.6, 4.4) 9, 9ʹ, 10a, 10aʹ  
8, 8ʹ 116.7, d (23.9) 6.86, td (8.6, 2.7) 6a, 6aʹ, 9, 9ʹ, 10, 10ʹ 
9, 9ʹ 157.6, d (236.9) -  
10, 10ʹ 115.6, d (26.6) 7.60, dd (9.4, 2.7) 6a, 6aʹ, 8, 8ʹ, 9, 9ʹ,10a, 
10aʹ,10b, 10bʹ  
10a, 10aʹ 130.4, d (8.7) -  
10b, 10bʹ 65.8, d (1.6) -  
11, 11ʹ 83.4 5.13, s 6a, 6aʹ, 10a, 10aʹ, 10b, 
10bʹ, 11a, 11aʹ 
11a, 11aʹ 76.2 -  
12, 12ʹ 27.2 3.01, s 1, 1ʹ, 3, 3ʹ 
13, 13ʹ 17.5 1.91, s 3, 3ʹ, 4, 4ʹ 
6-NH, 6ʹ-NH - 5.01, s 5a, 5aʹ, 10a, 10aʹ, 10b, 
10bʹ, 11a, 11aʹ 






















































Table S11. 1H and HMBC NMR Data for 9,9ʹ-di F-Verticillin H (9) in CDCl3. [500 
MHz]. 
 
Position δH, mult (J in Hz) HMBC (1H    13C) 
1, 1ʹ -  
3, 3ʹ -  
4, 4ʹ -  
5a, 5aʹ 5.66, s 10a, 10aʹ, 10b, 10bʹ, 11, 11ʹ, 
11a, 11aʹ 
6a, 6aʹ -  
7, 7ʹ 6.59, dd (8.6, 4.4) 9, 9ʹ 
8, 8ʹ 6.88, td (8.6, 2.6) 6a, 6aʹ 
9, 9ʹ -  
10, 10ʹ 7.60, dd (9.4, 2.6) 6a, 6aʹ 
10a, 10aʹ -  
10b, 10bʹ -  
11, 11ʹ 5.15, s 6a, 6aʹ, 10a, 10aʹ, 10b, 10bʹ, 11a, 
11aʹ 
11a, 11aʹ -  
12, 12ʹ 3.04, s 1, 1ʹ, 3, 3ʹ 
13, 13ʹ 2.19, m, 2.39, m 3, 3ʹ, 4, 4ʹ, 14, 14ʹ 
14, 14ʹ 1.26, t (7.1) 3, 3ʹ, 13, 13ʹ 
6-NH, 6ʹ-NH 5.66, s 5a, 5aʹ, 10a, 10aʹ, 10b, 10bʹ, 11a, 
11aʹ 





















































Table S12. 1H and HMBC NMR Data for 9,9ʹ-di F- Sch 52901 (10) in CDCl3. [500 MHz]. 
 
Position δH, mult (J in Hz) HMBC(1H    13C) Position δH, mult (J in Hz) HMBC(1H    13C) 
1 -  1ʹ -  
3 -  3ʹ -  
4 -  4ʹ -  
5a 5.66, s 4, 10a, 10b, 11, 11a 5aʹ 5.66, s 4ʹ, 10aʹ, 10b ʹ, 11ʹ, 11aʹ 
6a -  6aʹ -  
7 6.59, m (8.8, 4.4) 9, 10a 7ʹ 6.59, m (8.8, 4.4) 9ʹ, 10aʹ 
8 6.86a, td (8.8, 2.8) 6a, 9 8ʹ 6.88a, td (8.8, 2.8) 6aʹ, 9ʹ 
9 -  9ʹ -  
10 7.61b, m (9.4, 2.8) 6a, 9 10ʹ 7.63b, m (9.4, 2.8) 6aʹ, 9ʹ 
10a -  10aʹ -  
10b -  10bʹ -  
11 5.14c, s  6a, 10a, 10b, 11a 11ʹ 5.15c, s 6aʹ, 10aʹ, 10bʹ, 11aʹ 
11a -  11aʹ -  
12 3.02d, s 1, 3 12ʹ 3.04d, s 1ʹ, 3ʹ 
13 2.19, m, 2.39, m 3, 4, 14 13ʹ 1.91, s 3ʹ, 4ʹ 
14 1.26, t (7.0) 3, 13    
6-NH 5.05e, s,  10a, 10b 6ʹ-NH 5.07e, s 10aʹ, 10bʹ 
11-OH 5.66f, s 5a, 10b, 11a 11ʹ-OH 5.77f, s 5aʹ, 10bʹ, 11aʹ 





Figure S1. Phylogram of the Most Likely Tree. 
Figure S2. In situ Microextraction via Droplet Probe Directly from the Surface 
of Fungal Culture Showing the Spots where the Sampling was Performed. 
Figure S3. Photos of the Two Strains MSX59553 (top) and MSX79542 (bottom). 
Figure S4. The Amount of the Total Defatted Extracts of Both Strains  
MSX59553 and MSX79542. 
Figure S5. Total Defatted Extracts Weight of Strains MSX59553 and MSX79542. 
Figure S6. Full Scan MS Data of Strain MSX59553 Grown on Oatmeal Agar Medium 
Supplemented with a Racemic Mixture of 5-F-DL-Trp. 
Figure S7. Full Scan MS Data of Strain MSX59553 Grown on Oatmeal Agar Medium 
Supplemented with a Racemic Mixture of 5-F-DL-Trp.  
Figure S8. Full Scan MS Data of Strain MSX59553 Grown on Oatmeal Agar Medium 
Supplemented with a Racemic Mixture of 5-F-DL-Trp. 
Figure S9. Culture Conditions for MSX59553 Grown on Oatmeal Agar Medium 
Supplemented with a Racemic Mixture of 5-F-DL-Trp. 
Figure S10. 1H and 13C NMR Spectra of Verticillin H (1) in CDCl3. 
Figure S11. 1H (upper panel) and 13C (lower panel) NMR Spectra of  
Sch 52901 (2) in CDCl3. 
Figure S12. 1H (upper panel) and 13C (lower panel) NMR Spectra of  
Verticillin A (3) in CDCl3. 
Figure S13. 1H (upper panel) and 13C (lower panel) NMR Spectra of  
9-F-verticillin H (4) in CDCl3. 
Figure S14. 1H-1H COSY NMR Spectrum of 9-F-verticillin H (4) in CDCl3. 
Figure S15. 1H-13C HSQC NMR spectrum of 9-F-verticillin H (4) in CDCl3. 
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Figure S16. 1H-13C HMBC NMR Spectrum of 9-F-verticillin H (4) in CDCl3. 
Figure S17. 1H (upper panel) and 19F (lower panel) NMR Spectra of  
9-F-verticillin H (4) in CDCl3. 
Figure S18. 13C NMR (lower panel) and 19F-13C HMQC NMR Spectra of  
9-F-verticillin H (4) in CDCl3 
Figure S19. 1H (upper panel) and 13C (lower panel) NMR Spectra of  
9-F-Sch 52901 (5) in CDCl3. 
Figure S20. 1H-1H COSY NMR Spectrum of 9-F-Sch 52901 (5) in CDCl3. 
Figure S21. 1H-13C HSQC NMR Spectrum of 9-F-Sch 52901 (5) in CDCl3 . 
Figure S22. 1H-13C HMBC NMR Spectrum of 9-F-Sch 52901 (5) in CDCl3.  
Figure S23. 1H (upper panel) and 19F (lower panel) NMR Spectra of  
9-F-Sch 52901 (5) in CDCl3. 
Figure S24. 13C (lower panel) NMR and 19F-13C HMQC NMR Spectra of  
9-F-Sch 52901 (5) in CDCl3. 
Figure S25. Full Scan MS Data of 9-F-Sch 52901 (5). 
Figure S26. 1H and 13C NMR Spectra of 9ʹ-F-Sch 52901 (6) in CDCl3. 
Figure S27. 1H-1H COSY NMR Spectrum of 9ʹ-F-Sch 52901 (6) in CDCl3. 
Figure S28. (1H-13C HSQC NMR Spectrum of 9ʹ-F-Sch 52901 (6) in CDCl3. 
Figure S29. 1H-13C HMBC NMR Spectrum of 9ʹ-F-Sch 52901 (6) in CDCl3. 
Figure S30. 1H (upper panel) and 19F (lower panel) NMR Spectra of  
9ʹ-F-Sch 52901 (6) in CDCl3. 
Figure S31. 13C NMR (lower panel) and 19F-13C HMQC NMR Spectra of  
9ʹ-F-Sch 52901 (6) in CDCl3. 
Figure S32. Full Scan MS Data of 9-F-Sch 52901 (6). 
Figure S33. 1H (upper panel) and 13C (lower panel) NMR Spectra of  
9-F-verticillin A (7) in CDCl3. 
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Figure S34. 1H-1H COSY NMR Spectrum of 9-F-verticillin A (7) in CDCl3. 
Figure S35. 1H-13C HSQC NMR Spectrum of 9-F-verticillin A (7) in CDCl3. 
Figure S36. 1H-13C HMBC NMR Spectrum of 9-F-verticillin A (7) in CDCl3. 
Figure S37. 1H (upper panel) and 19F (lower panel) NMR Spectra of  
9-F-verticillin A (7) in CDCl3. 
Figure S38.13C NMR (lower panel) and 19F-13C HMQC NMR Spectra of  
9-F-verticillin A (7) in CDCl3. 
Figure S39. 1H (upper panel) and 13C (lower panel) NMR Spectra of  
9,9ʹ-di F-verticillin A (8) in CDCl3. 
Figure S40. 1H-1H COSY NMR Spectrum of 9,9ʹ-di F-verticillin A (8) in CDCl3. 
Figure S41. 1H-13C HSQC NMR Spectrum of 9,9ʹ-di F-verticillin A (8) in CDCl3. 
Figure S42. 1H-13C HMBC NMR Spectrum of 9,9ʹ-di F-verticillin A (8) in CDCl3. 
Figure S43. 1H (upper panel) and 19F (lower panel) NMR Spectra of  
9,9ʹ-di F-verticillin A (8) in CDCl3. 
Figure S44.  1H NMR Spectrum of 9,9ʹ-di F-verticillin H (9) in CDCl3. 
Figure S45. 1H-13C HMBC NMR Spectrum of 9,9ʹ-di F-verticillin H (9) in CDCl3. 
Figure S46. 1H (upper panel) and 19F (lower panel) NMR Spectra of 
 9,9ʹ-di F-verticillin H (9) in CDCl3. 
Figure S47. 1H NMR Spectrum of 9,9ʹ-di F-Sch 52901 (10) in CDCl3. 
Figure S48. 1H-13C HMBC NMR Spectrum of 9,9ʹ-di F-Sch 52901 (10) in CDCl3. 
Figure S49. 1H (upper panel) and 19F (lower panel) NMR Spectra of  
9,9ʹ-di F-Sch 52901 (10) in CDCl3. 
Figure S50. 1H (upper panel) and 13C (lower panel) NMR Spectra of  
5-F-Tryptophan in D2O. 
Figure S51. 19F NMR Spectra of 5-F-Tryptophan in D2O. 
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Figure S52. 19F-13C HMQC NMR Spectrum of 5-F-Tryptophan in D2O. 
Figure S53. Full Scan MS Data of Strain MSX59553 Grown on Oatmeal Agar Medium 
Supplemented with 5-F-D-Trp. 
Figure S54. Full Scan MS Data of Strain MSX59553 Grown on Oatmeal Agar Medium  
Supplemented with 5-F-D-Trp. 
Figure S55. Full Scan MS Data of Strain MSX59553 Grown on Oatmeal Agar Medium  
Supplemented with 5-F-D-Trp. 
Figure S56. Full Scan MS Data of Strain MSX59553 Grown on Oatmeal Agar Medium  
Supplemented with 5-F-L-Trp. 
Figure S57. Full Scan MS Data of Strain MSX59553 Grown on Oatmeal Agar Medium  
Supplemented with 5-F-L-Trp.   
Figure S58. Full Scan MS Data of Strain MSX59553 Grown on Oatmeal Agar Medium  
Supplemented with 5-F-L-Trp.   
Figure S59. Relative Production of Fluorinated Verticillin Analogues via UPLC-HRMS  
Analysis of Extracted Petri Dishes Used Previously for the Droplet Probe Analysis. 
Figure S60. 1H (upper panel) and 13C (lower panel) NMR Spectra of 3 in CDCl3. 
Figure S61. 1H (upper panel) and 13C (lower panel) NMR Spectra of 4 in CDCl3. 
Figure S62. 1H (upper panel) and 13C (lower panel) NMR Spectra of 5 in CDCl3. 
Figure S63. 1H (upper panel) and 13C (lower panel) NMR Spectra of 6 in CDCl3. 
Figure S64. 1H (upper panel) and 13C (lower panel) NMR Spectra of 7 in CDCl3. 
Figure S65. 1H (upper panel) and 13C (lower panel) NMR Spectra of 8 in CDCl3. 
Figure S66. 1H (upper panel), 13C (lower panel) NMR Spectra of 9 in CDCl3. 
Figure S67. 13C NMR Spectra of 9 in CDCl3 Showing the Split Carbon by the 19F. 
Figure S68. 19F NMR Spectrum of 9 in CDCl3. 
Figure S69. 1H (upper panel) and 13C (lower panel) NMR Spectra of 10 in CDCl3. 
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Figure S70. 1H (upper panel) and 13C (lower panel) NMR Spectra of 11 in CDCl3. 
Figure S71. 1H (upper panel) and 13C (middle panel) NMR Spectra of 12 in CDCl3. 
Figure S72. Calibration Curve for Verticillin A. 
Figure S73. Scanning Electron Micrograph of Verticillin A Expansile  
Nanoparticles (eNP). 
Figure S74. 2D Foci Assay on OVCAR4 and OVCAR8 Cells.  






Figure S1. Phylogram of the Most Likely Tree (-lnL = 1766.04) from a RAxML 
analysis of 67 Clonostachys strains based on ITS region (470 bp). Numbers refer to 
RAxML bootstrap support values ≥ 70% based on 1000 replicates. Type strains are 
highlighted in bold italics, authentic strains (bold). Three-week old cultures of MSX 
strains on Potato Dextrose Agar media are shown on right. Eight strains (MSX75281, 
MSX75296, MSX59553, MSX45374, MSX74391, MSX79542, MSX70777, 
MSX58124) are identified as members of the genus Clonostachys, while one strain 
MSX71844 is identified as Purpureocillium lavendulum. Bar indicates nucleotide 




Figure S2. In situ Microextraction via Droplet Probe Directly from the Surface of 
Fungal Culture Showing the Spots where the Sampling was Performed (black 
crosses, left). From the central spot towards the edge, the fungal colony goes from the 










































Figure S3. Photos of the Two Strains MSX59553 (top) and MSX79542 (bottom) 
grown on oatmeal agar, oatmeal, and rice (from left to right). Guttates were found only 
on the oatmeal agar culture of MSX79542 (black arrows). The cultures were grown for 4 
weeks at room temperature then analyzed by droplet probe prior to their extraction. 
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Figure S4. The Amount of the Total Defatted Extracts of Both Strains MSX59553 
and MSX79542. The cultures were grown on Petri dishes in three different media 







Figure S5. Total Defatted Extracts Weight of Strains MSX59553 and MSX79542 
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Figure S6. Full Scan MS Data of Strain MSX59553 Grown on Oatmeal Agar 
Medium Supplemented with a Racemic Mixture of 5-F-DL-Trp. The plates were 
microextracted in situ using a droplet probe coupled to a hyphenated system (UPLC-
PDA-HRMS-MS/MS). The peaks indicated with green arrows (m/z 725.1338, 743.1243, 
761.1152) correspond to the mass of verticillin H (1), the incorporation of one fluorine 
atom, and the incorporation of two fluorine atoms in the molecule, respectively.  















































Figure S7. Full Scan MS Data of Strain MSX59553 Grown on Oatmeal Agar 
Medium Supplemented with a Racemic Mixture of 5-F-DL-Trp. The plates were 
microextracted in situ using a droplet probe coupled to a hyphenated system (UPLC-
PDA-HRMS-MS/MS). The peaks indicated with green arrows (m/z 711.1183, 729.1087, 
747.0994) correspond to the mass of Sch 52901 (2), the incorporation of one fluorine 
atom, and the incorporation of two fluorine atoms in the molecule, respectively.  


















































Figure S8. Full Scan MS Data of Strain MSX59553 Grown on Oatmeal Agar 
Medium Supplemented with a Racemic Mixture of 5-F-DL-Trp. The plates were 
microextracted in situ using a droplet probe coupled to a hyphenated system (UPLC-
PDA-HRMS-MS/MS). The peaks indicated with green arrows (m/z 697.1030, 715.0930, 
733.0841) correspond to the mass of verticillin A (3), the incorporation of one fluorine 




























































Figure S9. Culture Conditions for MSX59553 Grown on Oatmeal Agar Medium Supplemented with a Racemic 
Mixture of 5-F-DL-Trp. The plate was used to inoculate 10 mL of YESD to be used to grow cultures on oatmeal 
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Figure S12. 1H (upper panel) and 13C (lower panel) NMR Spectra of Verticillin A (3) in CDCl3 [500 MHz for 1H and 125 











Figure S13. 1H (upper panel) and 13C (lower panel) NMR Spectra of 9-F-verticillin H (4) in CDCl3 [700 MHz for 1H and 






















































































Figure S16. 1H-13C HMBC NMR Spectrum of 9-F-verticillin H (4) in CDCl3 (700 
MHz). The red arrows show the correlations between the protons in positions H-7, H-8 












































Figure S17. 1H (upper panel) and 19F (lower panel) NMR Spectra of 9-F-verticillin H 





























































Figure S18. 13C NMR (lower panel) and 19F-13C HMQC NMR Spectra of 9-F-






















gradient enhanced HMQC with X-decoupling







Figure S19. 1H (upper panel) and 13C (lower panel) NMR Spectra of 9-F-Sch 52901 (5) in CDCl3 [700 MHz for 1H and 












































































Figure S22. 1H-13C HMBC NMR Spectrum of 9-F-Sch 52901 (5) in CDCl3 (700 
MHz). The red arrows show the correlations between the protons in positions H-7, H-8 

























































Figure S23. 1H (upper panel) and 19F (lower panel) NMR Spectra of 9-F-Sch 52901 

























































Figure S24. 13C (lower panel) NMR and 19F-13C HMQC NMR Spectra of 9-F-Sch 
















Figure S25. Full Scan MS Data of 9-F-Sch 52901 (5) with m/z 729.1060. HRMS-MS/MS fragmentation showed m/z 































































































Figure S29. 1H-13C HMBC NMR Spectrum of 9ʹ-F-Sch 52901 (6) in CDCl3 (700 
MHz) The red arrows show the correlations between the protons in positions H-7ʹ, H-8ʹ 



































































Figure S30. 1H (upper panel) and 19F (lower panel) NMR Spectra of 9ʹ-F-Sch 52901 


































































Figure S31.13C NMR (lower panel) and 19F-13C HMQC NMR Spectra of 9ʹ-F-Sch 
52901 (6) in CDCl3 [175 MHz for 13C and 470 MHz for 19F].  
102030405060708090100110120130140150160170
f1 (ppm)





Figure S32. Full Scan MS Data of 9-F-Sch 52901 (6) with m/z 729.1065. HRMS-MS/MS fragmentation showed m/z 







Figure S33. 1H (upper panel) and 13C (lower panel) NMR Spectra of 9-F-verticillin A (7) in CDCl3 [700 MHz for 1H and 
































































Figure S36. 1H-13C HMBC NMR Spectrum of 9-F-verticillin A (7) in CDCl3 (700 
MHz). The red arrows show the correlations between the protons in positions H-7, H-8 




























Figure S37. 1H (upper panel) and 19F (lower panel) NMR Spectra of 9-F-verticillin A 



































































Figure S38.13C NMR (lower panel) and 19F-13C HMQC NMR Spectra of 9-F-

























gradient enhanced HMQC with X-decoupling







Figure S39. 1H (upper panel) and 13C (lower panel) NMR Spectra of 9,9ʹ-di F-verticillin A (8) in CDCl3 [700 MHz for 1H 
















































Figure S41. 1H-13C HSQC NMR Spectrum of 9,9ʹ-di F-verticillin A (8) in CDCl3 








































Figure S42. 1H-13C HMBC NMR Spectrum of 9,9ʹ-di F-verticillin A (8) in CDCl3 
(700 MHz). The red arrows show the correlations between the protons in positions H-7, 
H-8, and H-10 with the characteristic carbon at C-9 that contains the fluorine atom. Those 





























Figure S43. 1H (upper panel) and 19F (lower panel) NMR Spectra of 9,9ʹ-di F-







































































Figure S45. 1H-13C HMBC NMR Spectrum of 9,9ʹ-di F-verticillin H (9) in CDCl3 
(500 MHz). The red arrow shows the correlation between the protons in position H-7 
with the characteristic carbon at C-9 that contains the fluorine atom. Those correlations 























































Figure S46. 1H (upper panel) and 19F (lower panel) NMR Spectra of 9,9ʹ-di F-


































Figure S48. 1H-13C HMBC NMR Spectrum of 9,9ʹ-di F-Sch 52901 (10) in CDCl3 (500 
MHz). The red arrows show the correlation between the protons in positions H-7 H-8, 
and H-10 with the characteristic carbon at C-9 that contains the fluorine atom. Those 

























































Figure S49. 1H (upper panel) and 19F (lower panel) NMR Spectra of 9,9ʹ-di F-Sch 















Figure S50. 1H (upper panel) and 13C (lower panel) NMR Spectra of 5-F-















Figure S52. 19F-13C HMQC NMR Spectrum of 5-F-Tryptophan in D2O [175 MHz for 



















Figure S53. Full Scan MS Data of Strain MSX59553 Grown on Oatmeal Agar 
Medium Supplemented with 5-F-D-Trp. The plates were microextracted in situ using a 
droplet probe coupled to a hyphenated system (UPLC-PDA-HRMS-MS/MS). The peaks 
indicated with green arrows (m/z 725.1339, 743.1243, 761.1144) correspond to the mass 
of verticillin H (1), the incorporation of one fluorine atom, and the incorporation of two 
fluorine atoms in the molecule, respectively. 
  




























































Figure S54. Full Scan MS Data of Strain MSX59553 Grown on Oatmeal Agar 
Medium Supplemented with 5-F-D-Trp. The plates were microextracted in situ using a 
droplet probe coupled to a hyphenated system (UPLC-PDA-HRMS-MS/MS). The peaks 
indicated with green arrows (m/z 711.1180, 729.1085, 747.0990) correspond to the mass 
of Sch 52901 (2), the incorporation of one fluorine atom, and the incorporation of two 
fluorine atoms in the molecule, respectively. 
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Figure S55. Full Scan MS Data of Strain MSX59553 Grown on Oatmeal Agar 
Medium Supplemented with 5-F-D-Trp. The plates were microextracted in situ using a 
droplet probe coupled to a hyphenated system (UPLC-PDA-HRMS-MS/MS). The peaks 
indicated with green arrows (m/z 697.1021, 715.0927, 733.0853) correspond to the mass 
of verticillin A (3), the incorporation of one fluorine atom, and the incorporation of two 
fluorine atoms in the molecule, respectively. 
  
























































Figure S56. Full Scan MS Data of Strain MSX59553 Grown on Oatmeal Agar 
Medium Supplemented with 5-F-L-Trp. The plates were microextracted in situ using a 
droplet probe coupled to a hyphenated system (UPLC-PDA-HRMS-MS/MS). The peaks 
indicated with green arrows (m/z 725.1344, 743.1246, 761.1137) correspond to the mass 
of verticillin H (1), the incorporation of one fluorine atom, and the incorporation of two 
fluorine atoms in the molecule, respectively. 
  













































Figure S57. Full Scan MS Data of Strain MSX59553 Grown on Oatmeal Agar 
Medium Supplemented with 5-F-L-Trp.  The plates were microextracted in situ using a 
droplet probe coupled to a hyphenated system (UPLC-PDA-HRMS-MS/MS). The peaks 
indicated with green arrows (m/z 711.1171, 729.1081, 747.0965) correspond to the mass 
of Sch 52901 (2), the incorporation of one fluorine atom, and the incorporation of two 
fluorine atoms in the molecule, respectively. 
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Figure S58. Full Scan MS Data of Strain MSX59553 Grown on Oatmeal Agar 
Medium Supplemented with 5-F-L-Trp.  The plates were microextracted in situ using a 
droplet probe coupled to a hyphenated system (UPLC-PDA-HRMS-MS/MS). The peaks 
indicated with green arrows (m/z 697.1025, 715.0929, 733.0826) correspond to the mass 
of verticillin A (3), the incorporation of one fluorine atom, and the incorporation of two 
fluorine atoms in the molecule, respectively. 
  





































Figure S59. Relative Production of Fluorinated Verticillin Analogues via UPLC-HRMS Analysis of Extracted Petri 
Dishes used Previously for the Droplet Probe Analysis. The in-situ extraction observed a detection of the expected masses 
of the fluorinated verticillin analogues in both 5-F-D-Trp and 5-F-L-Trp supplemented media. The relative percentages were 
normalized by multiplying the peak areas by the weight of their corresponding organic extracts. The results demonstrate that 


























































































































































































































































Figure S67. 13C NMR Spectra of 9 in CDCl3 Showing the Split Carbon by the 19F [ 125 MHz for 13C].  
010203040506070809010011012013014015016017080
f1 (ppm)











































































































Figure S72. Calibration Curve for Verticillin A. Measured via UPLC-HRMS, using a 
Waters Acquity UPLC system coupled with a Thermo Q-Exactive Plus mass 
spectrometer. The instrument was operated under positive mode using selected ion 
monitoring (SIM) of verticillin A [(M+H)+, m/z of 697.10]. To build the calibration cure 
(above), 3 µL of each concentration was analyzed in triplicate. These data represent 
means ± SD, and the orange line shows the amount of verticillin A in the diluted solution 
(1.29 µg/mL). In sum total, there were 0.91 mg of verticillin A per mL of eNP solution, 








































Figure S73. Scanning Electron Micrograph of Verticillin A Expansile Nanoparticles 
(eNP). Showing spherical particles of approximately 100 nm at pH 7.4. The right picture 















Figure S74. 2D Foci Assay on OVCAR4 and OVCAR8 Cells. The cells were treated 
with vehicle and verticillin A (50 nM) for 8 hrs. Following drug incubation, media was 
changed, and cells were incubated for 2 weeks to form colonies. Representative images 
of 2D foci assay performed in OVCAR4 and OVCAR8 cells are shown. Each experiment 
was performed in three biological replicates, and data represent mean ± SEM. 
Significance tested by Student’s t-test in comparison to vehicle control. p<0.05 was 







Figure S75. Cell Viability Test of Normal and Cancer Cells Treated with Verticillin 
A. Four ovarian cell lines (IOSE80, FT33, OVCAR4 and OVCAR8) were treated with 
vehicle (DMSO) and verticillin A (50 nM) for 72 hrs. Each experiment was performed in 
three biological replicates, and data represent mean ± SEM. Statistics were generated 
with Student’s t-test for Day 0 and Day 3 within each cell line. p<0.05 was considered 
statistically significant (* p<0.05; ** p <0.01; *** p<0.001; **** p<0.0001). 
 
 
 
 
